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Cancer of the mammary gland is the most common type of cancer in women worldwide, and 
the vast majority of breast cancers originate from a cluster of malignant cells in the epithelial 
tissue of the breast, which initially confines the ductal carcinoma in situ. Research has shown 
that the signalling pathways that increase differentiation and maintain proliferation in normal 
epithelial cells are of utmost importance for sustaining this barrier against malignant cells. As 
a model for normal mammary epithelial cells, the MCF-12A cell line was used to determine 
factors that are required for cell cycle progression of these cells. A discontinuous treatment 
assay was developed in which the MCF-12A cells were treated with epidermal growth factor 
(EGF) and insulin at two distinct times to induce cell cycle re-entry. The use of these 
chemically defined growth factors enabled us to determine that continuous stimulation with 
mitogenic factors is not required for these cells to re-enter the cell cycle. An initial activation 
of the MAP kinase pathway and an up-regulation of the transcription factor c-Myc, followed 
by activation of the PI3K pathway, resulted in full competence to progress into S phase. The 
order in which the growth factors were applied, and thus the sequence in which the 
subsequent proteins were triggered, was of great importance for successful S phase entry.  
We found that estradiol (E2) was unable to induce the factors necessary for cell cycle 
progression. Furthermore, we report for the first time that E2 did not affect estrogen-
regulated genes which normally are under the control of a ligand-bound estrogen receptor 
(ER). We suggest that the mechanism by which the ligand-activated ER usually interferes 
with the estrogen responsive element in the promoter region of the target genes is defective in 
the MCF-12A cell line. 
The results presented here may contribute to new approaches in chemotherapy, taking 
advantage of the diverse molecular mechanism in place for cell cycle progression and 
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1 GENERAL INTRODUCTION 
Breast cancer is the most frequently diagnosed cancer and now the leading cause of cancer 
deaths among women. It accounts for almost a quarter of all cancer cases worldwide, and for 
14% of all cancer deaths. This corresponds to almost half a million women who have died 
from breast cancer in 2008, and incidence rates are still rising in most countries (Jemal et al. 
2011). It is of utmost importance to investigate the reasons why some women will be 
diagnosed with breast cancer, whereas some women will not. Although some of the risk 
factors for developing mammary carcinoma are known, the molecular mechanisms for the 
development and progression of the disease are not yet fully understood. Independent of the 
known risk factors, almost all cancers originate in the milk ducts. Most of these neoplasms 
remain within the duct, confined by a protective barrier of healthy epithelial cells, however, 
some neoplasms will be able to break down this barrier and become invasive tumours. 
Much emphasis has been placed on the characterisation of the malignant cells. However, the 
signals that maintain proliferation in normal epithelial cells are the key element for sustaining 
the barrier against invasion and the research presented here focuses on the signalling 
pathways activated for cell cycle progression in normal epithelial cells. A better knowledge 
of the signalling network in normal cells can also provide the basis for understanding how the 
“wrong” signals can lead to increased proliferation, ultimately resulting in malignant 
transformation, and giving rise to the very first cancer cells. 
2 CANCER OF THE MAMMARY GLAND 
Cancer of the mammary gland is the most common type of cancer in women worldwide 
(Jemal et al. 2011). The risk for developing a mammary tumour increases with age, and 75% 
percent of women diagnosed with breast cancer are over the age of 50 (DeSantis et al. 2011). 
However, the disease also occurs in younger women (around 5% of all patients are under the 
age of 40), thus other risk factors must exist. 
2 
 
2.1 Risk factors for breast cancer 
Screening of tumour tissue has revealed that in around one quarter of all samples, one of the 
human epidermal growth factor receptors (HER), HER2, was overexpressed (Slamon et al. 
1987). This amplification is acquired over time, as a result of genetic damage, and increases 
the risk for the development of a tumour, since aberrant signalling through this receptor is 
believed to play a direct role in malignant transformation and progression (Wilson et al. 
2005; Pietras et al. 1995; Pierce et al. 1991). The overexpression of HER2 in human breast 
cancer cells can also enhance their metastatic potential (Tan et al. 1997). As a result of these 
findings, the drugs trastuzumab as well as lapatinib were developed, which interfere with the 
HER2 receptor and provide a more targeted therapy for the disease. 
Also a strong indicator for the risk of developing breast cancer is a woman’s genetic 
predisposition. For example, women with germline mutations on the breast cancer genes 
(BRCA1 or BRCA2) have a much higher risk of developing mammary carcinomas (Miki et 
al. 1994; Ford et al. 1994). A consequence of this finding was to develop a screening 
programme that monitors women affected by this genotype at close intervals from a young 
age, since they are prone to early-onset breast cancers. 
There are also external and life-style factors that increase the risk for developing a mammary 
carcinoma. Many of these are well known and include the late onset of menopause, use of 
menopausal hormone replacement therapy (HRT), (late) age at first pregnancy and 
nulliparity, as well as alcohol consumption and being overweight. Long term (> 10 years) use 
of HRT increases the risk for breast cancer by 30%, and a delay of 5 years in the onset of 
menopause results in an additional 17% risk (Colditz 1998; King and Schottenfeld 1996). 
Nulliparous women increase their risk for developing a mammary carcinoma by around one 
third (Schonfeld et al. 2011), whereas each full term pregnancy provides a protective effect 
(Hulka and Moorman 2001; Kelsey et al. 1993). The rise in cancer cases caused by alcohol 
consumption is modest (regular alcohol intake results in a 30% augmented risk), but obesity, 
especially post-menopausal, increases the risk for developing breast cancer considerable 
(three times higher than for women with a normal body mass index (BMI)) (Hulka and 
Moorman 2001; King and Schottenfeld 1996; Longnecker et al. 1995). Not to be dismissed is 
the risk emerging from exposure to environmental pollutants, since chemicals that can mimic 
the function of estrogens in the human body may account for a considerable number of breast 
cancer cases (Kortenkamp et al. 2007; Muir 2005; Sasco 2003; Bhatt 2000). Consequently, 
maintaining a healthy body weight, regular exercise and limiting the exposure to known 
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carcinogens (including alcohol), are currently the best strategy for every woman to reduce her 
risk of developing breast cancer (Magne et al. 2011; Kushi et al. 2006). However, these 
established risk factors are not rare and most women unaffected by the disease also carry 
them. More precisely, one study showed that 97 percent of cases, but also 96 percent of 
controls had one or more “traditional” hormone related risk factors for breast cancer, meaning 
that the effects of these risk factors are quite weak, even when they are found in combination 
(Millikan et al. 1995; Newman et al. 1995). Indeed, models that are based upon such well 
known risk factors are unable to predict with acceptable accuracy who will develop breast 
cancer (Rockhill et al. 2001). Actually, only around half of all breast cancer cases can be 
attributed to recognised risk factors, including nulliparity or late age of first pregnancy 
(Madigan et al. 1995), and only a fraction of these again are a result of genetic 
predispositions (Lichtenstein et al. 2000). Nevertheless, most mammary carcinomas do have 
one common feature, which will be discussed in the next section. 
2.2 Signalling between normal and malignant cells for the transition from 
in situ to invasive carcinoma 
The vast majority of breast cancers originate in the epithelial tissues of the breast, more 
specifically from a cluster of malignant cells initially confined to the milk ducts (Polyak and 
Kalluri 2010; Burstein et al. 2004; Radford et al. 1995). At first, these so-called ductal 
carcinoma in situ (DCIS) are surrounded by normal epithelial cells that form a natural barrier 
against increased progression of the neoplastic cells (cf. Figure 1). In the early phase of 
tumorigenesis, this barrier breaks down, probably as a result of signals emitted by the 
malignant cells, and gives way to invasive progression (invasive ductal carcinoma, IDC). The 
importance of the integrity of the myoepithelium to function as a barrier was demonstrated 
already in the 1970s when DeCosse and colleagues (1973 and 1975) showed that a normal 
mammary microenvironment in co-culture with breast cancer cells was capable of inducing a 
more differentiated state in the cancer cells and so to revert the malignant phenotype 
(reviewed by Polyak and Kalluri 2010; DeCosse et al. 1975; DeCosse et al. 1973). Taking 
these observations further, Hu and colleagues (2008) showed that co-injection of normal 
myoepithelial cells decreased tumour weights in a xenograft model (mice with human DCIS), 
whereas injection of cancer cells promoted tumour growth (Hu et al. 2008a). Similarly to the 
xenograft model, Booth and colleagues (2011) showed that in a mixture of normal mammary 
epithelial cells with mammary tumour cells, injected into (epithelium-free) mouse mammary, 
the tumour cells were reverted to normal cells, which even participated in the generation of a 
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normal, functional mammary gland in the animals (Booth et al. 2011). This suggests that 
normal epithelial cells are signalling to transformed cells to reverse their malignant fate. The 
question arises as to the potential for confined carcinoma to transform their 
microenvironment and to become invasive. There are currently (at least) two slightly 
different views that explain how the malignant cells, initially confined to the ducts, are able 
to break through the protective layer of the epithelium. First, the barrier evasion model 
suggests that the first tumour cells promote proliferation of each other and of newly aberrant 
cells. The malignant cells proliferate until they finally disrupt the myoepithelial cell layer, 
then degrade the basement membrane and eventually migrate into the stroma. From there on, 
the tumour cells can invade surrounding tissue or even migrate to distant organs. The second 
model sees barrier failure as the fatal event: tumour cells signal to normal myoepithelial cells 
in such a way as to disrupt their differentiation, and these cells are lost. Eventually, the 
epithelium lacks sufficient cells to form the protective barrier, resulting in invasive 
carcinomas (Polyak and Kalluri 2010).  
In both these proposed models, as well as in the studies showing that tumorigenic cells can be 
re-programmed when they are in a normal microenvironment, the signalling between the 
normal and the malignant cells has an important role for deciding if a small tumour remains 
confined, or becomes invasive and consequently more dangerous. The exact signals remain 
unknown, but paracrine interactions between malignant and normal cells seem likely, such as 
through cytokines or prostaglandins. Indeed, prostaglandin action, which is mediated by the 
NFκB pathway, was found to be the target of the crosstalk between normal epithelial and 
tumour fibroblast cells of the stroma, which has an important role in breast tumour 
progression (Hu et al. 2009). In particular the signals that increase differentiation and 
maintain proliferation in normal mammary epithelial cells are vital in this context and are 






Figure 1 Schematic representation of the different cell types found in the lobules and ducts of the 
mammary gland lobes 
The glandular tissue of the mammary gland consists of separate lobes, each containing several secretory lobules. 
The ducts are formed by an outer myoepithelial cell layer on the basement membrane (BM) and an inner 
luminal epithelial cell layer, and are surrounded by the extracellular matrix (ECM) and the stroma. Cells 
composing the stroma include fibroblasts, myofibroblasts, adipocytes and endothelial cells. The ducts leaving 






























3 MAMMARY GLAND EPITHELIUM 
3.1 The function of epithelial cells in the mammary gland 
The normal development of the mammary gland requires cell proliferation and 
differentiation, taking place in a tightly controlled manner. Many of these processes are 
regulated by hormones. Typically, the steroid hormones progesterone and estrogen are found 
in the mammary gland, and both play major roles for the development of this specialised 
tissue. The primordial function of epithelial cells in the mammary gland lies in the formation 
of the milk ducts, which are made up of elongated epithelial cells. This ductal outgrowth is 
stimulated by estrogens which, during the reproductive cycle, regulate cellular proliferation 
and turnover (for a recent review about this morphogenesis, see Gjorevski and Nelson 2011). 
Stimulation of normal ductal elongation and outgrowth by estrogens is transmitted through 
the estrogen receptor alpha (ERα) found in epithelial and stromal cells, and the loss of ERα 
expression in these cells results in impaired branching and elongation (Feng et al. 2007; 
Bocchinfuso et al. 2000; Bocchinfuso and Korach 1997). Thus, estrogens have an impact on 
cell proliferation in the normal epithelium, but they also strongly increase proliferation in ER 
positive (ER
+
) breast cancer cells. It is not entirely clear how the balance between desired 
proliferative estrogen signalling and repressing aberrant proliferation is maintained in normal 
cells, and yet this could explain, at least partially, why some cells become overly proliferative 
and eventually malignant. However, approximately one third of all breast cancers are 
characterised as estrogen receptor negative (ER
-
) (Putti et al. 2005; Pervez et al. 1994). ER
-
 
breast cancer cells lack the classical pathway of estrogen-stimulated proliferation. Signalling 
for their proliferation is mediated through the epidermal growth factor (EGF) receptor 
(EGFR).  
The EGFR (also known as HER or ErbB1) belongs to the ErbB family of receptor tyrosine 
kinases, which also comprises HER2, as well as ErbB3 and ErbB4. The EGFR is associated 
with increased proliferation of normal breast epithelial cells. For example, activation of the 
EGFR is readily detected in extracts of mammary glands of mice at puberty, late pregnancy, 
and lactation. Conversely, EGFR
-/-
 mice have impaired postnatal ductal development, and are 
characterized by a reduced proliferation of the mammary epithelium and stroma (Stern 2003). 
However, it is now also apparent that overexpression of any receptor of the ErbB family (or 
ectopic expression of ErbB agonists) has a role in human cancers (Jin and Esteva 2008; Stern 
2003; Yarden and Sliwkowski 2001). Indeed, in ER
-
 breast cancer cells, the EGFR is found to 
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be overexpressed, which explains their increased proliferation rate (Biswas et al. 2000; Ma et 
al. 1998; Fan et al. 1998; Newby et al. 1997). Therefore, simply treating breast cancer with 
anti-estrogenic compounds to suppress the proliferation of the malignant cells is by far not 
efficient in all cases. Treatment of breast cancer cells in culture with anti-estrogens even 
resulted in increased expression of several EGF receptor types. Subsequently, proliferation of 
such conditioned cells was dependent on EGF related, rather than hormone related pathways 
(Knowlden et al. 2003; McClelland et al. 2001). As mentioned above, approximately one 
third of all breast cancer patients display overexpression of the EGFR (ER
-
 tumours), and 
another 25% overexpress the ErbB receptor HER2. Consequently, inhibitors for the ErbB 
family have been approved for the treatment of some epithelial tumours that carry specific 
receptor gene amplifications. However, the efficacy of such therapies has been limited in the 
case of breast cancer: for example, only 25 to 30% of patients with tumours overexpressing 
HER2 respond to the classical HER2 targeting agents, trastuzumab and lapatinib (Jin and 
Esteva 2008).  
In order to optimise therapeutic efficacy, it is essential to untangle the complex signalling 
network in the mammary gland epithelium. Especially a better understanding of the receptor 
functions and the signals transmitted from the receptors onwards in normal tissue may reveal 
regulatory elements that may be exploited for developing more targeted therapies. The 
regulation of proliferation certainly holds a key position in the epithelium, and therefore is 
discussed in more detail in the next section. 
3.2 Signalling for cell cycle progression and proliferation 
It has become clear that the signalling pathways that increase differentiation and maintain 
proliferation in normal epithelial cells are of utmost importance for sustaining the barrier 
against invasiveness of malignant cells. Proliferation is the result of cells progressing through 
the cell cycle, which ends with the division of the cell into two daughter cells. The cell cycle 
is divided into four main stages, the first gap phase (G1), followed by the synthesis (S) phase 
where the DNA is duplicated, a second gap phase (G2) and finally mitosis (M phase). The 
progression through the different stages is tightly controlled by so-called cell cycle 
checkpoints which ensure the fidelity of the cell entity (Murray 1994). Since the G1 phase 
serves as a period where the cell can grow, the G1/S phase checkpoint may only be passed if 
the cell has reached a sufficient enough size. The G2 phase checkpoint is required to ensure 
that the entire genome has been replicated. The mitotic checkpoint, also called the spindle 
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checkpoint, safeguards the correct assembly of the mitotic spindle and alignment of the 
chromosomes on the spindle, before onset of cytokinesis. 
The work presented here will focus on the events occurring during cell cycle progression out 
of the quiescent state through G1 into S phase. On its way from G1 into S phase, the cell has 
to pass the restriction (R) point, where it is decided if the cell is allowed to continue with the 
cell cycle and divide, or not. This depends on the environmental conditions, and the cell will 
only progress through the cell cycle if it has received sufficient extracellular growth signals. 
The R point is lost in most cancer cells, and therefore they proliferate in an uncontrolled 
fashion. The biochemical mechanism underlying the R point is the hyperphosphorylation of 
the retinoblastoma protein (pRb), which, in its hypophosphorylated state, suppresses cell 
cycle progression. Successful hyperphosphorylation is a multistep process, involving many 
different proteins activated beforehand by mitogen-triggered signalling pathways, such as 
cyclin D, cyclin E and their respective partner cyclin-dependent kinases (CDK) (Planas-Silva 
and Weinberg 1997b; Weinberg 1995).  
Once the cell passes the R point, it becomes mitogen-independent and is committed to the 
cell cycle. It will complete the next round of mitosis (unless stopped at one of the subsequent 
checkpoints for DNA damage repair etc.). Because the R point is a decisive element in the 
cell cycle, it can be assumed that (growth) factors that activate the R point have a 
proliferative effect on the cell. Likewise, cells that have a phosphorylated pRb have acquired 
mitogen autonomy, because all signals required for entry in to S phase must have been 
received at this point. On the other hand, constitutive phosphorylation of the pRb is regarded 
as aberrant behaviour: such cells are thought to have lost any dependence on external 
mitogenic stimuli, and are assumed to proliferate excessively (Weinberg 1995; Pardee 1989; 
Pardee 1974). 
To conclude, these phosphorylation events taking place in G1 around the R point are the 
result of a finely balanced system of signalling pathways which are not yet fully defined in 
mammary epithelial cells. The research presented here will focus on a few aspects of these 







The paracrine signalling emanating from normal epithelial cells to malignant cells in the 
mammary ducts holds the potential of suppressing cancer progression at a very early stage. 
Therefore, the signalling in the mammary microenvironment is under investigation, but 
progress is slow because the signalling cascades activated in one cell at a time are extremely 
complex and involve a plethora of different kinases. Even if only one mechanism is examined 
at a time, the kinase cascades that are activated to achieve for example cell cycle progression 
are not linear. Research with fibroblast cells has made substantial progress in this regard: one 
interesting experimental set-up was established by Jones and Kazlauskas (2001) with 
fibroblasts, which allowed determination of factors that are absolutely necessary and 
sufficient for cell cycle re-entry (Jones and Kazlauskas 2001). These researchers showed that 
when fibroblasts were stimulated with growth factors in a discontinuous fashion, the cells 
were still able to progress through G1 phase, as long as all molecular requirements in terms 
of temporal availability of specific factors were met. They suggested that it is a general 
feature of cells that some proteins need to be activated at early times, which set the stage for 
the subsequent completion of pRb phosphorylation. The responsible signalling cascades are 
not activated constantly, but in (at least) two distinct waves, thus the external stimuli are 
required exclusively at these specific times. Intrigued by their so called two wave model, we 
were interested to find out if such a discontinuous experimental set-up could be applied to 
epithelial cells as well. If so, this would open new possibilities for investigating the signals 
triggered in the normal mammary microenvironment. Since we wanted to study the signalling 
events in place for cell cycle progression in normal mammary epithelial cells, the MCF-12A 
cell line was chosen as a model system. These cells are derived from non-transformed human 
mammary epithelial tissue obtained during reduction mammoplasty. They immortalised 
spontaneously after long term cultivation (Paine et al. 1992) and are therefore viewed as a 
good model for normal epithelial cells of the mammary gland. However, this cell line is 
delicate to maintain and requires rather complex culture conditions, when compared to other 
mammary epithelial cell lines, and therefore is not used widely, and comparatively few 
publications are available. 
The first aim was to remove the complex mixture of growth factors present in the serum rich 
growth medium the MCF-12A cells are usually maintained in, and to find chemically defined 
(growth) factors that are able to induce cell cycle progression in these cells. Cell cycle 
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progression was considered successful once cells had reached S phase, as determined by flow 
cytometric analysis of the combined percentages of S, G2 and M phase cells. 
After identification of such specific factors, the second objective was to develop an 
experimental set-up that applies a discontinuous treatment regimen to the cells. This is 
imperative because only a discontinuous stimulation would allow first to determine the 
sequence in which the signalling cascades are triggered, and second to what extent (how long 
the signalling cascades are kept functional). If there is no succession of cascades, it can be 
assumed that all signals are triggered at the same time. Consequently, the next objective was 
to identify these signalling pathways that are triggered for cell cycle re-entry. This includes 
the identification of the proteins that are activated in the course of these cascades. 
Finally, the effect of the endogenous hormone estradiol in the MCF-12A cell line was to be 
examined. As discussed above, estrogens have an important role in the development of the 
mammary gland in general, and for mammary epithelial cells in particular. However, the 
function of estradiol in the MCF-12A cells is not well characterised. Assessing the impact of 
estradiol on cell cycle progression was therefore another objective of the work presented 
here. Additionally, we wanted to monitor the influence on the expression of a few genes that 
are typically regulated by the steroid hormone, including some proliferative genes, such as 
PRAD1 (coding for cyclin D1) and MYC which is translated into the c-Myc protein 
transcription factor. 
5 THESIS OUTLINE 
Chapter 2 describes the material and methods used to carry out the work presented in this 
thesis. 
Chapter 3 covers the methodological issues that had to be addressed at the beginning of the 
work presented here. First, an appropriate method for cell synchronisation needed to be 
established and validated. Synchronicity of the cell cultures was monitored with flow 
cytometric analysis, for which also a suitable protocol was developed. Second, the 
characteristics of the cell cycle profiles of the cell line used needed to be considered so that 
the best fitting model for flow cytometric cell cycle analysis could be determined. The 
reproducibility of data was determined and sources for data variability were discussed. An 
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appropriate normalisation method for the obtained data was introduced to account for the 
inter-experimental data variability due to the method chosen for cell synchronisation.  
Chapter 4 is dedicated to the experimental establishment of the discontinuous stimulation 
assay using MCF-12A cells. The parameters that are essential for successful S phase 
progression are discussed and additionally, the effect of a variety of growth factors utilised in 
the discontinuous stimulation assay is assessed. 
In Chapter 5, the effect of EGF on the regulation of selected genes is presented. The findings 
are compared with the effect of estradiol on the same set of genes, and are put into context 
with the observations made on cell cycle progression with these two compounds. 
In Chapter 6, some of the signalling cascades triggered for cell cycle progression are 
revealed; more precisely, the MAP kinase, PI3 kinase and the PLC pathways are investigated 
in detail. The conclusions about the signalling network are drawn from experiments that 
illustrate the impact of different kinase and lipase inhibitors on cell cycle progression. 
Chapter 7 discusses several proteins that are required for cell cycle progression. First, the 
activation of the kinases found to be involved in Chapter 6, is confirmed. Secondly, the 
expression of the transcription factor c-Myc is followed during the discontinuous stimulation 
assay. 







Material and Methods 
1 LIST OF CHEMICALS 
Table 1 List of chemicals used and suppliers 
Chemical Supplier 
17β-estradiol Sigma 
acetic acid BDH 
acrylamide BioRad 
ammonium persulfate Sigma 
bovine serum albumin Sigma 
bromophenol blue Sigma 
charcoal GE Healthcare 
cholera toxin Sigma 
coumaric acid Sigma 
dextrane GE Healthcare 
dimethylsulfoxide Merck 




Hank’s balanced salt solution Invitrogen 
HCl Sigma 
horse serum Invitrogen 
hydrocortisone Sigma 
insulin Invitrogen 
insulin like growth factor 1 Sigma 






M-MLV reverse transcriptase Promega 







propidium iodide Calbiochem 
PP2 Sigma 
protein standard for Bradford assay Sigma 
random primers Invitrogen 
rDNase Macherey-Nagel 
ribonuclease inhibitor (recombinant RNasin) Promega 
RNase A Sigma 
sodium dodecyl sulfate BDH 
TEMED BioRad 
Tris HCl Sigma 
Tris Base Sigma 
Trypsin EDTA Invitrogen 
Tween-20 ® Sigma 
U73122 Calbiochem 
ultra pure ethanol Fisher Scientific Laboratories 
 
Phosphate buffered saline (PBS) was prepared with 155 mM NaCl, 7.7 mM Na2HPO4 and 2.3 
mM NaH2PO4 in 1 litre of UHQ. The pH was adjusted to 7.4. TBS was prepared as a 10x 
concentrated stock solution with 200 mM Tris base and 137 mM NaCl in UHQ water (pH 
7.6). It was diluted to the work solution with UHQ water before use. TBS-T was prepared 





2 ROUTINE CELL CULTURE 
2.1 Routine maintenance of cells 
MCF-12A cells (from ATCC) were cultured in 75 cm
2
 canted neck flasks (T75 flasks, Helena 
Biosciences, Gateshead, UK) with 12 ml of DMEM/F12 (1:1) medium (Invitrogen, Life 
Technologies, Paisley, UK), supplemented with 5% horse serum (Invitrogen), epidermal 
growth factor (EGF, 20 ng/ml), insulin (Sigma-Aldrich Ltd, Gillingham, UK, or Invitrogen, 
10 µg/ml), cholera toxin (Sigma, 100 ng/ml), hydrocortisone (Sigma, 0.5 µg/ml) and 
penicillin/streptomycin (Invitrogen, 5000 µg/ml). This medium is referred to as “complete 
growth medium”. 
Flasks were kept in a humified incubator at 37°C with 5% CO2. Cells were media changed 
every other day and subcultured when cells were around 70% confluent, usually every four to 
five days. 
In order to avoid changes in growth rates based on variations of the serum composition, the 
same batch of horse serum was used throughout the work for this thesis. 
2.2 Media 
Several different media were required for various stages of this work, which are described 
here: 
 Basal medium (Phenol red free medium DMEM/F12 (1:1), Invitrogen) 
 Freezing medium (complete growth medium with 20% instead of 5% horse serum, 
and additional 10% (v/v) DMSO) 
 Re-suspension medium (complete growth medium with 20% instead of 5% horse 
serum) 
 Starvation medium (Phenol red free medium DMEM/F12 (1:1), Invitrogen, 
supplemented with 0.5% (v/v) charcoal-dextran treated horse serum) 
 Assay medium (Phenol red free medium DMEM/F12 (1:1), Invitrogen, supplemented 






2.3 Sub-culturing (passaging) 
When the cells had reached around 70% confluency in the T75 flasks, they were subcultured, 
or passaged. For this, the medium was removed from the flask and cells washed once with 10 
ml Hank’s balanced salt solution (HBSS, Invitrogen). 1-2 ml of 0.05% trypsin EDTA 
(Invitrogen) was added and cells were incubated for 15-20 min at 37°C, until detached. The 
cells were then resuspended in 10 ml re-suspension medium. The higher amount of serum 
present in the re-suspension medium was required to inactivate all enzymatic action of the 
trypsin, which could have a detrimental effect on the cells. The suspension was pipetted up 
and down several times to break cell clumps, then centrifuged at 1000 rpm for 5 minutes for 
removal of the trypsin solution. The cell pellet was resuspended in fresh complete growth 
medium and cells were plated in new T75 flasks at a ratio of 1:10. Cells were used for no 
more than 10 passages after resurrection from cryopreservation.  
2.4 Cryopreservation and resurrection from cryogenic stocks 
Stocks were prepared from low passage cells. After trypsinisation (as before, see above), an 
aliquot of the cell suspension was counted to determine the total cell concentration. Cells 
were then centrifuged at 1000 rpm for 5 minutes, the supernatant was removed and the 
resulting cell pellet re-suspended in a volume of cold freezing medium that ensured the final 
cell suspension contained 10
6
 cells/ml. 1ml aliquots of the cell suspension was transferred 
into cryogenic vials (Nalgene, through VWR International, Lutterworth, UK). The vial was 
placed in a freezing container (Nalgene) that cools down the content at a constant rate of 
1°C/min when kept in a freezer and stored at -80 °C. After 24 hours, the cryogenic vial was 
placed in liquid nitrogen for long term storage. 
Cells were resurrected from cryopreservation by placing the cryogenic vial into a water bath 
at 37°C, until the medium was thawed. The cell suspension was then transferred into a 
centrifuge tube containing 10 ml of pre-warmed re-suspension medium, and centrifuged for 5 
min at 1000 rpm. The pellet was resuspended in complete growth medium and cells were 
plated in a 25 cm
2
 canted neck flask. After 72 hours, the cells were passaged and plated into 





2.5 Charcoal-dextran treatment of serum 
For some assays, the serum was charcoal-dextran (CD-) treated beforehand. This was 
necessary because serum contains an undefined mixture of lipids, hormones and other growth 
factors. In order to obtain a chemically more defined medium with lower amounts of steroidal 
hormones and other factors that could interfere with our results, the serum was treated with a 
charcoal/dextran mixture which removes lipophilic components present in the serum. Briefly, 
a suspension of 5% charcoal and 0.5% dextran T70 (Amersham, GE Healthcare Life 
Sciences, Little Chalfont, UK) was prepared in a volume of ultra-high quality (UHQ) water 
equal to the volume of serum to be treated. This was allowed to equilibrate by rolling for 30 
min (10 cycles / min) at room temperature (RT) and centrifuged for 10 min at 1000 g. The 
supernatant was then removed, and the serum was added to the charcoal/dextran pellet and 
mixed by rolling (10 cycles / min) for 1 hour at RT. The mixture was finally centrifuged for 
20 min at 50000 g and then sterilised by filtration. The CD- treated serum was stored at -
20ºC. 
3 GROWTH FACTORS 
Growth factors were kept as powders or stock solutions, as provided by manufacturers, at 
temperatures specified on the containers. Powders were dissolved as follows: 
Epidermal growth factor (EGF, Sigma) was dissolved in 10 mM acetic acid with 0.1% (m/v) 
bovine serum albumin (BSA, Sigma) to produce a stock concentration of 100 µg/ml. IGF-1 
was purchased from Sigma and dissolved into a 1 µg/ml stock solution in UHQ-H2O. PDGF-
BB was purchased from Biolegend (through Cambridge Bioscience Ltd, UK) and dissolved 
in 10 mM acetic acid with 0.1% (m/v) BSA. Stock solutions of 10 µM 17β-estradiol (Sigma) 
were prepared in ultra-pure ethanol.  
Insulin (Sigma) was kept as provided at 10 µg/ml. 
All stock solutions were diluted using basal medium to yield the required final concentrations 
immediately before use. The concentrations of the stock solutions were chosen in such a way 
as when the final solutions were prepared, the concentration of ethanol (the solvent used for 
preparing the stock solutions), did not exceed 0.1% (v/v) in the final medium. This was to 
ensure that the solvent present in the final solutions was too diluted to have an effect on cell 




The inhibitors were kept as powders as provided by manufacturers, at temperatures specified 
on the containers. Upon reception, an aliquot of each compound was dissolved into stock 
solutions which were aliquoted and kept at -20°C.  
LY294002 (Promega, Southampton, UK) was resuspended in DMSO to produce a stock 
solution of 50 mM, and was used at a final concentration of 20 µM. PD98059 (Promega) was 
resuspended in DMSO to produce a stock solution of 20 mM, and was used at a final 
concentration of 20 µM. PP2 (Sigma) was resuspended in DMSO to produce a stock solution 
of 20 mM and was used at a final concentration of 25 µM. U73122 (Calbiochem, through 
VWR International, UK) was resuspended in DMSO to produce a stock solution of 5 mM, 
and was used at a final concentration of 1 µM. 
All stock solutions were diluted using basal medium to yield the required final concentrations 
immediately before use. The final DMSO concentration never exceeded 0.1% (v/v). This was 
to exclude any effect of the solvent on cell growth or proliferation.  
Before adding the inhibitor solutions, cells were washed twice with HBSS. The inhibitor, 
diluted in basal medium, was added and the cells were incubated for 20 minutes. The medium 
was removed and fresh basal medium, containing the inhibitor at the same concentration as 
before, in addition to the growth factor(s), was added. The cells were then incubated for the 
time specified for the assay. The time pre-incubating with inhibitors was disregarded for the 
total release time. Instead, timing for the pulses was started once the growth factor had been 
added. 
5 FLOW CYTOMETRY 
5.1 Discontinuous exposure assay 
5.1.1 Seeding of MCF-12A cells 
MCF-12A cells were seeded in 6-well plates at 10
5
 cells/well, with 2ml of complete growth 




5.1.2 Serum depletion for induction of quiescence 
After attachment of the cells, the complete growth medium was removed from the wells and 
cells were washed twice with HBSS, using 2 ml buffer each time. 2 ml of starvation medium 
was added to each well, and the plates were incubated for 24 hours.  
5.1.3 Incubation with growth factors 
After the starvation period, the starvation medium was removed and each well was washed 
twice with HBSS (using 2ml each time). The growth factors to be tested were diluted in basal 
medium to the concentration required, and 2 ml of that medium was added to each well. The 
plates were then incubated for 30 minutes (duration of the first pulse). Afterwards, the growth 
factor containing medium was removed and each well washed twice with HBSS (2 ml each 
time), and fresh basal medium was added. The plates were then incubated for 3.5 hours until 
the start of the second pulse. For the second pulse, the basal medium was removed and fresh 
basal medium containing the growth factors to be tested (prepared immediately before use) 
was added to the wells. The plates were then incubated for 10 hours (duration of the second 
pulse). At the end of the incubation period, the medium was removed and all wells washed 
twice with HBSS (2 ml each time), and fresh basal medium was added and the cells 
incubated another 4 hours until the end of the assay time.  
5.1.4 Incubation with inhibitors 
5.1.4.1 Inhibitors tested during the first pulse 
When inhibitor compounds were to be tested in addition to growth factors, the cells were pre-
incubated with the inhibitor alone: after removal of the starvation medium, followed by two 
wash steps with HBSS (2 ml each time), 2 ml of basal medium containing the inhibitor to be 
tested, at the concentration required, was added to each well. The inhibitor solutions were 
prepared immediately before use. The plates were incubated for 20 minutes, after which the 
medium was removed and fresh basal medium containing the inhibitor (at the same 
concentration as before) and the growth factor was added. Countdown of the assay time was 
started now, and the plates were incubated for 30 minutes (duration of the first pulse). The 
medium was then removed and the wells washed twice with HBSS (2 ml each time) before 
addition of fresh basal medium. Cells were incubated for 3.5 hours before the start of the 
second pulse, which was carried out as described before.  
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5.1.4.2 Inhibitors tested during the second pulse 
After the first pulse (carried out as described before), the cells were incubated with basal 
medium for 3 hours 10 minutes. The medium was then removed and fresh basal medium with 
the inhibitor to be tested (solutions were prepared immediately before use) was added to each 
well. The cells were incubated for 20 minutes, after which the medium was removed and 
fresh basal medium containing the inhibitor and growth factors was added to the wells, so 
that the second pulse started at the time point t=4h as before. The plates were then incubated 
for 10 hours (duration of the second pulse) and the assay completed as described before.  
5.2 Sample preparation for flow cytometric analysis 
At the end of the assay time, the medium was removed and each well was washed once with 
HBSS (2 ml). 0.5 ml of trypsin solution was added into each well and cells were incubated, 
and after detachment centrifuged, as described before (see above). The pellet was 
resuspended in 2 ml HBSS and centrifuged again at 1000 rpm (5 min) to remove any 
remaining traces of media. 1 ml of 70% ice cold ethanol was added drop wise to the cell 
pellet whilst vortexing, and the cells were kept on ice for at least 30 min afterwards to fix 
them. Cells were either processed immediately for flow cytometric analysis or kept at -20°C 
(in ethanol) until further treatment. 
5.3 Staining of cell DNA 
After the incubation on ice, cells were spun down at 7500 rpm for 5 min, and the ethanol was 
removed carefully to avoid disturbing the cell pellet. 1 ml of cold phosphate buffered saline 
(PBS) was added to each sample, and the cells centrifuged for 5 min at 6500 rpm. This wash 
step was repeated once more. After removal of the supernatant, 50 µl of RNase solution 
(Sigma, 100 µg/ml in PBS) was added to each sample and the cells were incubated for 15 
min at room temperature. Following the RNA digestion, 450 µl of a propidium iodide (PI) 
solution (Calbiochem, 50 µg/ml in PBS) was added and the samples were kept on ice and 
covered until analysis.  
5.4 Analysis on flow cytometer 
All samples were analysed on the MACSQuant® Analyzer flow cytometer (Miltenyi Biotec 
Ltd, Bisley, UK), with the following parameters: 
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 Flow rate 100 µl/min 
 Trigger for detection was 1 µm in FSC 
 Excitation with laser at 488 nm 
 Emission was detected in channel 4 (FL4), which detected fluorescence between 655 
and 730 nm 
 A minimum of 10.000 events were detected for each sample 
The flow cytometer was calibrated before each use, according to the manufacturer’s 
instructions, using MACSQuant calibration beads (Miltenyi Biotec). All other solutions and 
buffers required for the flow cytometer were also purchased from Miltenyi Biotec. 
5.5 Data analysis with MACSQuantify™ software 
Data acquired on the MACSQuant® Analyzer flow cytometer was analysed with the 
MACSQuantify™ Software, version 2.3.1129.1 (Miltenyi Biotec).  
5.6 Data analysis with FlowJo software 
Additional data analysis was performed with FlowJo flow cytometry analysis software (free 
trial software, version 7.6, Tree Star Inc., Ashland, USA) using embedded algorithms. 
6 IMMUNOBLOTTING 
6.1 Discontinuous exposure assay 
6.1.1 Seeding of MCF-12A cells 
MCF-12A cells were seeded in Petri Dishes (10 cm). 5x10
5
 cells were seeded into each dish, 
using 10 ml of complete growth medium. Dishes were incubated for 24 hours to allow cells 
to attach.  
6.1.2 Serum depletion, incubation with growth factors and inhibitors  
After the attachment period, the cells were processed for starvation, incubation with growth 
factors and incubation with inhibitors as described before, but for each step, 10 ml of medium 
(or washing buffer) were used in the Petri dishes. 
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6.2 Sample preparation for immunoblotting 
After the relevant incubation periods, the medium was removed and the wells were washed 
with cold PBS. To each dish, 350 µl of cold lysis buffer were added and the cells were 
scraped off. The suspension was immediately boiled for 10 min at 95°C. The lysates were 
kept at -20°C until further use.  
6.2.1 Determination of protein concentration and protein separation with 
SDS-PAGE 
The protein concentration of the lysates was determined using Bradford assay. Absorption 
was read at 595 nm for each sample. To separate the proteins, SDS-PAGE was used. For this, 
1mm space glass plates (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) were utilised to 
prepare a running gel with 12% acrylamide (3.3 ml H2O, 4 ml 30% acrylamide (Bio-Rad), 
2.5 ml 1.5M Tris pH 8.8, 100 µl 10% SDS, 100 µl 10% ammonium persulfate, 4 µl TEMED 
(Bio-Rad)). On top of the polymerised running gel, a layer of stacking gel (2.1 ml H2O, 0.5 
ml 30% acrylamide, 380 µl 1M Tris pH 6.8, 30 µl 10% SDS, 30 µl 10% ammonium 
persulfate, 3 µl TEMED) was cast over, in which the wells (into which the samples were 
loaded) were created. Each well had a capacity of maximal 35 µl. The sample with the lowest 
protein concentration was used to determine the protein load (concentration [µg/µl] x 35 µl) 
for all samples, which was approximately 1 µg. For the higher concentrated samples, the 
volumes equal to this protein amount were loaded into the wells. A molecular size marker 
was added to each gel (Cell Signaling Technology (CST), New England Biolabs Ltd, Hitchin, 
UK). Proteins were separated by their mass in the running gel by electrophoresis, which was 
run for 2 hours at 80 Volt, in running buffer (190 mM glycine, 0.1% SDS, 25 mM Tris base, 
adjusted to pH 8.3).  
6.2.2 Transfer 
The separated proteins were transferred from the gel onto nitrocellulose membranes 
(Amersham) in blot sandwiches, kept in cold transfer buffer. The protein transfer was 
performed at 40 Volt (1 hour). 
6.2.3 Incubation with antibodies 
After successful transfer of the proteins onto the membranes, the membranes were blocked 
with 5% (w/v) BSA (Sigma) in TBS-T (0.05% Tween-20 (v/v) in TBS) for 1 hour at room 
temperature (RT), followed by incubation with the primary antibody at the appropriate 
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dilution for up to 2 hours at RT, or overnight at 4°C (see Table 2 for incubation conditions for 
each antibody). Then, the membranes were washed 3x 15 min in TBS-T, followed by 
incubation with the secondary antibody for 1 hour at RT. All secondary antibodies (anti-
mouse HRP-linked, or anti-rabbit HPR-linked, both from CST) were diluted 1:2000 in 5% 
BSA in TBS-T. 
 
Table 2 Overview of antibodies used for immunoblotting assay 
All antibodies were purchased from CST and used under these optimised conditions 
target dilution dilution medium incubation time 
β-actin 1:2000 5% BSA in TBS-T overnight (4°C) 
Akt 1:1000 5% BSA in TBS-T overnight (4°C) 
phospho-Akt 1:1000 5% BSA in TBS-T 2h (RT) 
Erk1/2 1:2000 5% BSA in TBS-T overnight (4°C) 
phospho-Erk1/2 1:3000 5% BSA in TBS-T 2h (RT) 
Myc 1:1000 5% BSA in TBS-T 2h (RT) 
phospho-Src 1:1000 5% BSA in TBS-T overnight (4°C) 
 
6.2.4 Protein detection 
After incubation with the secondary antibody, the membranes were washed 3x 15 min in 
TBS-T. Detection of proteins was performed by ECL reaction. The ECL buffer was prepared 
with 50 µl of luminol solution (250 mM luminol in DMSO), 25 µl of coumaric acid solution 
(90 mM coumaric acid in DMSO) and 4 µl of H2O2 in 10 ml of 100 mM Tris HCl (pH 8.5).  
Membranes were incubated for 1 min with ECL buffer, followed by exposure (10 sec to 2 
min, depending on signal strength) of hyperfilm (Amersham) to the membranes. To ensure 
that the developed band was generated from the assumed protein, the position of the bands 
were compared to the molecular size marker added to each gel.  
6.2.5 Re-probing of membranes 
Changes in the amount of phosphorylated proteins may be caused by changes in the 
phosphorylation status or by changes in the amount of total protein. To assess which one was 
the case in the MCF-12A cells, the total amount of the protein was detected on the same 
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membrane in addition to the phosphorylated protein. For this, the membranes were stripped 
of all antibodies after detection of the phosphorylated protein by incubating them for 45 
minutes (50°C) in stripping buffer (67.5 ml UHQ-H2O, 20 ml 10% SDS, 12.5 ml 0.5M Tris 
HCl pH 6.8, 800 µl mercaptoethanol). The membranes were washed 4x 10 min with TBS-T 
and then blocked again with 5% (w/v) BSA (Sigma) in TBS-T (0.05% Tween-20 (v/v) in 
TBS) for 1 hour at RT, followed by incubation with the antibodies as described before.  
7 QUANTITATIVE REAL-TIME PCR ANALYSIS 
7.1 Discontinuous exposure assay 
7.1.1 Seeding of MCF-12A cells 
MCF-12A cells were seeded in 6-well plates at 10
5
 cells/well, with 2 ml of complete growth 
medium per well, and incubated for 24 hours to let them attach.  
7.1.2 Serum depletion for induction of quiescence 
The complete growth medium was removed from the wells and cells were washed twice with 
HBSS, using 2 ml buffer each time. 2 ml of starvation medium was added to each well, and 
the plates were incubated for 24 hours.  
7.1.3 Incubation with growth factors 
After removal of the starvation medium, followed by two wash steps with HBSS (2 ml each 
time), 2 ml of basal medium containing the growth factor(s) to be tested was added to each 
well. Incubation times were according to the protocol established for discontinuous exposure 
assay, or for 12 hours continuously. 
7.1.4 Incubation with complete growth medium 
For the incubation with complete growth medium during the discontinuous exposure assay, 
all wash steps were included in order to perform the exact same procedure on all samples. 
7.2 Sample preparation for rt-PCR analysis 
At the end of the incubation time, the medium was removed and each well was washed once 
with HBSS (2 ml). 0.5 ml of trypsin solution was added into each well and cells were 
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incubated for 15 min at 37C. After detachment, the cells were centrifuged for 15 min at 0°C, 
the supernatant was removed and the cells were snap-frozen in liquid nitrogen and kept at -
80°C until further analysis.  
7.2.1 RNA extraction 
For extraction of the RNA, an extraction kit from Macherey and Nagel (NucleoSpin
®
 RNA 
II) was used according to the manufacturer’s protocol: 
The frozen cell pellet was left to thaw at room temperature, then a lysis buffer was added. 
The lysate was transferred to centrifuge columns in eppendorf tubes, and spun down at 
11,000 rpm for 1 minute, to separate the cell debris from the cytoplasm. The cytoplasm was 
centrifuged through another column to bind the RNA. An enzyme to digest the DNA was 
added, and the RNA was washed several times before elution in RNase-free water. 
7.2.2 Determination of RNA concentration 
The concentration and purity of the RNA solution was measured on a NanoDrop™ 1000 
spectrophotometer (Thermo Scientific, software version 3.7), according to the manufacturer’s 
protocol. The absorbance at 260 nm was measured, and the results of the concentration 
measurements were used to calculate the amount of the solution that was needed for 
transcription of 2500 ng RNA into cDNA. The absorbance at 280 nm was also measured to 
calculate the 260/280 ratio. This ratio was used to assess the purity of the mRNA, and a 
260/280 nm ratio of approximately 2 was regarded as acceptable (manufacturer information). 
All samples used for the work presented here were above this threshold.  
7.2.3 Reverse transcription 
For reverse-transcription of the extracted mRNA into cDNA, the volume of RNA solution 
equal to 2500 ng total RNA, 7 µl of 5x buffer, 4 µl of 10 mM dNTP, 1 µl of RNAse inhibitor 
and 1 µl of hexamer primers was pipetted. The volume was adjusted to 20 µl with RNase and 
DNase free water, and the samples were incubated in a Mini Thermal Cycler (Bio-Rad) for 
10 min at 65°C. The samples were then snap-cooled on ice for 2 minutes and 2 µl of reverse 
transcriptase (M-MLV RT, Promega) added to each sample before further incubation at 42°C 




7.2.4 Real-time PCR analysis on iCycler iQ Real-Time PCR detection 
system 
cDNA was diluted 1 in 10 in RNase/DNase free water prior to use. For each reaction, 0.8 µl 
of diluted cDNA, 10 µl of iQ SYBR Green Supermix (Bio-Rad) and the appropriate volumes 
of primers, as well as water (to give a final volume of 20 µl), were added. The sequences of 
the primers and the concentrations used are shown in Table 3. All primer concentrations have 
been optimised previously in our group, to yield between 98 and 100% amplification 
efficiency. 20 µl of the mix of each sample were pipetted into 96-well plates and analysed on 
the iCycler iQ Real-Time PCR detection system with the iCycler Software (version 3.1, Bio-
Rad).  
 
Table 3 Sequences and concentrations of primers used for PCR analysis 
Gene Primer Sequence concentration (nM) 





























7.2.5 Determination of threshold cycles 
Real-time PCR detects the fluorescence emitted by the SYBR Green molecules which are 
incorporated into double-stranded DNA during the amplification process. The more cDNA 
with the same sequence as the primer is present in the sample, the faster this set of DNA is 
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amplified, and the more fluorescence is detected in a shorter time. Each round of 
amplification is called a cycle, and the PCR detection system recognises at which cycle 
number the fluorescence intensity in the sample has exceeded the background fluorescence. 
The value at which fluorescence in the sample is detected for the first time is consequently 
called threshold cycle (Ct) and is expressed as a cycle number. Thus, the smaller the Ct value 
for a target sequence, the more of it was present in the original sample and the higher the 
expression level of this target gene was in the specimen. For amplification of the cDNA, the 
protocol provided by the iCycler iQ Real-Time PCR detection system was used, and 
fluorescence was detected in the exponential amplification phase only. The amplification 
process was performed with the following parameters: cycle 1 (1 repeat), dwell time 3 min, 
95°C; cycle 2 (step 1) 10 sec at 95°C, followed by 45 sec at 55°C (step 2). Cycle 2 was 
repeated 40 times. Cycle 3 (1 min at 95°C), cycle 4 (1 min at 55°C) and cycle 5 (10 sec at 
55°C, repeated 80 times) were performed for generation of the melting curve. The melting 
curved was used to control that the correct DNA sequence was amplified. If only the DNA 
sequence specified by the primer is amplified, the melting curve peaks at a single 
temperature, whereas contaminating amplicons have a different melting curve.  
7.2.6 Calculation of expression levels 
In order to determine from the Ct value of a target sequence if it was affected by treatment, 
i.e. if its expression level was up- or down-regulated in the MCF-12A cells as a result of the 
treatment, the values need to be compared to the Ct value of a gene that is not affected by 
treatments of the cells. Some genes are always expressed at the same levels. These are called 
housekeeping genes and are used as markers to which the target genes are normalised to. For 
the analysis of the MCF-12A cells, β-actin was used as the reference gene. Ct values obtained 
after treatment were also normalised against values from untreated cells (incubated with 
ethanol at 0.1% (v/v) in basal medium as the vehicle control). Analysis of the Ct values was 
carried out according to the Pfaffl equation (Pfaffl 2001). The method calculates the ratio 
between the target gene and the reference (housekeeping gene), taking into account the 
differences between the treated and the vehicle control samples, and generates the rate of the 





Equation 1 Calculation of absolute gene regulation with the Ct values from target and reference genes, 
according to Pfaffl (2001) 
Ratio = gene regulation, E = efficiency, target = target sequence, ref = housekeeping reference sequence, Ct = 








Methodological considerations for cell 
cycle analysis by flow cytometry 
1 PRINCIPLE OF FLOW CYTOMETRY 
Flow cytometry is a valuable tool to study a variety of questions in cell biology, including 
cell cycle analysis (e.g. degree of apoptosis after drug treatment), protein expression (e.g. 
receptor distribution) or the composition of cell populations (e.g. in blood samples) by 
analysing various parameters, such as DNA content, surface markers, or incorporated bodies, 
and this for each individual cell in the population. In this thesis, flow cytometry was used 
extensively to conduct cell cycle analysis, with the aim of determining the fraction of cells 
that have entered the cell cycle. Various methods are available for this purpose. The subject 
of this chapter is to briefly explain the principle of flow cytometry and to carry out a 
comparative analysis of methods for cell cycle analysis. 
By bringing a cell suspension into a hydrodynamically focused fluid, cell after cell passes 
through a tube into which light is sent. When the light beam hits the cell, part of the light is 
absorbed by the cells, whereas other photons are deviated. On the other side of the flow tube, 
the light is captured by a detector, and from the number of photons, and the angle in which 
these reach the detector, conclusions about the physical characteristics of the cell may be 
made. The most basic information provided by a flow cytometer is the forward scatter (FSC) 
and the side scatter (SSC). The FSC or low angle scatter is generated when the light beam 
hits the cell and is deviated slightly. The FSC is roughly proportional to the size of the cells 
(e.g. for apoptotic cells, FSC becomes smaller). The orthogonal SSC is caused by 
intracellular bodies. Therefore, the more granular the cell, the higher the SSC (e.g. 
granulocytes display a higher SSC than lymphocytes). 
Prior to analysis, cell components may be tagged with fluorophores, which in turn may be 
excited by a laser beam of the appropriate wavelength. The fluorescence emitted is captured 
by the detectors and translated into a signal which allows conclusions about the cell. For 
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example, if cell surface markers specific for tumour cells are tagged then the amount of 
tumour cells in a population can be assessed, whereas measuring the amount of apoptotic 
cells can be an indicator for the efficiency of an anti-cancer drug. In general, cell cycle 
analysis is used to study the effects of a treatment on a cell population; conversely, 
understanding the critical points of cell cycle progression in a specific population creates the 
possibility to deliver drugs in a more targeted fashion. In the following section, the flow 
cytometric analysis of the cell cycle, its underlying method and the arising limitations are 
discussed: 
The different phases of the cell cycle are characterised by their different DNA content. In the 
gap phase 1 (G1), cells possess a single set of DNA (2n), which they duplicate during the 
synthesis (S) phase of the cell cycle. The DNA quantity (4n) remains stable throughout the 
second gap phase (G2) before the cells enter mitosis (M phase). Therefore the DNA content 





Figure 2 Schematic representation of the cell cycle 
The cell progresses through gap phase 1 (G1). Once it has passed the restriction point (R point), it is committed 
to start DNA synthesis in S phase, followed by a second gap phase (G2) and mitosis (M). The cell can withdraw 
from the cell cycle (any time between completed mitosis and the R point) into the quiescent G0 phase, which 
can be induced by changes in culture conditions (cf. page 51). For each cell cycle phase (G0/G1, S and G2/M), a 
typical flow cytometric histogram is depicted (obtained from MCF-12A cells). 
 
 
Several different fluorescent dyes are available that stain specifically nucleic acids. 
Commonly used stains include diaminophenylindole (DAPI), Hoechst stains, 7-
aminoactinomycin-D (7-AAD) and DRAQ5. Each of these stains binds stoichiometrically to 
nucleic acids which makes them an excellent use for quantification of DNA. However, it also 









must be removed prior to analysis. The RNA is digested by a specific enzyme (RNase) before 
adding the stain, so that only DNA is bound.  
For the purpose of this thesis, the fluorescent compound propidium iodide (PI) was chosen 
which intercalates between the bases of double stranded nucleic acids. The maximum of the 
absorption curve of PI lies at λEx=495 nm, therefore an argon laser emitting at 488 nm is used 
to excite this dye. The maximum of the light emitted by PI is at λEm=637 nm. Prior to flow 
cytometric analysis, the cells were fixed in their shape, and the cell membrane is 
permeabilised before incubation with the DNA stain, followed by flow cytometric analysis 
(for details of the fixation protocol please refer to Chapter 2, page 19). 
Initially, all events (= single cells, stained or unstained) were recorded. A variety of formats 
is available to display the information gathered from the cell population. The basic 
representation for unstained samples is a so-called dot plot that displays the SSC over the 
FSC, shown in Figure 3. Additionally, this heat map illustrates where most cells were 
accumulated on the dot plot. Red indicates the spot with the highest cell density, and the 
cooler colours represent the least dense areas. In the example, the cells were concentrated 
between 300 and 400 AU on the x-axis, and therefore no major difference between the cell 
sizes existed (the units on the axes are arbitrary for the number of photons). The cells also 
had a similar granularity, as indicated by the SSC, with only a few events being detected 
above 600 AU. These events were likely to consist of cell clumps or, further upwards, air 
bubbles, and should therefore be eliminated from the subsequent analysis. No signals were 
detected below 300 AU, which would have been indicative for cell debris. The data analysis 
software lets the user draw manually a gate around the region of interest, and, like in this 
case, to exclude some events from the subsequent analysis (see the oval in Figure 3). The gate 
signifies the cells considered for further analysis, and the percentage of the cells within or 
outside the gate can then be calculated. It is important to assess the FSC as well as the SSC 
for each experimental set-up before the fluorescence analysis, in order to exclude any 
noteworthy changes between different cell batches (e.g. significant change in cell size), as 
well as air bubbles that are recorded as real events and can lead to misinterpretation of the 





Figure 3 Density scatter dot plot of a sample of MCF-12A cells 
The x-axis shows the FSC recorded, which allows conclusions about the size of the cells. On the y-axis, the SSC 
(intracellular complexity) is shown. The units on both axes are arbitrary for the number of photons (AU). In this 
flow cytometric analysis all the information was acquired with white light. The dots represent the individual 
events detected and the heatmap illustrates the amount of events in the respective area with red indicating a high 
and blue a low number of events. The oval shows the cell population chosen for subsequent analysis; it defines 
the gate.  
 
When cells are stained with a fluorescent marker prior to cytometric analysis, the 
fluorescence emission of each single cell is measured and can be shown on both axes in a 
similar dot plot as the basic version with white light (Figure 3), but this time with the peak 
height of the fluorescence signal versus the integral of the signal. An example for the 
detection of PI labelled cells, indicating the DNA content of the analysed cells is shown in 
Figure 4. If a homogeneous population (in terms of cell type) has been stained evenly (i.e. no 
gradient in PI concentration), the height of the signal is proportional to the intensity of the 
signal. Therefore, all events should lie on a diagonal line. Events that show a larger area 









with increased fluorescence on both axes are polyploid. An increase in signal height, with no 




Figure 4 Dot plot of fluorescence signals acquired of PI-stained MCF-12A cells 
On the ordinate, the area under the fluorescence signal is shown, whereas the x-axis represents the height of the 
signal. The sample shown is from MCF-12A cells (serum depleted for 24 hours, fixed with 70% ethanol on ice 
and stained with PI). The axes show arbitrary units of fluorescence intensity (0 to 1000 AU). The heatmap 
indicates the concentration of cells in the respective area, with red being the densest spot, and blue showing 
where fewer events were detected. The polygon drawn around the dot plot shows the cells considered for 






















The cells analysed in the example used in figures 2-8 were accumulated in the G1 phase. 
Cells in G1 are detected at around 300 AU and indeed a high density of cells was seen at this 
intensity, as shown by the red colour. Cells that had duplicated their DNA content and were 
in G2 phase emitted double the amount of fluorescence and were found at roughly 600 AU. 
Again, unwanted events (cell debris, found in the lower left corner, and agglomerated cells, 
above the diagonal) were excluded from the subsequent analysis by drawing a gate manually 
around the region of interest. In Figure 4, the percentage of cells included in the gate (i.e. all 
events inside the polygon, here referred to as the fluorescence gate) was calculated based on 
the proportion included in the scatter gate (Figure 3). Thus, 88% found in the fluorescence 
gate correspond to around 81% of the total number of events recorded initially. The number 
of cells included for further analysis, even if the gates were drawn automatically (a function 
available in some software), is variable and strongly dependent on several parameters, such 
as the cell type, the amount of serum used in the cell culture medium, and the fixative. For 
instance, cells grown in medium with a high percentage of animal serum tend to clump 
together more than cells grown in low-serum medium. However, if the proportion of cells 
detected as single events is stable (within a range), for samples prepared under the same 
conditions, it indicates that the protocol used is robust. 
After the exclusion of all unwanted events by gating them out of the initial population, the 
data from the remaining cells was used for cell cycle analysis. To this end, the dot plot was 
transformed into a single parameter histogram, which plots the cell count versus fluorescence 
intensity recorded for each cell. The fluorescence intensity can represent the height of the 
signal, the width of the signal, or, more commonly, the area under the signal. The 
representation in such a frequency histogram allows the user to more easily distinguish 





Figure 5 Frequency histogram of fluorescence signals acquired from PI-stained MCF-12A cells 
The ordinate shows the number of cells counted for each discrete fluorescence intensity, whereas the x-axis 
represents the area under the signal acquired at each intensity increment. The x-axis is graduated with arbitrary 
units of fluorescence intensity (0 to 1000 AU). The sample shown is from MCF-12A cells (serum depleted for 
24 hours, fixed with 70% ethanol on ice and stained with PI). The shaded areas were added automatically by the 
analysis software; the green shading shows the proportion of G1 phase cells, the ochre area shows the 
distribution of S phase cells, and the blue area stands for the cells in G2+M phase.  
 
The frequency histogram is also the basis for calculating the distribution of cells in the 
different cell cycle phases. In a frequency histogram, the peak furthest to the left corresponds 
to cells in G1 with the respective DNA content, whereas the second peak will be found at 
approximately double the fluorescence intensity, showing the cells in G2 phase (cells that 
have duplicated their DNA). Since it is not possible to distinguish the G2 phase from the 
early M phase, because they comprise the same amount of DNA, the second peak is usually 
referred to as G2+M. In a normally distributed population, a small (low counts), but broad 










area (equal to many different amounts of DNA per cell) in between the two peaks can be 
seen, which characterises the cells that are in the process of replicating their genome in the S 
phase of the cell cycle. The proportions found to the left of the G1 peak and to the right of the 
G2+M peak are termed sub-G1 and super-G2 respectively. The latter represents an important 
population in cancer cells, as the super-G2 portion consists of events with more than two 
copies of the DNA set (> 4n), found in polyploid cells. Accordingly, the sub-G1 population 
contains cells with less than 2n DNA. Different methods to perform these calculations are 




2 CELL CYCLE ANALYSIS – CHOOSING THE RIGHT METHODS 
Cell cycle analysis is performed by dividing a frequency histogram according to the peaks of 
the G1, S and G2+M phase. The peaks may be determined by the user, or automatically with 
the use of specific cytometry software. The differences between these methods, and the 
parameters that need to be considered when deciding for or against a specific method, are 
discussed in the following section. Furthermore, the cell cycle distributions of MCF-12A 
cells according to three different methods are presented and compared to each other, and the 
deviations between the methods are tested for their significance. 
2.1 Cell cycle phase distributions: automated calculation methods vs. 
manual gating 
2.1.1 Mathematical models used for cell cycle analysis  
The flow cytometer used in the work described here was the MACSQuant® Analyzer, with 
the integrated MACSQuantify™ Software for data analysis. This software does not perform 
automatic cell cycle analysis, but the populations in the different cell cycle phases had to be 
distinguished visually by the user, followed by manually drawing the gates for each phase. 
However, the data acquired on the MACSQuant® Analyzer can be exported into a standard 
file format (flow cytometry standard (FCS) format) and analysed with other cytometry 
software. Some commercially available cytometer programs allow automatic calculation of 
the percentages of cells comprised in each peak. As can be seen in the example in Figure 5, in 
the originally acquired curve it is particularly difficult to decide visually where the S phase 
starts and ends, because overlaps between the phases occur. In contrast, when analysing the 
data automatically, the overlaps are taken into account by the mathematical estimations. 
Many different models have been developed, customized to various research goals. The 
different models use one or more of the possible model components, such as Normal 
distribution (used for the G1 and G2+M populations), a broadened rectangle, trapezoid or 
polynomial to fit the S phase, and exponential curves for the debris. 
All models make the assumption that the G1 and G2+M peaks follow the Normal 
distribution, but they differ in the way in which the S-phase component is calculated. Which 
component to choose depends on the characteristics of the sample, for example the rectangle 
component is preferred for histograms generated from solid tumours (Rabinovitch 1994). 
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It is evident that for the same sample, the results for the percentages will vary with each 
model, depending on how well the model fits the actual curve. One possibility to decide 
which algorithm is the most suitable is to determine the values for the root mean of the square 
(RMS). The RMS value states the gaps that occur where the model does not align with the 
true curve and therefore the smaller the values for the RMS are, the better the model fits the 
data. However, the RMS values from one model cannot be compared to the values obtained 
for a different calculation, and there is no absolute threshold value above which the fitted 
curve should be rejected. Instead, the RMS values acquired within the same analysis method 
should be compared to each other and ideally to an internal control sample, and the decision 
to reject an outlier is at the user’s discretion. Secondly, the mathematical curve that is drawn 
onto the sample curve should be assessed visually and rejected if major discrepancies are 
noticed. If rejected, the user must assign the peaks manually, or use a different model 
entirely. 
Two of the models that are favoured for cell cycle analysis by most analytical software, the 
Dean-Jett-Fox model and the Watson model, will briefly be discussed here. 
The algorithm suggested by Dean, Jett and Fox (Fox 1980) fits Normal distributions to the 
G1 as well as the G2 peak. It has the advantage that in addition to this, it also fits the S phase 
with a smooth polynomial curve. It is based on the model originally developed by Dean and 
Jett (Dean and Jett 1974). The original model lays a curve onto the synthesis phase, which 
was chosen to be very broad in order to account for the spreading of the fluorescence 
intensity due to staining variability or biological factors. The limitation of this model was that 
the distributions fit only where a second order polynomial can actually represent the S phase 
data. This left out many synchronised populations where actual peaks can be observed for the 
S phase population, depending on the synchronisation method and efficiency. Fox enhanced 
this mathematical model by adding a single normal curve on top of the polynomial in the S 
phase region, which should make the function fit more complex S distributions data, such as 
most synchronised populations. A central issue for this model relates to cases where a large 
amount of late S phase cells dominates the G2+M peak, and therefore the second peak is not 
easily recognised. In this case, the location of the G2+M peak and its coefficient of variation 
(CV) must be fixed in relation to the G1 peak. In this case, the CV is forced to be the same as 
that found for the G1 peak, and the peak location is a constant times the x value for G1 
(location of G1 peak maximum on abscissa, xG1). The constant is usually 1.9 for this system, 
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but the proper value to be used depends on the flow cytometer system being employed, thus 
must be determined independently by the user. 
The model developed by Watson and co-workers (Watson et al. 1987) calculates gap phase 
peaks in a way similar to Dean, Jett and Fox, but it does not attempt to construct a fit curve 
for the S phase. Instead, it calculates the probability for finding an S phase cell at each point 
of the curve. Because of this, it is applicable for most populations and therefore is the more 
widely used algorithm. It employs the following approach: 
The program starts by looking for the highest frequency of cells, where it sets a first, 
approximate value for the G1 mean and its standard deviation (SD, the width at 60% of the 
maximal height). Afterwards, a least-square fit is performed between the Normal distribution 
and the curve from the actual data (cf. RMS on page 38). In the next step it computes the 
mean and SD values for the G2+M peak. The mean for the second peak is assumed to be at 
1.75 times the G1 mean, and the SD value is again taken at 60% of the maximal height. 
Again, a least-square control between the Normal distribution and the real curve is processed. 
The least-square fit is carried out over a range of -1 to +3 SDs (for the G2+M peak) and -3 to 
+1 SDs for the G1 peak, respectively, to minimise contributions from the overlapping S 
phase proportions. Then the model constructs a probability distribution for the S phase cells. 
Underlying are the two constants kG1 and kG2, which designate the boundary between G1 
and S, and between S and G2+M, respectively, where the probability to find an S phase cell 
is exactly 0.5 each time. The values for the constants are determined in an iterative process, 
starting from estimates as before. Once the S phase distribution has been estimated, it is 
subtracted from the total histogram to obtain the plain values for G1 and G2+M. These are 
cross-checked with the initially computed ones, and if they deviate too much, the values for 
the mean and the standard deviations are adapted. This iterative process is repeated until a 
good agreement between the prediction and the actual curve is achieved (< 2.5% discrepancy 
between any two pairs) (Watson 1992; Watson et al. 1987).  
2.1.2 Variability of cell cycle analysis with the exemplary methods 
In order to make a valid decision about which method to employ for the data analysis in this 
thesis, all samples were analysed for their cell cycle distribution by 3 different means, and the 
results obtained by the three approaches were compared: 
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Firstly, the model of Dean-Jett-Fox was used for automatic estimation of the percentages for 
each cell cycle phase. This algorithm places a Normal distribution on the two G peaks, and 
additionally a polynomial component on the S phase curve. 
Secondly, the algorithm according to Watson was applied to the samples and the cell cycle 
phase figures calculated automatically. The Watson model fits a Normal distribution onto the 
G1 and the G2+M peak, and calculates the S phase proportion by computing the probability 
to find a S phase cell at every channel (along the abscissa).  
The third method consisted of drawing the gates manually for the three main phases. This 
was accomplished by initially analysing one sample that allowed for good visual 
differentiation between the different cell cycle stages, which was always the negative control 
sample, i.e. cells that had been serum-depleted for 24 hours and therefore accumulated in the 
G1 phase. In these samples, the first peak (G1 phase peak) was relatively sharp which 
facilitated setting the limits. Once the gates had been set on this population, the exact same 
gates were applied to all other samples in the same experiment (i.e. equivalent batch of cells 
and preparation for flow cytometry and cytometric analysis on the same day). The gates 
obtained in this way were only adjusted if major differences in the scatter or the fluorescence 
dot plots were observed; the latter is the case when the fluorophore : DNA ratio is altered, 
either due to a sample containing a much higher (or lower) number of cells and / or a 
significantly different amount of fluorescent dye in the sample, therefore changing the overall 
number of emitted photons. If the values for the control samples (i.e. a sample that should 
show the same cell cycle phase distribution for every independent experiment) are 
comparable between batches, and the analysis is done by the same user, this analysis can be 
as accurate as a mathematical model. This is true especially if many samples have very 
differently shaped curves, because in these cases, the model curves set by the automatic 
system must be adapted yet again manually by the user.  
For the following section, one sample was chosen as representative example, with the 
purpose of demonstrating in more detail the differences between the methods, when applied 
on the same data set. The representative sample was a negative control, i.e. cells had been 
serum-starved for 24 hours to accumulate them in G1 phase. The raw data obtained by flow 
cytometric analysis was used subsequently for analysis by the three different methods 
described before. The various steps that are taken for the analysis by each approach will be 
shown in more detail, and the cell cycle phase distributions obtained through each method 
will be presented. As will become apparent in the following section, the results vary from one 
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method to the other, and the reason for these differences shall be discussed in more depth, in 
order to explain the rationale behind the selection of the method, used in the remainder of this 
thesis.  
Figure 6 shows the cell cycle profile of a sample that was chosen for the comparative analysis 
(MCF-12A cells, 24 hours serum-depleted for accumulation in G1 phase). The data was 
acquired with a MACSQuant® Analyzer, and was either analysed manually using the 
integrated software (MACSQuantify™), or transformed from mqd format into fcs format (cf. 
page 37) and re-analysed automatically using FlowJo™ software (Tree Star Inc., version 7.6, 
free trial license) with the embedded algorithms. 
 
 
Figure 6 Frequency histogram of fluorescence signals, as acquired on the MACSQuant® Analyzer 
Fluorescence signals were acquired from PI-stained MCF-12A cells (serum depleted for 24 hours and fixed with 
70% ethanol on ice). The ordinate shows the number of cells counted for each discrete fluorescence intensity, 
whereas the x-axis represents the area under the signal acquired at each intensity increment. The x-axis is 




2.1.2.1 Analysis applying the algorithm based on Dean-Jett-Fox 
The pink line in Figure 7 represents the curve as calculated by the Dean-Jett-Fox-algorithm 
and is fitted onto the acquired data. The Normal distribution for the G1 peak, as estimated by 
the mathematical model, is shown in green, the Normal distribution for the G2+M peak is 
coloured in blue, and the ochre area shows the distribution of the S phase cells. For each cell 
cycle phase, the following percentages were calculated: G1=63.3%, S=12.8% and 
G2+M=17.5% (RMS=2.4). This algorithm models the S phase by adding a polynomial curve 
to it, and hence its estimate is not as precise as the actual (experimentally observed) curve 
shown in black. A difference is also seen for the G2+M peak, since not the entire area is 
covered by the model. 
 
Figure 7 Analysis of frequency histogram based on Dean-Jett-Fox model 
Example of flow cytometric data represented as frequency histogram and analysed with the Dean-Jett-Fox 
model: the algorithm (pink curve) is fitted to the experimentally observed curve (black). Green shows the area 
attributed to the G1 peak, the ochre area represents the S phase population, and blue shows the area of the 
G2+M peak. Axis labelling: y-axis shows cell count, x-axis shows the fluorescence intensity based on the area 
under the signal, in arbitrary units (0 to 1000 AU). 










2.1.2.2 Analysis applying the algorithm based on Watson 
Next, the same sample was subjected to an automatic analysis using the Watson algorithm. 
For each cell cycle phase, the following percentages were determined by the software: 
G1=62.5%, S=15.7% and G2+M=15.1% (RMS=2.5). As can be seen in Figure 8, the pink 
model fits neatly onto the acquired black curve, and the peak of the G2+M phase cells is 
found at twice the fluorescence intensity of G1. The sub-G1 frequency (5.3%) and super-G2 
(2.1%) are also estimated, but no model curve is used for these populations. Simply, 
everything to the left of the G1 peak is considered as the sub-G1 population, likewise for the 
super-G2 to the right hand end of the histogram. It will be noticed that the percentages, when 
added up, exceed 100% because the overlapping areas are not subtracted from each other, as 
the values derive from estimates for each phase. 
 
Figure 8 Analysis of frequency histogram based on Watson model 
Example of flow cytometric data represented as frequency histogram and analysed with the Watson model: the 
algorithm (pink curve) is fitted onto the actual curve (black). Green shows the area attributed to the G1 peak, the 
ochre area represents the S phase population, and blue shows the area of the G2+M peak. Axis labelling: y-axis 
shows cell count, x-axis shows the fluorescence intensity based on the area under the signal, in arbitrary units (0 
to 1000 AU). 










2.1.2.3 Analysis with manually set gates 
Since the sample chosen for this analysis was derived from cells that had been accumulated 
in the G1 phase, the resulting G1 peak was reasonably sharp and the limits could be set 
relatively straightforward (Figure 9). However, the border between the S and the G2+M 
phase was not easily distinguished visually. It was taken into account that the value for the 
G2+M peak should be calculated from the G1 phase (G2 = 2x G1) and the gate was set 
accordingly. The frequencies for the sub-G1 and the super-G2 populations were based on 
visual estimations only. Obviously, these also depended on how narrow the gates for the 
other peaks were set, but contrary to the main peaks, these were not of interest and variations 
were neglected. The proportion of cells in S-phase resulted from the gate positioned between 
the G1 and G2+M gates. Generally, this method underrates the amount of cells in the 
synthesis phase, because the overlaps between G1 and S, as well as between S and G2+M, 
cannot be estimated.  
The manual analysis yielded the following results for this sample: G1=69.9%, S=8.6%, 
G2+M=18.8%, sub-G1=1.3%, super-G2=1.4%. Since the boundaries for the different phases 
are not set overlapping, the total estimates must add up to a total of 100%. This is different 
for the automated calculations, and an overview of the final results obtained by the three 




Figure 9 Analysis of frequency histogram based on manual gating 
Example of flow cytometric data represented as frequency histogram and analysed with manually drawn gates 
for each cell cycle phase. Axis labelling: y-axis shows cell count, x-axis shows the fluorescence intensity based 
on the area under the signal, in arbitrary units (0 to 1000 AU). 
 
Table 4 Overview of results from cell cycle phase calculations 
Three different methods were used to analyse the same sample for calculating the percentages for the cell cycle 
phases.  
[%] Dean-Jett-Fox Watson Manual 
G1 63.3 62.5 69.9 
S 12.8 15.7 8.6 
G2+M 17.5 15.1 18.8 
sub-G1 - 5.3 1.3 
super-G2 - 2.1 1.4 
sum 93.6 101.3 100 
RMS 2.4 2.5 - 
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In summary it can be said that analysis with the Watson model resulted in higher S phase 
percentages than the application of the Dean-Jett-Fox algorithm. The Dean-Jett-Fox model 
again yielded higher S phase percentages than the manual analysis of the frequency 
histograms. Based on the results with the one sample chosen as an example, it was important 
to understand if this was a general feature for similar analyses on the same cell line. More 
importantly, it should be excluded that the result obtained with one algorithm depended on 
the cell cycle distribution of the sample. This means, no pattern in the outcome should be 
seen, e.g. that all samples with a high G1 percentage always yield the highest S phase 
percentage with the Watson model, but that this is not the case anymore when G1 is lower. 
Hence, two questions need to be answered: 
Is the finding that the sum of S+G2+M phase percentages are highest with the Watson 
algorithm and lowest with the manual analysis a general feature of this analysis? And if not, 
does the percentage found with each method depend on the cell cycle distribution of the 
sample? 
In order to answer these questions, a systematic comparison between the three methods of 
frequency histogram analysis for all samples presented in this work was performed. The 
findings are discussed in the following section. 
 
2.1.3 Systematic comparison of results obtained by the exemplary methods 
Since the results of the work performed for this thesis were expressed by the differences in 
the number of cells able to progress into the cell cycle, i.e. to leave G1 phase, the sum of the 
percentages found for S and G2+M phase was calculated. Thus it was more useful to 
document the differences between the samples in terms of this sum, rather than to compare 
the absolute values for each phase of each sample, for evaluating the three different methods 
for cell cycle phase analysis. In order to compare the methods, the differences between the 
sums of S+G2+M phase for all analysed samples were calculated. In total, 511 samples 
analysed with flow cytometry are presented here. Table 5 gives an overview of how many 
samples were found to be different from each other through the different methods, and to 
what extent. It was decided to assess the number of samples different for each method in 
relation to the manual method, because with the user-based approach, the gates for the 
distinct phases were set manually solely on the negative control (i.e. serum-depleted, G1 
phase accumulated cells), and these very gates were then applied to all other samples. 
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Therefore this method provided a good origin for comparisons between the negative control 
and treated samples.  
 
Table 5 Overview of the total number of samples found to be different for the three approaches for cell 
cycle analysis 
The sum of the percentages obtained for S, G2 and M phase was calculated for each sample, for each analysis 
method. The difference between the sums obtained with the three different methods was calculated for each 
sample.  
difference in the 
percentages of the 
sum of S+G2+M 
number of samples found to be different 
 S+G2+M (Watson) – 
S+G2+M (manual) 
S+G2+M (Dean-Jett-Fox) – 
S+G2+M (manual) 
S+G2+M (Watson) – 
S+G2+M (Dean-Jett-Fox) 
<-10% 19 96 33 
<-5 to -10% 28 20 43 
<-0.1 to -5% 55 45 137 
from 0 to 5% 222 168 171 
>5 to 10% 118 96 36 
>10 to 15% 51 40 14 
>15% 18 46 77 
 
The automated analyses were performed subsequently with the aim of possibly increasing the 
significance between negative controls and treated cells, because the manual method often 
underestimates the S phase. Since this was the phase of outmost importance for the work 
presented here, a model that takes this phase into account more precisely was preferred. The 
differences between the approaches mainly arise from the overlaps between S and G1 phase, 
which could not be taken into account with the manual method. This is a clear disadvantage 
of the manual approach, and another reason for preferring an automated calculation for the 
final analysis. The overview in Table 5 was generated in order to evaluate precisely which of 
the two models was more suitable. The majority of samples (340 out of 511) analysed using 
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the Watson model included no more than 10% more cells in S+G2+M phase than the original 
results (“original” refers to the values obtained with manual gating). Surprisingly, for some 
samples (102 samples), the Watson model calculated less cells in S+G2+M phase than the 
manual method. However, this was still less often the case than with the Dean-Jett-Fox 
model. The finding that this other automated calculation underestimated more often the 
amount of cells in S+G2+M phase had already been suspected, because when looking at the 
modelled distributions, they did not match well the true curve, as seen in Figure 7. 
Nevertheless, a systematic analysis of the deviations between the methods was performed. 
Firstly, a comparison of the sum of S+G2+M phase percentages was carried out by 
performing a Student’s t-test for all 511 samples, analysed by the three methods, which 
showed that no significant difference exists between the results obtained by the distinct 
methods (Table 6).  
Table 6 Overview of the differences between the three methods analysed 
The mean was calculated for the sum of S+G2+M phase percentages obtained with each analysis method for 
511 samples. The differences between the methods are not statistically significant (Student’s t-test, P=0.01). 
 mean [%]  SD 
manual gating 29.7 ±16.3 
Watson algorithm 33.2 ±17.4 
Dean-Jett-Fox algorithm 34.0 ±18.2 
 
Next, the samples were analysed based on the differences between two methods. Albeit not 
statistically significant, as presented in Table 6, it must be excluded that these differences 
occurred following to a trend, since clearly this would bias the choice of the best suited 
method. Notably, the deviation must not be generated according to the cell cycle distribution 
(since this was the parameter by which samples were distinguished). First, the deviation 
between the manual and the Watson method was assessed. To this end, all samples were 
expressed as the difference in the sum of S+G2+M phase between manual analysis and 
analysis with the Watson algorithm. Then, these values were divided into three groups. Group 
1 consisted of the samples with the majority of cells in G1 phase (319 samples), group 2 
included the samples were S phase cells were predominant (107 samples), and the samples 
with mostly G2+M phase cells were in group 3 (77 samples). (The division was based on the 
original results obtained with the manual gating analysis.) A Student’s t-test was then 
49 
 
performed between two groups. It was expected that no statistical significance between the 
mean values of the groups was found, because only then could be excluded that the deviation 
between the analysis methods was due to the cell cycle phase distribution. Indeed, the 
difference between the mean values of all possible comparisons between the groups (group 1 
with group 2, group 2 with group 3 and group 1 with group 3) was statistically not relevant, 
as shown in Table 7. The same analysis was then performed for the deviations between the 
Dean-Jett-Fox model and the manual gating method, also shown in Table 7. Here it was seen 
that for the samples that were found to be in G2+M phase, the difference in the cell cycle 
analysis between the Dean-Jett-Fox algorithm and the original method was statistically 
significant, meaning that the outcome for each method was highly dependent on the phase 
distribution. This is due possibly to the shape of the frequency histogram which makes it 
difficult to find the correct cut off between the S phase and the G2+M phase peaks. The 
reason why such an important difference is found between the manual and the Dean-Jett-Fox 
method, but not with the Watson model, lies in the mode in which the two algorithms 
generate the models on the actual curves. The Dean-Jett-Fox algorithm fits a polynomial 
curve on the S phase distribution which is especially problematic with samples having a large 
number of (late) S phase cells, as discussed before (cf. section 2.1.1 of this chapter). In 
contrast, the Watson algorithm calculates the probability of finding an S phase cell at each 
point and therefore provides a model much closer to the actual curve.  
 
Table 7 Overview of the differences between the methods 
Samples were expressed as the difference in sum of S+G2+M phase percentages obtained with manual or 
Watson or Dean-Jett-Fox method, respectively. The values obtained were divided into 3 groups according to the 
cell cycle distribution of the sample and a Student’s t-test was performed between the groups. Shown are the 
mean values of the differences for each group (standard deviation in brackets). The value that is statistically 
different from the other groups is marked with *** (P=0.01). 
 sum S+G2+M 
(Watson - manual) 
sum S+G2+M 
(DeanJettFox - manual) 
group 1 (G1 phase samples) 4.02% (±7.6) 1.45% (±17.4) 
group 2 (S phase samples) 3.70% (±8.5) -0.87% (±17.4) 




2.1.4 Summary of results obtained by the exemplary methods 
Since it is preferable to eliminate subjective analysis of samples, generated during the gating 
applied by the user, the aim was to find an automated algorithm for cell cycle analysis of the 
MCF-12A cells. Due to the method of manual gating, differences between this method and an 
automated analysis were found, as expected. It was important, however, to assure that this 
was not a systematic error, for example depending on the cell cycle phase distribution. 
Hence, a systematic analysis of the differences was performed. The deviations between the 
results obtained with manual gating and the model according to Dean-Jett-Fox were caused 
by the method underlying the automated algorithm and resulted in a systematic error when 
the frequency histogram displayed a large number of G2+M phase cells. Therefore, this 
algorithm was not suitable for cell cycle analysis of the MCF-12A cells. In contrast, the 
differences between manual gating and the Watson model were not significant and in good 
agreement with each other. Besides, this model generates curves very close to the true data 
because of the theory underlying the algorithm (discussed above in section 2.1.1 of this 
chapter).  
2.1.5 Discussion 
All the results presented in this thesis were initially analysed manually with the 
MACSQuantify™ Software, i.e. the software generated a frequency histogram in which the 
gates for the cell cycle phases were positioned. In each batch, the negative control samples 
were analysed in this way first, and then the gates were applied to the remaining samples of 
the same batch. However, this software was developed specifically for analysing clinical 
blood samples with a focus on population studies. Furthermore, the algorithm by which this 
software transforms fluorescence signals into a frequency histogram is not well suited for 
subsequent cell cycle analysis (personal communication from manufacturer). Additionally, 
the data analysis requires manual input from the user, resulting in possibly significant inter-
experimental variations. 
In order to pool data acquired in independent experiments, automatic analysis is preferable. 
The commercially available Flow Jo software was specifically developed for cell cycle 
analysis and was suitable to apply with the data acquired from MCF-12A samples. Therefore 
a second stage of analysis was performed, where all samples were subjected to an automated 
calculation with the FlowJo software (version 7.6). Two different mathematical models were 
explored for the analysis, one based on Dean-Jett-Fox, and one according to Watson (Watson 
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et al. 1987; Fox 1980). In general, both automatic calculations yielded higher numbers for the 
S phase than the manual system, the main reason being that all phases are shown in an 
overlapped manner in the histogram, which cannot be estimated visually, whereas the 
mathematical models take these portions into account to some extent. However, the same 
problem may persist even when an automated approximation is used, as was found in a 
comparative review of many models carried out by Baisch and colleagues (Baisch et al. 
1982). The methods they compared yielded reasonably accurate numbers for each cell cycle 
fraction (relative error between 10 and 20%), but also here, mostly the G1 part tended to be 
overestimated, and the S phase value to be underestimated. In addition, variations in the 
shape of the S phase distribution caused considerable errors. These can be corrected by the 
user but not automatically, which is a clear advantage of the manual method. 
With the samples analysed for the present work, it was noticed that with the Dean-Jett-Fox 
calculations, the G2+M peak had to be adapted quite often by the user. This was due to the 
fact that this model assumes the G2+M peak at 1.9x the cell number corresponding to the G1 
value (cf. page 38) hence the proportion of the second peak became much greater. However, 
it was more appropriate to place the second peak at 2x the G1 peak. This was one reason for 
deciding against the Dean-Jett-Fox model. The second reason was the fact that it models the 
S phase populations. Since this was the fraction of outmost interest, the model according to 
Watson was more appropriate because it actually calculates (iteratively) the percentage 
contained in this population. Indeed, by visual comparison, the curves proposed by the 
Watson approach seemed to fit better the original data. Thus, the Watson model was 
preferred over the Dean-Jett-Fox model. Furthermore it was decided to present the findings as 
calculated by the automatic software, according to the Watson model, rather than the results 
found with the manually drawn gates in order to eliminate variations emerging from the user. 
When a difference >±10% was noted, the histogram was assessed visually to detect the 
reasons for such major discrepancies between the original curve and the model, and the 
model distributions were subject to manual corrections, if appropriate.  
2.2 Methods for synchronisation of human normal mammary epithelial 
cells (MCF-12A cell line) 
To evaluate the effect of a treatment on cell cycle progression and to make it comparable to 
untreated controls, the cell populations under investigation should be at the same point of 
“departure” in the cell cycle. To achieve this, it is crucial to synchronise the populations 
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beforehand, so that the results obtained at the end of the treatment are comparable to each 
other without bias. To minimise the variability of cell synchronicity and make the results 
comparable within and between experiments, an effective synchronisation method had to be 
determined for the cell lines in use for this work. 
The synchronisation of a cell population may be achieved by different means. One example is 
the method of the mitotic shake off, which takes advantage of the fact that cells round up 
shortly before and during mitosis and therefore are less attached to the cell culture dish. This 
method, first described in the 1960s (Terasima and Tolmach 1963), is suitable for all 
adherently growing cell types, but yields only very low numbers of mitotic figures, because 
mitosis represents a very short process within the total length of the cycle, so that only a 
small number of cells are found in M phase at any given time in unsynchronised cultures. 
More efficient are protocols that halt the onset of specific cell cycle phases and so accumulate 
the population in the previous phase. For example, in mammalian cells, the nucleoside 
thymidine interrupts DNA synthesis, when added in excess to the culture. As a result, the 
cells are blocked at the boundary between G1 and S phase, with very high efficiency (Puck 
1964). However, if the events that are taking place in the G1 phase are to be studied, this 
method may be less suitable. 
A method of choice for reversibly blocking cells before the onset of G1 is serum depletion. 
Cells in culture usually require relatively high amounts of serum in the culture medium for 
healthy growth and proliferation. Serum provides many factors essential for cell growth and 
proliferation, such as hormones and cytokines, and for cells in suspension it also provides 
some protection against shear stress. When the cells are depleted of serum for a long enough 
time (usually 24 to 72 hours), because of nutrient starvation they will withdraw from the cell 
cycle and go into the quiescent G0 phase. Upon addition of serum, the starved cells will 
resume the cell cycle and progress through G1 phase. The efficiency of this method depends 
on several parameters, mainly the reduction in serum concentration, the duration of serum 
depletion and the ability of the studied cells to survive under these conditions. The lower the 
percentage of serum contained in the culture medium, the higher synchronicity is achieved, 
but a compromise must be found between the highest amount of serum sufficient for G0 
accumulation, and the lowest amount tolerated by the cells over a longer period. Greater 
synchronicity may also be achieved by extending the depletion period, although a starvation 
period of one full cell cycle length should be sufficient for maximal G0 blocking. A high 
degree of G0 accumulation might also come at the cost of fewer cells being able to re-enter 
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the cell cycle. When decreasing the amount of serum in the culture medium and choosing the 
duration of starvation, the characteristics of the cell line need to be considered. Generally, 
tumour lines tolerate well the complete removal of serum for up to 3 days, whereas cells 
derived from normal tissue are more delicate and require a minimal amount of serum at all 
times for survival. For these, a starvation period of 24 to 48 hours is often sufficient for 
synchronisation. 
The synchronicity achieved is also a fair indicator of the overall health of the cell culture, and 
of potential variations in the following cell cycle progression: it is possible to synchronise the 
same cell line to approximately the same degree (more or less), but when one batch shows a 
substantially higher rate of synchronisation (for example, 90% vs. usually 80%), this surge 
could indicate a problem within the culture (e.g. a higher rate of apoptotic cells that were 
counted towards the G1 population). The differences from one batch to the other could also 
lead to a slower cell cycle progression, or to a lower amount of cells that are able to leave the 
quiescent state (consequences for the outcome are cell-type specific). In order to screen for 
such deviations, it is important to include control samples in the analysis. Therefore, in every 
batch analysed for this thesis, a negative control sample (serum-depleted cells synchronised 
in G1 phase), a positive control sample (cells stimulated to leave G1 phase and allowed for 
release until they reached a specific point in the cell cycle), and a growth control sample 
(asynchronous population) were included to monitor if the cell batch used was proliferating 
healthily. 
2.3 Variability of synchronicity in MCF-12A cells and the need for 
normalisation 
For this thesis, the MCF-12A cell line was used. The primary cells were derived from normal 
epithelial tissue obtained during mammary reduction surgery. When put into culture, the cells 
immortalised spontaneously, and the MCF-12A cell line was generated. For the cell cycle 
progression studies performed for the work presented here, the focus was on the progression 
through the G1 phase, and therefore, the serum depletion method for synchronisation in the 
G0 phase was applied. The reduction of the amount of horse serum in the culture medium 
from 5% to 0.5% (v/v) over 24 hours resulted in approximately 70% of cells being in the G0 
phase. However, this percentage was subject to variation, with the yields for G0 ranging from 
just over 60% to almost 90% between experiments, whereas the samples within one 
experiment showed comparable synchronisation rates. In order to be able to compare data 
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from different batches and / or days, and to allow for pooling the results from different 
experiments, this variability needs to be accounted for in the subsequent analyses. The 
approach for this normalisation is explained in this section. 
To allow for a quantitative comparison of flow cytometric results acquired from different 
batches, it is essential to normalise the results to a control value: cell sizes may be different 
from batch to batch, and for fluorescence tagged samples, the amount of fluorescent 
molecules per cell may differ, due to the several steps involved in sample preparation. 
However, these were minor variations that could be neglected. With the human mammary 
cell line MCF-12A, the largest batch-to-batch variations seen resulted from differences in the 
efficiency of the synchronisation and of the ability of the cells to re-enter the cell cycle, as 
monitored by the release with a positive control (as mentioned in the previous section). 
Therefore, normalisation of the acquired data to an internal control is crucial to account for 
these variations. 
For the work with the MCF-12A cell line, the objective was to study the effect of various 
treatments on the progression of cells from the quiescent G0 state through the G1 stage into 
the S phase. The efficiency of a substance to induce cell cycle re-entry can be derived from 
the fraction of cells that were able to leave the G0 block, so the sum of cells in S and G2+M 
phase should be measured. In our experimental approach, the cells were accumulated in the 
G0 stage by incubating them with 0.5% of serum over 24 hours; this treatment successfully 
blocked around 70 to 80% in the desired phase. However, this result also meant that at least 
around 20% of all cells continued to cycle, i.e. were present in S and G2+M. Thus, the effect 
of a treatment was expressed as the increase in S and G2+M phase percentages in relation to 
the quiescent control sample. As the aim was to study the effects of the treatments, the 
variations introduced by different synchronisation efficiencies between experiments had to be 
eliminated. This was achieved by setting the S+G2+M fraction of the (negative) control 
sample with serum-depleted cells to 1 and normalising the results from treatments and 
positive controls accordingly.  
The importance of normalising the acquired data to a control value for the work presented 
here becomes clearer by considering the following example: the data in Figure 10 shows on 
the y-axis the sum of the percentages of cells found in S+G2+M phase, as calculated by the 
cytometry software using the Watson model after data acquisition with flow cytometry. Three 
different samples were analysed, a negative control sample (serum-starved, G1 accumulated 
cells), a positive control (mitogen-stimulated, S+G2+M accumulated cells), and one treated 
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sample. This assay was repeated two more times independently, on different days, so that a 
total of three independent repeats was obtained. As can be seen, the differences between the 
experiments, although not very pronounced for the negative control samples, were 
considerable in the positive controls, as well as for the treatment. For representative purposes, 
the original histograms acquired for each sample are shown in Figure 11. 
In order to assess the reproducibility of the results, as well as the significance of the effects of 
the treatment, taking into account all independent repeats, the data had to be pooled. 
However, the raw data varied too much and could not be pooled. For this reason, the data had 
to be normalised before pooling. The normalisation was conducted by setting one of the 
control samples to 1, and setting the other samples from the same experiment in relation the 
control. This normalisation was based on the assumption that the proportion of each phase 
remains the same for the same treatment, although the absolute reading may vary between 
experiments. The variation in synchronisation is introduced for example by different cell 
densities. In order to eliminate these inter-experimental variations, the S+G2+M fractions of 
the treatment and of the positive control were normalised to their corresponding negative 
control sample. Either positive or negative control may be chosen as the baseline sample, but 
for the purpose of this thesis, the use of the negative control was more appropriate, as 
outlined above. As shown in Figure 12, this elimination of the variation introduced by the 
different synchronisation efficiency on the three different days decreased the variation 
between the treatments considerably. Finally, the data normalised in this way could be pooled 
and was suitable for further statistical analysis (Figure 13). For an overview of the range of 
percentages found in the different experiments of which the results are usually presented 






Figure 10 Example for variations in cell cycle distributions in 3 independent experiments 
Sample treatment, preparation for analysis and data acquisition and analysis was performed according to 
protocol. Results of three independent experiments are shown to illustrate the inter-experimental variations 
obtained. Negative control = serum depleted cells (G0 accumulated); positive control = cells released into 
S+G2+M phase.  
 
 

























Figure 11 Examples for variation in cell cycle histograms in 3 independent experiments 
Flow cytometric histograms of samples after identical treatments are shown to illustrate the variations between 
independent experiments (results of S and G2+M percentages are shown in Figure 10). The MCF-12A cells 
utilised for these samples are from two different batches (batch 1 used for 01/2011, batch 2 for 04/2011). 
Beneath each histogram, the sample ID, the analysis mode (“Cell Cycle”), the analysis model (“Watson”) and 













Table 8 Results of flow cytometric analysis of 3 samples from 3 independent experiments 
The percentages for each cell cycle phase for the 3 different samples presented in Figure 10 and Figure 11 are 
shown to illustrate the inter-experimental variability of the flow cytometric results. 
sampled ID treatment Freq. G1 Freq. S Freq. G2/M 
AO2011-01-19_2104.012.fcs negative control 87.5 5.17 5.9 
AO2011-01-21_2104.008.fcs negative control 82.2 9.4 2.93 
AO2011-04-08_2104.008.fcs negative control 92.9 17.2 8.05 
AO2011-01-19_2104.015.fcs positive control 71.7 10.1 15.3 
AO2011-01-21_2104.006.fcs positive control 67.8 22.7 8.71 
AO2011-04-08_2104.028.fcs positive control 58.01 34.17 7.82 
AO2011-01-19_2104.011.fcs treatment 88.19 4.81 7.01 
AO2011-01-21_2104.021.fcs treatment 78.6 14.1 3.81 
AO2011-04-08_2104.002.fcs treatment 67.9 20.2 12 
 
Figure 12 Normalised cell cycle data 
The data presented in Figure 10 (results from three independent experiments) was normalised to the respective 
negative control value, which was set to 1.  
 


















































Figure 13 Normalised data pooled from three independent experiments 
The normalised data presented in Figure 12 were pooled together; values shown are the mean of the three 
independent experiments; error bars show SEM. Student’s t-test was performed for significance testing, samples 
marked with ** (P=0.05) are significantly different from the negative control. 
 
  


















































All data presented in this work was acquired on the MACSQuant® Analyzer. The raw data 
files were transformed into the flow cytometry standard file format for data analysis. The 
method for cell cycle phase analysis was chosen to be the algorithm as proposed by Watson. 
The software to perform these calculations was FlowJo™ (Tree Star, Inc., version 7.6, free 
trial licence) with the embedded algorithm. The analysis was performed in unconstrained 
modus (no modification by the user), unless the peaks could not be detected by the algorithm. 
In this case, the user set a fixed number for the G1 peak (if visual estimation was possible), 
and forced the G2+M peak to be at 2.0 times xG1.  
For pooling the data and to compare treatments, as well as to account for differences in 
synchronisation efficiency, samples were normalised to the internal negative control (cells 
accumulated in G1), unless otherwise stated. This might occur in specific cases, as for some 
samples (depending on the treatment and the purpose of the analysis), it might be more 







Implementing the discontinuous exposure 
assay with MCF-12A cells 
1 INTRODUCTION 
Cell proliferation is a fundamental process that ends in a cell dividing into two daughter cells, 
by going through one round of the cell cycle. The description of the phases of the cell cycle 
(Figure 2) by Howard and Pelc in 1953 (Howard and Pelc 1953) was followed by a surge of 
research on cell cycle kinetics in normal and cancer tissue culture (for example, Sisken and 
Morasca 1965; Quastler 1960; and references herein). 
Identifying the substances (hormones, growth factors) that are responsible for cell cycle 
progression is rendered difficult by the presence of serum that is usually added to cell 
cultures in order to maintain them at their optimal health. Different cell types require specific 
sera, but they all have in common that these are undefined mixtures of hundreds of 
components, such as proteins, electrolytes, lipids, carbohydrates, hormones and enzymes. 
Serum also supplies factors for growth, proliferation, differentiation and attachment. 
Adjusting the concentration of the serum is a convenient method to control the proliferation 
rate of fibroblast cells (Holley 1975). Culturing cells in completely serum-free and / or a 
chemically defined medium has been attempted many times since the very early beginning of 
cell culture research (Eagle 1955), in order to identify the strictly necessary substances, to 
better understand what enables (cancer) cells to proliferate (Hutchings and Sato 1978), or to 
discover new growth factors (Karey et al. 1989; Eastment and Sirbasku 1978). Also for 
production of therapeutic products from (mammalian) cells, serum-free cultures are preferred 
(for an overview, see Jayme et al. 1997). 
When nutritional conditions are not optimal, cells can go into a quiescent state, with slowed 
down or completely halted growth. Cells survive well in this state, as demonstrated by their 
ability to resume proliferation upon re-addition of serum to the medium. The quiescent state 
can also be induced by amino acid starvation or increased levels of cAMP, as shown in 
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Chinese Hamster Ovary (CHO) cells (Rozengurt and Pardee 1972), and through high cell 
density, although this is mediated by contact inhibition rather than nutrient deprivation.  
Evidence that the quiescent state means a slowing down of metabolism to endure suboptimal 
environmental conditions, rather than a simple arrest somewhere in the G1 phase, was first 
given by Arthur Pardee (Pardee 1974). Using fibroblasts he showed that the quiescent state, 
induced by any nutrient deprivation or cAMP augmentation, stopped the cells at the same 
point of the cell cycle, since the transit time until induction of DNA synthesis was the same 
for all means of quiescence. This “lag time” stayed unchanged when the cells were kept 
under the inhibitory conditions for a prolonged time. The effect (and therefore the 
mechanism) was different when non-physiological methods were tested for cell cycle arrest 
such as hydroxyurea (stops cells in S phase because it inhibits ribonucleotide reductase) or 
colchicine (stops cells in mitosis because it inhibits attachment of tubulin to the 
microtubules).  
The concept of a “switch” in the cell, from either being committed to the cell cycle or from 
staying in the non-proliferating state, had been described some few years earlier by Howard 
Temin in chicken fibroblasts (Temin 1971). Temin also recommended a further division of 
the G1 phase into several critical stages, but Pardee suggested for the first time the term 
restriction point (R point) for the specific time in the cell cycle at which their switch back 
into the normal cell cycle occurs. The importance of this observation was acknowledged 
immediately, since Pardee suggested at the same time that malignant cells may have lost the 
control mechanism of such a restriction point, resulting in excessive proliferation. 
The return to normal cell cycle progression is achieved by restoring optimal nutrition (re-
addition of serum to the culture medium). Interestingly, the nutritive effect of serum could be 
divided into two functions, each provided for by a distinct fraction of the serum, the first 
function being to maintain cell viability, the second to induce replication (Paul et al. 1971). A 
similar idea evolved from work with Balb/c3T3 fibroblast cells, that saw the transition of 
quiescent cells into the cell cycle divided into at least two different stages, each under the 
control of a different set of mitogens (Pledger et al. 1977). For fibroblasts which had been 
depleted with platelet-poor plasma, Pledger et al. showed that upon addition of platelet 
extract, the cells resumed DNA synthesis, and cell replication took place again. Moreover, 
the percentage of stimulated cells was linear to the platelet concentration. But interestingly, to 
bring 100% of the cells into S phase, the concentration of the platelet-poor plasma had to be 
increased as well, showing that the platelet extract and the depleted plasma act synergistically 
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for maximum DNA synthesis. Inspired by these observations, Pledger and his co-workers 
were the first to introduce the concept of competence versus progression: the addition of 
platelet extracts to quiescent (contact-inhibited) cells rendered them competent to enter the 
cell cycle, i.e. to pass the R point, and this competent state lasted for several hours, but if no 
plasma was added afterwards for progression, the cells lost their ability to pass the R point. 
The rate of entry into S phase depended on the concentration of the plasma. Hence, this work 
was a first indication towards the later discovery that a sequence of signals has to be activated 
in an orderly fashion to promote cell cycle progression, and that these signals may be 
triggered by different factors.  
Much work in this field has been done using fibroblasts, where growth factors such as the 
platelet derived growth factor (PDGF) have been identified to be a major contributor to cell 
cycle progression (Balciunaite and Kazlauskas 2002; Jones and Kazlauskas 2000; Balciunaite 
et al. 2000; Jones et al. 1999; Simm et al. 1998; Harrington et al. 1987). Especially 
Kazlauskas’ group attempted to identify the signalling events that mediate the effect of 
PDGF. Taking further the discoveries made by Pledger and colleagues in 1977, Jones and 
Kazlauskas developed a discontinuous treatment assay that allowed the conclusion that 
growth factors commit cells to the cell cycle by using distinct sets of signals or pathways, at 
distinct times, and that these are not interchangeable (Jones and Kazlauskas 2001; Pledger et 
al. 1977). These observations suggested that the transition from quiescence into S phase is 
composed of (at least) two segments, the accomplishment of both depending on growth factor 
stimuli. A new terminology was proposed accordingly, with the early G1 phase (G1E) that 
follows when cells are enabled out of quiescence (and which is still poorly defined), and the 
late G1 phase (G1L) where cells are ready to be driven into S phase.  
To identify if such a segmented G1 phase is existent in human breast epithelial cells was one 
of the aims of this thesis. To address this issue, it is important to understand which factors are 
able to induce cell cycle progression in epithelial tissue, not least because most breast cancers 
originate from epithelial cells with a few excessively progressing cells. Normal cells can form 
a barrier to stop the aberrant cells from spreading. In this chapter the focus was on identifying 
growth factors that provide competence and progression to the human mammary epithelial 





The signalling pathways that are activated for proliferation in normal breast epithelial cells 
are not well known. In order to study these pathways, our aim was to investigate the 
applicability of the two-wave concept to human mammary epithelial cells. To achieve this 
aim, a discontinuous exposure assay for the MCF-12A cell line had to be set up. The specific 
objectives for this part of the project were 
 To find a suitable serum depletion protocol for synchronising these cells in the 
quiescent G0 phase 
 To identify the time point when the cells enter S phase, once they have been released 
from the starvation block 
 To eliminate the serum from the releasing medium in order to use a chemically 
defined medium 
 To test various growth factors for their mitogenic properties in this cell line 
 To establish a (time) protocol for a discontinuous release in order to be able to study 
the R point in this cell line 
3 METHODOLOGICAL CONSIDERATIONS 
3.1 Establishing a synchronisation protocol 
Several methods are described in the literature for synchronising cells derived from breast 
tissue and tumours in various stages of the cell cycle: 
 Mitotic shake off 
 Thymidine block and double-thymidine block 
 Contact inhibition 
 Serum-depletion 
The method of the mitotic shake off, takes advantage of the fact that cells round up shortly 
before and during mitosis and therefore the cells detach more readily. This method, first 
described in the 1960s (Terasima and Tolmach 1963), is suitable for all cell types, but yields 
only very low numbers of mitotic figures, because mitosis covers only a short period in the 
cell cycle, so that only a small number of cells are found in M phase at any given time. An 
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often used protocol is the addition of thymidine to the culture medium for up to 24 hours (a 
“thymidine block”). In a double thymidine block this method is used with a recovery period 
in between two exposures. The method was first mentioned by Puck more than 40 years ago 
(Puck 1964). Thymidine specifically interrupts the DNA synthesis, and when given in excess 
to mammalian cells, it arrests the cells that are in G2 phase, mitosis, or G1 at the G1/S phase 
boundary (Tobey et al. 1966). 
Serum-depletion or simply nutrient starvation forces the cells out of the cell cycle into a 
quiescent stage, the G0 phase, where they can survive for a prolonged period of time, and 
from where they can also re-enter the cell cycle when sufficient nutrients are available again. 
However, if the nutrient-depleted state lasts too long, cells will undergo apoptosis. In MCF-7 
cells, starvation for 72 hours was shown to yield a high synchronicity of 80-85%, with no 
apparent apoptosis (Yoon et al. 2004). 
Contact-inhibited cells accumulate in the G1 stage, and the mechanism by which this is 
induced is different from the other methods: when cells have grown to complete confluency 
in the culture vessel, physical contact between them triggers membrane proteins to signal that 
the cell should stop growing.  
The purpose of the work presented here was to study how a cell line of human breast 
epithelial cells (MCF-12A cell line) becomes committed to the cell cycle; therefore cells 
caught in the quiescent state were considered the most suitable material to begin with, and 
serum-depletion seemed the appropriate method to achieve G0 synchronicity.  
For all assays, the complete serum was replaced by charcoal/dextran (CD-) treated serum. 
This treatment removes lipophilic components and endogenous steroid hormones and results 
in a chemically more defined serum.  
3.2 Release of cells from G0 block 
3.2.1 Continuous exposure of cells for release from G0 block 
The ability of cells to leave the quiescent state was monitored after addition of mitogens 
following the starvation period, either in the form of serum (the starvation medium was 
replaced with fresh complete growth medium), or as chemically defined growth factors (the 
starvation medium was replaced with fresh starvation medium supplemented with growth 
factors at various concentrations). To assess efficiency in cell cycle progression, the 
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percentages of the cells in S and G2+M phase were normalised to the respective negative 
control samples (G0 blocked sample). 
3.2.2 Determination of the intervening time between administration of the 
two pulses in the discontinuous exposure assay 
The possibility of stimulating cells in a discontinuous regime with two pulses only, instead of 
continuously with mitogens, provides a valuable tool to study the events that lead to cell 
cycle progression. The incubation time for the first pulse was based on published results 
which showed that an initial burst of signalling factors is triggered after no more than 10 
minutes of contact with a growth factor in hepatocytes (Balciunaite et al. 2000) and 30 
minutes in fibroblasts (Jones and Kazlauskas 2001). The length of the second pulse, as well 
as the gap phase between the two incubations, needed to be determined specifically for the 
MCF-12A cells. Between 4 and 10 hours were tested for the length for the gap phases, and 
these times were iterated from previously published data, obtained in fibroblasts: 
 A gap of 12 hours was too long for the second exposure to be efficient (Temin 1971), 
but 8 hours between the two administrations were tolerated.  
 The small G protein Ras showed a biphasic pattern of activity in serum stimulated 
cells: it peaked very early (after 30 min), dropped and was elevated again at the time 
points between 2 and 4 hours after exit from quiescence (Gille and Downward 1999). 
This information was important to be considered because Ras is a key molecule for 
activating mitogenic signals in all cell types. 
3.2.3 Determination of growth factors to be tested 
The effect of different growth factors on cell cycle progression was tested. The growth 
factors chosen (PDGF, EGF, IGF-1, insulin) are known to be strong mitogens in many 
different cell lines, and some of them are contained in the growth medium used for the MCF-
12A cell line. 
3.2.3.1 Platelet-derived growth factor (PDGF) 
A growth factor initially discovered through the use of platelet-enriched serum and platelet 
extracts, the PDGF exists as a heterodimer (PDGF-AB) and as AA- and BB- homodimers 
(Eastment and Sirbasku 1978; Westermark and Wasteson 1976). It is one of the best studied 
growth factors, extensively used for studies on proliferative pathways, with strong mitogenic 
properties for fibroblasts and other cell lines, of different species (Ross et al. 1986). PDGF 
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was also used for discontinuous exposure of NIH3T3 cells to study the signalling pathways 
activated for G1 to S phase transition in these mouse embryonic fibroblasts (Jones and 
Kazlauskas 2001; Jones et al. 1999). 
3.2.3.2 Epidermal growth factor (EGF) 
During studies on nerve growth factors (NGF), Stanley Cohen isolated a protein from the 
submaxillary gland of mice, which showed to accelerate teeth eruption and eyelid opening in 
newborn mice (Cohen 1962). This protein turned out to be a growth factor for epithelial cells, 
and was termed epidermal growth factor (EGF). Later, urogastrone was isolated from urine, 
and identified as the human equivalent to EGF (Gregory and Willshire 1975; Gregory 1975). 
The corresponding receptor was also described by Cohen for the first time (Cohen et al. 
1980). EGF is contained in the culture medium of the MCF-12A cell line and essential for its 
maintenance in prolonged culture. Therefore it may be assumed that this growth factor is 
important for cell cycle progression. 
3.2.3.3 Insulin and insulin-like growth factor type I (IGF-1) 
Insulin and IGF-1 stimulate pathways that mediate G1 / S phase transition: in MCF-7 cancer 
epithelial cells, insulin increased the rate of DNA synthesis after long-term exposure (12 
hours), but protein synthesis was increased after only 1 hour of incubation with insulin, and 
the cell cycle progression was also markedly accelerated (Mawson et al. 2005; Rillema and 
Linebaugh 1977). Insulin is also part of the complete culture medium for the MCF-12A cell 
line. Therefore it may be assumed that this hormone has a role in supporting cell growth and / 
or proliferation.  
4 RESULTS 
Before setting up a discontinuous exposure assay, it was important to find a suitable protocol 
for serum-depletion that allowed good yields for synchronisation as well as release from the 
serum-depleted state. The results from these cytometric experiments are presented as 
percentages for each cell cycle phase, in order to determine at which time point(s) the 
percentage for S phase cells is maximal. Once a suitable depletion and release regime was 
found, it was attempted to eliminate the serum gradually from the medium; subsequently, 
instead of the serum, various growth factors were tested for their effect on the cells. For these 
assays, cells were analysed always at the same, previously determined time point, and the 
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cytometric results from then on were normalised to the negative control samples, in order to 
have a standardised basis on which results from independent experiments are compared to 
each other. A schematic overview of the sequence of experiments to be performed to achieve 
a discontinuous exposure with defined growth factors is given in Figure 14. As discussed in 
the previous chapter, flow cytometry was performed on a MACSQuant® Analyzer. The 
acquired data was transformed into flow cytometry standard files and cell cycle analysis was 
performed using FlowJo™ analysis software based on the Watson algorithm (cf. Chapter 3, 






Figure 14 Schematic overview of experimental design for the discontinuous stimulation of MCF-12A cells 
The schema depicts the sequence of experiments necessary to test the hypothesis that discontinuous stimulation 
of MCF-12A cells with defined growth factors is sufficient to induce cell cycle re-entry. After induction of 
quiescence, the cells were stimulated with complete growth medium and monitored over an entire cycle in order 
to determine the time at which synthesis phase starts. This time point was the end point for all following assays. 
Subsequently, the stimulation was performed in two distinct pulses, and the serum-containing medium was 
replaced by defined growth factors.  
48h/72h serum depletion and 
different





Release cells from quiescence with complete growth medium (continuously)
over 27 hours to monitor S phase entry
18 hours after release was determined as time point of S phase entry (Fig. 17+18)
Test continuous exposure to defined growth factors (in starvation medium);
at18 hours of continuous stimulation (Fig. 19)




stimulation with 20ng/ml EGF 
for cell cycle re-entry (Fig. 20)
Insulin and IGF-1 with little 
effect on cell cycle re-entry
Initial stimulation of 30 minutes + distinct second incubation (after intervening time of 
4 hours) is sufficient for successful cell cycle re-entry
2nd pulse = 14 hours (resulting from intervening time and total assay time of 18 hours) 
Different growth factors were tested in the first and the second incubation period
Optimal discontinuous exposure assay, used routinely for 
the remainder of the work presented (Fig. 24+ff.) 
Combination of EGF in the initial exposure, followed by EGF + insulin in the second 
exposure successful cell cycle re-entry (Fig. 22)
Assay to shorten the second exposure (Fig. 23)
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4.1 Cell synchronisation in the G0 phase through serum depletion 
Around 70% of the MCF-12A cells accumulated in the G0 phase after 24 hours of serum 
depletion, whereas a longer starvation period did not increase the number of cells blocked in 
G0, as seen in Figure 15. The cells that were not found to be in the quiescent state were 
distributed to equal parts in the other two cell cycle phases distinguishable by flow cytometry 
(S phase or G2+M phase). The lower G0 count after 48 hours of starvation very likely was 
from cells that were able to continue the cell cycle despite the low amount of growth factors 
available. In order to confirm this, cells were released into basal medium after 48 hours of 
depletion. It was expected that cells would be unable to further progress into the cell cycle, 
once all mitogens remaining from the starvation medium had been washed out. Indeed, the 
results, presented in Figure 16, confirmed this explanation, since it was observed that the 
percentages found for each phase did not change considerably over time.  
 

























Figure 15 Efficiency of serum depletion on MCF-12A cells for G0 accumulation 
Cells were incubated with 0.5% CD-treated horse serum for the times shown, and analysed by flow cytometry 
after DNA staining with propidium iodide (PI). Values are the mean of 5 independent experiments and error 




Figure 16 Release of MCF-12A cells into basal medium after 48 hours of serum-depletion 
After a serum-depletion period of 48 hours, starvation medium was removed and cells were incubated with basal 
medium for the times shown. Cell cycle analysis was performed by flow cytometric analysis after DNA staining 
with PI. The results of one representative experiment are shown. 
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4.2 Release of cells from G0 block 
4.2.1 Release with complete growth medium 
It had been shown previously in our laboratory
1
 that MCF-12A cells progress in 
approximately 18 to 21 hours out of the G0 blocked state into the synthesis phase. 
Nevertheless, the timeline of the MCF-12A cell cycle needed to be confirmed beforehand, as 
the work presented here was carried out using a different batch of this cell line. After starving 
the cells for 24 hours with 0.5% charcoal/dextran treated horse serum (CD-HS), complete 
culture medium was added to facilitate release from the G0 block. As shown in Figure 17, the 
maximum number of cells in S phase was reached after 21 hours of release. However, the 
percentage after 18 hours was almost as high, and since the overall aim of the project was to 
determine the requirements for pushing cells past the R point, which occurs several hours 
before the start of DNA synthesis, the early S phase at 18 hours from G0 onwards was 
regarded as a suitable endpoint for all subsequent assays. 
                                               
1 Alonso Gonzalez, C.: Interactions between multiple growth factors and hormones in cell cycle progression; 





Figure 17 Fraction of MCF-12A cells in S phase after release into complete growth medium following 24 
hours of serum-depletion 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS), after which the starvation 
medium was removed and complete medium was added. Cell cycle analysis was performed by flow cytometry 
carried out after staining of DNA with PI. Shown are the results of a representative experiment. 
 
4.2.2 Replacement of complete medium by starvation medium plus EGF 
As mentioned above, the complete growth medium for MCF-12A cells contains several 
growth factors. In order to establish which of these factors are necessary and sufficient for 
proliferation, they were tested in addition to the starvation medium. 
Firstly, the mitogenic properties of EGF alone were tested. To this end, G0 blocked cells 
were treated with EGF (20 ng/ml) in starvation medium (= 0.5% CD-HS in basal medium) to 
see whether this combination of growth factors was sufficient to drive the cells into the cell 
cycle. As shown in Figure 18, the pattern of accumulation of S phase cells was very similar to 
the one seen when cells were released with complete growth medium. Cells started to enter S 
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phase at 18 hours after release from block, and DNA synthesis required approximately 6 
hours. At 27 hours, cells had already begun to exit S phase. The concentration of EGF had 
been chosen according to preliminary results (cf. Appendix Figure i in the appendices’ 
section).  
 
Figure 18 Fraction of MCF-12A cells in S phase after release into starvation medium with EGF following 
24 hours of serum-depletion 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS), after which the starvation 
medium was removed and EGF (20 ng/ml) in fresh starvation medium was added. Cell cycle analysis was 
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4.2.3 Other growth factors in starvation medium 
We tested if the addition of growth factors other than EGF would yield similar results in 
terms of cell cycle progression. Insulin, IGF-1, and a combination of insulin with EGF were 
chosen. The results are presented as fractions normalised to the negative control sample. The 
addition of EGF, alone or together with insulin, in starvation medium had by far the strongest 
effect on cell cycle progression (Figure 19). Insulin or IGF-1 as the sole growth factor did not 
significantly induce progression in these cells.  
 
Figure 19 Proportion of MCF-12A cells re-entering the cell cycle 18 hours after release into starvation 
medium supplemented with various growth factors 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cells were released with EGF 
(20 ng/ml), EGF+insulin (20+100 ng/ml), insulin (100 ng/ml), IGF-1 (20 ng/ml), each in in fresh starvation 
medium, or complete growth medium (= positive control). Incubations lasted for 18 hours before flow 
cytometry analysis was performed after staining of DNA with PI. Values were normalised to negative control 





















































































4.3 Varying the intervening time between administration of the two pulses 
Next, it was necessary to test if a discontinuous exposure regimen, with two pulses of 
administration of growth factors would be sufficient to stimulate cell cycle re-entry of MCF-
12A cells. To this end, we utilised an experimental set-up where the G0 blocked cells were 
incubated during two distinct pulses of different duration with EGF (20 ng/ml) in starvation 
medium. The length of the first pulse (30 minutes) had been established from published 
reports (Jones and Kazlauskas 2001), but the gap phase between the two incubation times 
needed to be determined empirically. The results are presented in Figure 20. An intervening 
time of 4 hours from the start of the release to the start of the second exposure (meaning an 
actual waiting time of 3.5 hours after the end of the first incubation), was optimal for 
recovering most of the cells from the G0 phase into the S phase. Prolongation of the gap 
phase beyond 4 hours to 6, 8 or 10 hours led to fewer cells entering the cell cycle. The 
positive control (C+) was a sample that was incubated continuously with 0.5% CD-HS and 
EGF (20 ng/ml). 
 
Figure 20 Proportion of MCF-12A cells re-entering the cell cycle 18 hours after discontinuous exposure to 
EGF in starvation medium 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cells were released with EGF 
(20 ng/ml) in fresh starvation medium. Incubation was carried out at two distinct times; the gap phase (g) 
between the two exposures was varied from 4 to 10 hours. Flow cytometric analysis was performed after 
staining of DNA with PI. Values were normalised to negative control (G0 blocked sample, set to 1), positive 
control (C+) is from cells that were continuously exposed. Shown are the results of a representative experiment.  
 







































4.4 Omission of serum from culture media 
The complete omission of serum, from both exposure pulses, was important for all 
subsequent assays. The effect of the tested growth factor may be assessed properly only if 
interference from serum factors can be excluded. It was decided to remove the serum initially 
only from the first pulse, before removing it completely. 
To compensate for the removal of serum during the first pulse, the cells were treated with 
higher concentrations of EGF (50 ng/ml), while serum was included during the second pulse, 
with 20 ng/ml EGF plus 0.5% CD-HS (Figure 21). The number of cells able to re-enter the 
cell cycle upon discontinuous stimulation remained virtually the same when the initial pulse 
consisted of EGF only, when compared to the cells that were treated with serum containing 
medium both times.  
 
Figure 21 Proportion of MCF-12A cells re-entering the cell cycle with EGF in basal medium (first pulse) 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Incubation for release was 
carried out at two distinct times. Cell cycle analysis was performed 18 hours after start of release. Values were 
normalised to negative control (G0 blocked sample, set to 1), positive control (C+) shows results from cells that 
were exposed to 0.5% CD-HS + 20 ng/ml EGF in both pulses. Complete omission of CD-HS during the first 
pulse after serum-depletion, instead cells received EGF alone (50 ng/ml) in the first pulse, and 0.5% CD-HS + 
20 ng/ml EGF in the second pulse. The results shown are from one representative experiment. 
 











































For the subsequent experiments the serum was left out during both pulses. In all these 
experiments, EGF (50 ng/ml) was administered during the first pulse and the effect of 
different growth factors in the second pulse was tested. The investigated combinations are 
listed in Table 9.  
 
Table 9: Growth factor combinations tested in the discontinuous exposure assay 
Overview of the combinations of growth factors tested in the discontinuous experimental set-up in order to 
eliminate gradually the serum from both pulses. 
growth factor in 
1st incubation 
concentration growth factor in  
2nd incubation 
concentration 
EGF 50 ng/ml EGF 50 ng/ml 
EGF 50 ng/ml insulin 100 ng/ml 
EGF 50 ng/ml EGF + insulin 20 + 100 ng/ml 
positive control:    








The results, obtained by flow cytometry as percentages for each cell cycle phase, were 
normalised to the negative control (which was set to 1) as before and are shown in Figure 22. 
As can be seen, two samples without serum showed a very similar amount of cells in the cell 
cycle after the total release time of 18 hours to the positive control, namely the one that 
received EGF only, and the sample exposed to EGF together with insulin. It is obvious that 
the MCF-12A cells did not require serum for entering S phase after arrest in G0.  
 
Figure 22 Proportion of MCF-12A cells re-entering the cell cycle with defined growth factors 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Incubation for release was 
carried out at two distinct times, and cell cycle analysis was performed 18 hours after start of release. Values 
were normalised to negative control (G0 blocked sample, set to 1). Cells were incubated with EGF (50 ng/ml) in 
the first pulse, and the named growth factors in the second pulse; positive control (C+) was exposed to EGF in 
the 1st pulse and EGF+CD-HS in the 2nd pulse (cf. Table 9). Values show the mean of three independent 
experiments; error bars show SEM. Student’s t-test was performed for significance testing, samples marked with 
** (P=0.05) are significantly different from the positive control (C+). 
 
 













































4.5 Varying the length of the second pulse 
The discontinuous exposure regimen established thus far for MCF-12A cells has the 
following features: 
During 24 hours, cells received a reduced amount of serum of 0.5% (v/v) (instead of 5% (v/v) 
in the complete growth medium) which led to accumulation in G0. Subsequently, the cells 
were incubated for 30 minutes with 50 ng/ml EGF in basal medium, then washed out with 
aqueous buffer and left in basal medium for three and a half hours, before treatment with 20 
ng/ml EGF and 100 ng/ml insulin in basal medium. The cells were incubated until the end of 
the assay, which was determined by the length of the total release time, 18 hours, where S 
phase percentages peaked. The second incubation therefore lasted for 14 hours. Since the 
overall aim of this project was to study the signals important for inducing cell cycle entry, 
past the R point before the start of S phase, we next investigated the influence of shortening 
the duration of the second incubation. The purpose was to find out whether a shorter second 
pulse would be sufficient, in terms of yielding the same S phase figures as before, if the 
overall release period of 18 hours remained unchanged. To this end, the length of the second 
cycle was varied to last between 4 and 14 hours. When the 2
nd
 incubation was shorter than 14 
hours, the cells were incubated afterwards with basal medium once more in order to give 
them sufficient time to progress into S phase, until completion of the total release time of 18 
hours. The intervening time between the two distinct exposures was not changed (4 hours 
between the start of the 1
st
 and the start of the 2
nd
 incubation); hence the duration of the final 
cycle in basal medium was variable. It was found that a second pulse of 8 hours was 
sufficient to bring most cells past the R point (Figure 23). However, for practical reasons, a 
10 hour incubation was chosen as the standard protocol. The diagram (Figure 24) gives a 
summary of the standard protocol and its timing. This protocol was used for in-depth studies 





Figure 23 Varying the duration of the second pulse for release of MCF-12A cells 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Incubation for release was 
carried out at two distinct times. Cells were incubated with EGF (50 ng/ml) in the first pulse, and EGF (20 
ng/ml) plus insulin (100 ng/ml) in the second pulse. The length of the 2nd pulse was varied. Flow cytometry was 
performed 18 hours after start of release. Values were normalised to negative control (G0 blocked sample, set to 
1). Values show the mean of three independent experiments; error bars show SEM. Student’s t-test was 
performed for significance testing, samples marked with ** (P=0.05) are significantly different from the 
negative control (G0 blocked). The pulsed samples are not significantly different from each other.  
 
 
Figure 24 Schematic representation of the discontinuous regime 
The incubation times applied in the discontinuous exposure assay as used for the routine exposures for the 
remainder of the work presented here.  


















































It was important to confirm that the discontinuous exposure regimen as established above, 
truly reflects the distribution of the cell cycle phases as would be obtained with the complete 
growth medium (shown in Figure 17). To this end two assays were performed in parallel, one 
where cells were treated continuously with complete growth medium, the second where cells 
were stimulated according to the discontinuous exposure assay, under otherwise exactly the 
same conditions (same seeding densities, attachment and starvation period). Cells were 
analysed at different time points after the initiation of S phase. The results are shown in 
Figure 25. For better legibility, the cell cycle phases are illustrated in 2 bars only, one that 
represents the cells in G0/G1 phase, the other bar showing the percentage of cells that re-
entered the cycle, i.e. the sum of the percentages obtained for S, G2 and M phase. It can be 
seen that the fraction of cells to be found in S+G2+M phase at each time point after 
discontinuous stimulation did not differ significantly from the continuously exposed cells. 
Accordingly, the bars representing the G1 phase cells reached very similar heights with either 
treatment. This allowed the conclusion that the pulsed regimen did not alter the cell cycle, but 
that it induced the same cell cycle activities as did continuous treatment with complete 
growth medium. Therefore, the discontinuous treatment provided a good method for studying 



































G1 phase (complete medium)
S+G2+M phase (complete medium)
G1 phase (2-pulse exposure) 
S+G2+M phase (2-pulse exposure)
 
Figure 25 Comparison of cell cycle progression in MCF-12A cells released from cell cycle arrest by 
treatment with complete growth medium or by using the discontinuous exposure regimen 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed after release with continuous exposure to complete growth medium (blue bars) or with two distinct 
exposures to mitogens (EGF (50 ng/ml) in the first pulse, and EGF (20 ng/ml) plus insulin (100 ng/ml) in the 




4.6 Investigating the influence of omitting the 1st pulse 
Since the first pulse was so much shorter than the second pulse, its contribution to enable the 
cells to enter the cell cycle was unclear. The relevance of the 1
st
 pulse for cell cycle entry was 
investigated by omitting it completely (Figure 26). The total number of cells able to enter the 
cell cycle was significantly reduced when the first round of EGF was omitted. However, in 
approximately one third of all cells, the second incubation period seemed to activate 
sufficient signals that allowed them to pass the R point.  
 
Figure 26 Comparison of cell cycle progression in MCF-12A cells released with or without the first pulse 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed 18h after start of release with two distinct incubation times (EGF (50 ng/ml) in the first pulse, EGF 
(20 ng/ml) plus insulin (100 ng/ml) in the second pulse), or with the second pulse only. Values were normalised 
to the negative control (G0 blocked sample, set to 1). Values show the mean of five independent experiments; 
error bars show SEM. Student’s t-test was performed for significance testing, both pulsed samples are 
significantly different from the negative control (G0 blocked; ** (P=0.01); * (P=0.1)), but they are not 
significantly different from each other.  
 















































4.7 Combinations of growth factors in each pulse 
Apart from the routine combination of EGF and insulin (cf. Figure 24), it was of interest to 
assess other combinations of growth factors for their ability to facilitate cell cycle entry of 
MCF-12A.  
4.7.1 EGF as the sole growth factor 
As EGF in combination with a small amount of serum had such a positive effect on cell cycle 
re-entry (as seen in Figure 18 in comparison to Figure 17), EGF alone was tested in both 
exposures, but replacing the combination of EGF + insulin in the second pulse by a higher 
dose of EGF alone (50 ng/ml). The efficiency of this combination of EGF was as high as that 
of the positive control, shown in Figure 27. 
4.7.2 Insulin 
Next, the effects of the hormone insulin in each pulse were assessed. As seen in the same 
figure (Figure 27), some cells were able to leave the G0 block when they received insulin 
instead of EGF in the first pulse, but the effect was not as strong as in the positive control 
where cells were treated with EGF in the first pulse (and a combination of EGF with insulin 
in the second pulse). When insulin alone was added in the second pulse, its effect was even 
lower and closer to the percentages of the negative control, independently of which growth 
factor the cells received during the first pulse (EGF or insulin). Interestingly, the slight 
stimulation effect by insulin in the second pulse seemed to be dose-dependent, as 





Figure 27 Effect of different combinations of growth factors on cell cycle re-entry of MCF-12A cells 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed 18h after start of release with two distinct incubation times. Cells were incubated with the 
combinations shown for each bar (concentrations used were: insulin=200ng/ml; EGF=50ng/ml). Positive control 
sample (C+) was incubated with the routine combination (1st pulse EGF (50ng/ml), 2nd pulse EGF+insulin 
(20+100ng/ml), Figure 24). Values were normalised to the negative control (G0 blocked sample, set to 1). 
Values shown are the mean of at least three independent experiments; error bars show SEM. Student’s t-test was 
performed for significance testing, samples marked with ** (P=0.05) and * (P=0.1) are significantly different 



















































































Figure 28 Effect of different concentrations of insulin on cell cycle progression of MCF-12A cells released 
with the discontinuous exposure assay 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed 18h after start of release with two distinct incubation times. Cells were incubated with the 
combinations shown for each bar (EGF=50ng/ml). Positive control sample (C+) was incubated with the routine 
combination (1st pulse EGF (50ng/ml), 2nd pulse EGF+insulin (20+100ng/ml), Figure 24). Values were 
normalised to G0 blocked sample which was set to 1. Values show mean of four independent experiments, 
except from the sample with insulin=100ng/ml (n=2); error bars show SEM. Student’s t-test was performed for 
significance testing, samples marked with ** (P=0.05) and * (P=0.1) are significantly different from the positive 












































































PDGF was tested for its ability to promote cell cycle progression the discontinuous exposure 
assay, and the findings of this set of experiments are presented in Figure 29. Similar to 
insulin, PDGF was able to stimulate the cells slightly when administered during the 1
st
 pulse, 
followed by EGF in the second pulse, but no effect was observed compared to the G0 
blocked sample when it was added in the second pulse, or in both incubation periods.  
 
Figure 29 Effect of different combinations of PDGF on cell cycle progression of MCF-12A cells 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed 18h after start of release with two distinct incubation times. Cells were incubated with the 
combinations shown for each bar (concentrations used were: PDGF=50 ng/ml; EGF=50 ng/ml; EGF+insulin= 
20+100 ng/ml). Positive control sample (C+) was incubated with the routine combination (1st pulse EGF (50 
ng/ml), 2nd pulse EGF+insulin (20+100 ng/ml), Figure 24). Values were normalised to G0 blocked sample 
which was set to 1. Values show the mean of three independent experiments; error bars show SEM. Student’s t-
test was performed for significance testing, samples marked with ** (P=0.05) are significantly different from 






































































Finally, the effect of the endogenous hormone estradiol (E2) was examined. Clearly, E2 was 
unable to promote cell cycle progression in quiescent MCF-12A cells (Figure 30). 
Administration during the second pulse resulted in no difference of S phase percentages from 
the negative control sample. The percentages were slightly higher when E2 was added during 
the first pulse, but not significantly when compared to the positive control. 
 
Figure 30 Effect of E2 in the discontinuous exposure assay on cell cycle progression of MCF-12A cells 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS). Cell cycle analysis was 
performed 18h after start of release with two distinct incubation times. Cells were incubated with the 
combinations shown for each bar (E2=10nM; EGF=50ng/ml; EGF+insulin=20+100ng/ml). Positive control 
sample (C+) was incubated with the routine combination (1st pulse EGF (50ng/ml), 2nd pulse EGF+insulin 
(20+100ng/ml), Figure 24). Values were normalised to the negative control (G0 blocked sample, set to 1). 
Values show mean of four independent experiments; error bars show SEM. Student’s t-test was performed for 
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5.1 Cell synchronisation 
The human breast epithelial cell line MCF-12A was well synchronised when the amount of 
serum in the culture medium was reduced from 5% of full serum to 0.5% of CD-treated horse 
serum for 24 hours, which resulted in more than 70% of cells arrested in the G0 phase of the 
cell cycle. The remainder of the cells (approximately 30%) was able to progress through the 
cell cycle when only 0.5% of CD-HS was available, but extended starvation periods did not 
result in higher synchronicity and even led to the loss of cells through induction of apoptosis. 
In general, serum starvation never renders all cells quiescent, but for some cells it only slows 
down the process of cell division. This emphasizes once more the importance of normalising 
the flow cytometric results to the negative control (G0 blocked cells), which was discussed in 
the previous Chapter 3 (page 53). 
5.2 Cell cycle re-entry with continuous stimulation 
The cells could be released from quiescence by replacing the starvation medium with 
complete growth medium. The majority of cells reached S phase 21 hours later. The complete 
culture medium contained a variety of growth factors, originating from the horse serum used 
for supplementation, as well as from separate additions, namely cholera toxin, EGF, 
hydrocortisone and insulin. Essentially the same results were achieved when the complete 
medium was replaced with EGF in the presence of 0.5% CD-HS. However, the number of 
cells in S phase stayed high for longer (3 hours longer compared to the release with complete 
medium), indicating that the progression through S phase was slowed down. An explanation 
for this may be that EGF+0.5% CD-HS did not elicit the same mitogenic signalling pathways 
as the combination of several growth factors present in the complete growth medium. Then 
the rate of DNA synthesis would be slowed down compared to a fully stimulated population. 
This explanation is backed up by the fact that the maximal number of S phase cells is higher 
with EGF in starvation medium (in Figure 18) than with complete growth medium (in Figure 
17), because the probability of finding a S phase cell at any point of the analysis is greater, 
the longer the process of accumulating replicated DNA takes (cf. Chapter 3, page 37).  
Insulin, when tested alone to replace EGF, was ineffective in inducing cell cycle progression 
in MCF-12A cells. This was surprising, given the pronounced effects of this compounds on 
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various other cell lines (Tamm and Kikuchi 1990; Straus 1984), including malignant human 
mammary epithelial cells (Dufourny et al. 2000), and considering the presence of insulin in 
the complete growth medium for the MCF-12A cells. It is possible that insulin exerted 
proliferative properties only in conjunction with hydrocortisone (which was included in the 
complete growth medium), as was reported for MCF-7 cells (Linebaugh and Rillema 1977). 
Also, the MCF-7 cell line slightly over-expresses the insulin receptor (Oleksiewicz et al. 
2011), which might account for its more pronounced effect, and which may not be the case 
for the normal MCF-12A cells. Indeed, in rat normal mammary cells low expression of the 
insulin receptor (IR) was observed (Hvid et al. 2011). To better assess the results, an 
examination of the expression profile of the relevant receptors would be useful. 
5.3 The discontinuous exposure assay 
All observations so far were made after the cells had been stimulated continuously. Taking 
the assay further, the cells were subjected to a discontinuous stimulation with EGF+0.5% 
CD-HS. The length of the incubation periods and the intervening time between the two pulses 
was determined firstly on the basis of published methods (Jones and Kazlauskas 2001; 
Balciunaite et al. 2000; Pledger et al. 1977; Temin 1971), and then refined empirically. 
Subsequently, the serum present during both pulses was removed, and a routine experimental 
set-up, as shown in Figure 24, was established. 
The length of the first pulse (30 minutes) had been based on observations that kinases 
essential for mitogenesis were activated within 10 minutes of serum stimulation, and that 
their initial activity was required for no more than 30 minutes (Stacey and Kazlauskas 2002; 
Jones et al. 1999; Gille and Downward 1999). The length of incubation was sufficient to 
make a significant contribution to cell cycle re-entry, although a remarkable number of cells 
were able to leave the quiescent state upon incubation with the 2
nd
 pulse only. This was in 
disagreement with reports from fibroblasts, where the omission of the 1
st
 pulse resulted in 
completely unsuccessful cell cycle re-entry (Jones and Kazlauskas 2001). This difference can 
be explained with the competence / progression system assumed to be underlying cell cycle 
re-entry: cells need to receive a first input from growth factors which pushes them out of G0 
and so they become competent for the subsequent stimulation, which will result in 
progression through G1, followed by passing the R point. If the cells do not receive a first 
stimulation, but if the second pulse is strong enough (strength would possibly be determined 
by the time span that mitogens are available), the second incubation may be sufficient to 
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provide for all necessary signals. To test this possibility, quiescent cells could be incubated 
with the second pulse only (omission of 1
st
 pulse), but for a shorter period of time. A decrease 
in the number of cells in S phase after a shorter second pulse compared to a population 
exposed to both pulses (but also with a shorter second pulse, cf. Figure 23) would be 
expected. The differences in responsiveness may be attributed to variances in physiological 
factors, such as the number of receptors expressed on the membrane.  
The suggestion that the mechanism of competence and progression is in place in MCF-12A 
cells was supported by the finding that the intervening time between the two pulses could not 
be stretched beyond 6 hours, which is in good agreement with the time line suggested by 
others (Jones and Kazlauskas 2001; Temin 1971). 
5.4 Assessment of growth factors 
Having established a discontinuous experimental set-up, which allowed quiescent MCF-12A 
cells to re-enter the cell cycle upon incubation with only insulin and EGF (presented in 
Figure 24), it was attempted to find other growth factors that would have a similar effect on 
cell cycle progression. 
The most pronounced effect in terms of the percentage of cells brought into S phase was 
observed when the MCF-12A received first EGF, followed by EGF combined with insulin. 
However, application of EGF during both pulses gave nearly as strong a result, which 
provokes the question as to the actual role of insulin. It has been reported for malignant 
mammary epithelial cells, that insulin’s effect on proliferation was stronger when added in 
combination with EGF (van der Burg et al. 1988), possibly because crosstalk between insulin 
receptors and EGFR occurred, and also in combination with hydrocortisone (Linebaugh and 
Rillema 1977). That insulin indeed contributed to the progression of MCF-12A cells could be 
seen when it was given alone in the second pulse, and its effect became more pronounced 
with a higher concentration. The dose-dependent effect of insulin may be explained by 
considering that EGF alone triggers signals more potently; therefore a higher concentration of 
insulin was needed to compensate for the missing EGF and to activate pathways to the same 
extent. Interestingly, a similar pattern was observed in fibroblast cells: insulin given in the 
first pulse did not contribute to initiating DNA replication, but when used as the 2
nd
 mitogen, 
it was very powerful (Jones and Kazlauskas 2001). This points towards the concept already 
developed in the 1970s (Pledger et al. 1977), namely, that quiescent cells needed a first input 
to render them competent, followed by a second stimulus that enabled the competent cells to 
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actually progress in G1 phase. From this point of view, insulin seemed to be more of a 
progression factor than a competence factor, independently of the cell type. 
As PDGF was extensively used in fibroblast cells, it was also tested on the MCF-12A, with 
very little effect on cell cycle re-entry when used during the 1
st
 pulse, and no effect when 
used during the 2
nd
 pulse. It was suspected that the MCF-12A cell line did not express 
sufficiently the appropriate receptor, and therefore PDGF was unable to elicit mitogenic 
signalling pathways in these cells. The minor effect of PDGF during the first cycle may be 
explained by the three-dimensional structure of the isoform PDGF-BB used here. It shows 
some resemblance to the structure of the transforming growth factor-β (TGF-β). TGF-β is a 
potent ligand for the EGFR, therefore an activation of the EGFR by PDGF-BB could not be 
ruled out entirely (Heldin and Westermark 1999). More likely, however, is that here again, 
some cells received sufficient signals during the second incubation period for passing 
successfully the R point, as has been considered before (cf. page 91).  
Finally, the effect of the endogenous hormone estradiol (E2) was assessed. This was of 
special interest as estradiol plays a crucial role in the development and differentiation of the 
mammary gland, in particular of the luminal compartment (for a recent review see Bussard 
and Smith 2011) from which the MCF-12A cell line is derived. E2 increases proliferation 
through binding to the estrogen receptor alpha (ERα). The activated ER can either localise to 
the nucleus to activate proliferative genes, or act directly on mitogenic signalling pathways 
(Moriarty et al. 2006). E2 triggers cell proliferation in MCF-7 (ER+) cells (Karey and 
Sirbasku 1988; van der Burg et al. 1988), although the degree to which E2 promotes 
proliferation also depends on the culture condition, i.e. other factors present in the culture 
medium (Ruedl et al. 1990; Najid et al. 1989; Katzenellenbogen et al. 1987; Soto and 
Sonnenschein 1985).  
The MCF-12A cells express the ERα, and therefore, a positive impact of E2 on the transition 
from the G0 block into S phase was expected. Surprisingly, no significant effect of E2 was 
observed when added instead of growth factors during the discontinuous assay (Figure 30). 
This is in apparent contrast to the physiological situation where mammary gland epithelial 
cells are reliant on the input of estrogens for growth and branching. The MCF-12A cells used 
here are immortalized non-transformed cells that may well have lost their sensitivity to 
estradiol (despite the presence of the ERα). This view is supported by reports that these cells 
display very different transcriptional activities and phenotypes when cultured in a three-
dimensional context (contrary to our two-dimensional populations) which is closer to the 
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original environment in vivo (Polyak and Kalluri 2010). On the other hand, the effect of E2 
on MCF-12A cell proliferation may also depend on the expression of other, not estrogen-
related receptors. Such a dependency has been shown in MCF-7 cells: Hamelers and 
colleagues (2003) studied three different strains of this cell, each displaying a different 
sensitivity to estrogens, despite their similar ER expression activity levels (Hamelers et al. 
2003). It was found that induction of proliferation by E2 was dependent on IGF-1R 
activation, and this was blocked by antibodies for the IGF-1R, in both E2-sensitive cell lines. 
Similarly, Surmacz and Burgaud (1995) reported that overexpression of the principal 
substrate for the IGF-1R, IRS1, reduced the requirement of MCF-7 cells for E2 for growth. 
Furthermore, induction of IRS1 facilitated the cells’ growth in soft agar, which is a measure 
for malignant transformation (Surmacz and Burgaud 1995). Thus, sensitivity of breast 
epithelial cells to estrogens may be regarded as a feature of transformation to malignancy, as 
has been suggested already more than two decades ago (Nenci et al. 1988). This would 
support the opinion that the lack of effect of E2 in the MCF-12A cells indeed reflects their 
original phenotype.  
6 CONCLUSIONS 
It is intriguing that MCF-12A cells responded to a variety of growth factors in terms of 
transition from quiescence into S phase only if these were administered in a specific 
sequence. This raises several questions: 
First, what is the role of the estrogen receptor in the MCF-12A cells, if exposure to the ligand 
estradiol does not result in cell cycle progression? And secondly, what is the nature of the 
signalling pathways during the different pulsed exposures? Are similar pathways activated at 
the distinct incubation times, or do the cells employ different signalling cascades at different 






Regulation of genes by estradiol compared 
to EGF in MCF-12A cells 
1 INTRODUCTION 
As was shown in the previous Chapter 4, the endogenous hormone estradiol (E2) did not have 
a pronounced effect on cell cycle progression of MCF-12A cells when it was applied instead 
of a growth factor, during the discontinuous exposure assay. This was unexpected, since the 
hormone has a major function in the development of the mammary gland, from which the 
MCF-12A cell line was derived, and these cells express the ERα on a transcriptional and 
translational level. As such, the role of this receptor for these cells is unclear. In order to 
better define its function, the mRNA levels of genes normally controlled by the receptor were 
investigated after incubation with E2. The genes to be investigated were chosen according to 
their role in MCF-7 cells, which is the correspondent malignant line to the MCF-12A cells. 
Additionally, to compare the effect of this hormone with a truly mitogenic compound (in the 
context of MCF-12A cells), cells were treated with EGF, which was shown to have a positive 
impact on proliferation in MCF-12A cells.  
The roles of E2 and the expression of genes affected by ERα are described in this section: 
E2, together with its metabolites estrone (E1) and estriol (E3), belongs to the estrogen group 
of steroid hormones. Estrogens are involved in the development, growth and homeostasis of 
many different tissues, but their best known effects are observed in mammalian reproduction 
and the mammary gland. In contrast to most other organs, the development of the human 
mammary gland occurs mainly postnatally. Its completion requires the action of estrogens 
appearing cyclically during adulthood. The mammary epithelial cells even necessitate the 
high levels of estrogens produced only during a full term pregnancy for differentiation and 
resulting full maturation of the duct system (Polyak and Kalluri 2010). 
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E2 does play a critical role in vivo, but for obvious reasons is mainly studied in vitro. In many 
human breast cancer cell lines, the hormone induced proliferation (Papendorp et al. 1985; 
Soto and Sonnenschein 1985; Darbre et al. 1983). The proliferative effect of estrogens is 
mediated through specific receptors (Katzenellenbogen 1996), of which to date, three 
different types are known, the estrogen receptor (ER) alpha (ERα), ERβ and the G-protein 
coupled estrogen receptor (GPER or GPR30). ERα and ERβ are members of the large family 
of nuclear receptors, whereas GPR30 is a transmembrane receptor. Compared to ERα, ERβ 
has a limited expression pattern and is found mostly in the ovaries, while ERα is abundant in 
the breast and other target organs (Couse et al. 1997). In mammary epithelial cells ERα action 
is required for the normal development of the milk ducts in the gland because it signals for 
ductal elongation (Bocchinfuso et al. 2000). Thus, we will focus on the function of ERα. 
In the absence of a ligand, the receptor is held in an inhibitory complex in the nucleus of the 
target cell. Upon binding of the hormone, the ERα forms a homodimer, and translocates 
towards a specific sequence in the DNA, the estrogen responsive element (ERE). EREs are 
found in the promoter region of a gene and thus enhance the transcription of their target 
(Means and O'Malley 1972; O'Malley et al. 1968). The target is often a gene with 
proliferative characteristics, but depending on the cell, the DNA-bound receptor also can 
exert a suppressive effect on the expression of such a target gene, or bind completely 
different types of genes, such as the pro-apoptotic BCL2. The different effects (inducing or 
inhibitory) may be explained either in terms of the final conformation that the ERs take after 
ligand binding or in terms of the cell’s or promoter context, i.e. the multiple molecular factors 
present in each cell which might interact with the ligand-receptor complex, thus changing the 
ability of the complex to interact with the ERE (Ciocca and Fanelli 1997).  
A few genes with perfect ERE palindromes, i.e. a high affinity for binding the ERα, have 
been identified, but the ERα also binds to and induces transcription through an imperfect 
responsive element. Examples of genes controlled by imperfect ERE include the TFF1 and 
the BCL2 genes (Bourdeau et al. 2004; O'Lone et al. 2004). In some cases a half-ERE site is 
located in proximity to a so called Sp-1 site (the Specificity Protein (Sp-) 1 is a transcription 
factor). Binding of the activated receptor to an ERE may even be omitted completely when 
the ERα engages in protein-protein interactions instead (so-called tethering), such as with the 
activating protein 1 (AP-1) complex. AP-1 is a dimeric transcription factor composed of Fos 
and Jun, and both proteins are strong promoters of cell cycle progression and proliferation. 
Since these many different mechanisms of action of the ERα on the genome exist, the effects 
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of ERα ligand binding are diverse and differ according to cell type. The information available 
to date about the impact of estrogens on specific target genes is provided mostly by estrogen-
sensitive cancer cell lines, whereas data from normal cells is scarce.  
1.1 Genes coding for nuclear steroid receptors (ESR1 and PGR) 
Evidence from ERα-competent cell lines such as MCF-7 shows that the genes first and 
foremost affected by the endogenous hormone estradiol include ESR1, coding for ERα, which 
contains three ERE half-sites in its promoter region, and the gene PGR, coding for the 
progesterone receptor (PR). Together with estradiol, progesterone signalling is crucial for the 
normal development of the mammary gland: studies with PGR knockout mice suggested that 
progesterone is responsible for the formation of the lobes, whereas estrogens drive the ductal 
elongation in the gland. The effect of E2 on the PGR is mediated by binding of the activated 
ERα to estrogen-responsive regions (half ERE sites) located in proximity to a Sp-1 binding 
site in the regulatory region of the PGR gene (O'Lone et al. 2004; Kastner et al. 1990). The 
PGR is one of the best studied estrogen-dependent targets and a recognised marker for 
studying estrogen action (Graham and Clarke 1997), and also has been recognised to have a 
role in tumorigenesis (reviewed byAnderson 2002). 
In MCF-7 cells the ESR1 is down-regulated as a result of negative feedback provided by E2, 
whereas E2 has a highly up-regulating effect on the PGR (Silva et al. 2010; Bourdeau et al. 
2008; Cho et al. 1991; Berkenstam et al. 1989; May et al. 1989; Nardulli et al. 1988), and a 
similar gene expression pattern is expected to be found in MCF-12A cells after E2 
stimulation.  
1.2 Target gene TFF1 (trefoil factor 1) 
In MCF-7 cells, stimulation with E2, as well as with EGF increased TFF1 mRNA levels to a 
similar extent. This effect became even stronger when E2 was added together with EGF (El-
Tanani and Green 1997). The TFF1 gene codes for a secreted protein of the trefoil class, pS2, 
which can act in a growth factor-like manner, promoting cell survival and motility (Prest et 
al. 2002) and even oncogenic transformation (Radiloff et al. 2011). The pS2 protein is found 
at a higher expression level in aberrant tissue compared to normal breast epithelium (Poulsom 
et al. 1997), and for these reasons can be considered a proto-oncogene. The role of this 
protein on cell cycle progression and proliferation is less clear, since it was shown to induce 
the expression of the PRAD1 gene (coding for cyclin D1, required for G1 progression). 
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However, it can also delay the G1 to S phase transition (Perry et al. 2008; Bossenmeyer-
Pourie et al. 2002). As mentioned above, the TFF1 gene contains an imperfect palindromic 
ERE in its promoter region, and is therefore up-regulated by the ligand-bound, activated ER 
in estrogen-sensitive cells (Henry et al. 1990).  
1.3 The breast cancer susceptibility gene BRCA1 
Other genes that have been investigated in the context of mammary carcinoma include the 
breast and ovarian cancer susceptibility (BRCA1) gene, and the PRAD1 gene, coding for the 
cyclin D1 protein. BRCA1 encodes a transcription factor, which contributes to DNA repair 
functions (Scully et al. 1997), preventing aberrant DNA from being passed on to daughter 
cells and thus helping to prevent carcinogenesis (Deng 2006). Reduced levels of wild-type 
BRCA1 protein have been detected in a large percentage of sporadic breast tumours in the 
absence of mutations in the BRCA1 gene, suggesting that disruption of BRCA1 expression 
may contribute to the onset of mammary carcinogenesis (Wilson et al. 1999; Thompson et al. 
1995). The transcription of BRCA1 is regulated by diverse extracellular stimuli including 
mitogenic compounds, and provides a feedback control that monitors the growth effects of 
estrogen in hormone-responsive cells. In ERα competent cells, such as MCF-7, expression of 
BRCA1 is controlled through the binding of the receptor to an alternative ERE and an AP-1 
site in the promoter region of the gene (Jeffy et al. 2005; Xu et al. 1997). In MCF-7 cells, 
BRCA1 was induced after E2 treatment (Silva et al. 2010; Jeffy et al. 2005; Spillman and 
Bowcock 1996; Gudas et al. 1995), and an increase of BRCA1 mRNA levels would be 
expected in the non-transformed MCF-12 cells due to the effects of activated ERα on the 
BRCA1 promoter. 
1.4 Target gene PRAD1, coding for cyclin D1 (CCND1) 
The protein cyclin D1, encoded by PRAD1, occupies an important role in all cell types for 
cell cycle progression, as its expression needs to be highly increased for successful transition 
from the G1 into S phase. In non-transformed cells, PRAD1 is one of the genes that assess the 
mitogenic potential of the cellular environment during cell-cycle entry from quiescence, and 
therefore cyclin D1 acts as a control protein (the importance of cyclin D1 for cell cycle 
progression is discussed in more length in Chapter 7). During cellular transformation, such 
controls are lost, and correspondingly the PRAD1 gene is found to be overexpressed in a 
number of cancers, including breast cancer. In MCF-7 cells, cyclin D1 was shown to be 
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induced as a result of estrogen stimulation, at the mRNA level as well as in terms of protein 
expression levels (Silva et al. 2010; Sabbah et al. 1999; Prall et al. 1997; Planas-Silva and 
Weinberg 1997a; Foster and Wimalasena 1996). Both mRNA and protein level increases 
were suppressed in the presence of the ERα antagonist ICI182780, confirming that the ERα 
was involved in the transduction of the proliferative signals. Several mechanisms of action 
for inducing the gene expression are suggested, such as binding of the estrogen receptor to 
the AP-1 (Albanese et al. 1995), the CREB or the Sp-1 consensus site in the PRAD1 promoter 
(Klein and Assoian 2008).  
All the genes discussed so far (TFF1, PGR, ESR1, PRAD1 and BRCA1) have been 
extensively studied in the MCF-7 cell line by our group (Silva et al. 2010), and since this is 
the correspondent malignant line to the non-transformed MCF-12A cells, we were especially 
interested in investigating the effects of E2 on these same targets in the normal epithelial 
cells. In addition to the targets mentioned, the MYC gene is an important endpoint to be 
considered as well.  
1.5 Transcription factor MYC 
MYC codes for the Myc protein, which is a transcription factor, known to have a function in 
normal cell cycle progression. In non-transformed cells, MYC mRNA levels are up-regulated 
upon mitogen stimulation, followed by an increase in Myc protein expression (Dean et al. 
1986; Kelly et al. 1983). Aberrant cells display high copy numbers of the MYC gene, and 
such cells are prone for increased proliferation rates (Wasylishen and Penn 2010). In ERα+, 
G1 blocked MCF-7 cells, treatment with E2 resulted in a significant accumulation of c-Myc 
mRNA (Dubik and Shiu 1988; Dubik et al. 1987), which is a prerequisite for cell cycle 
progression and proliferation, and we expected to find an up-regulation of the MYC gene in 
normal cells after mitogen stimulation as well.  
2 OBJECTIVES AND METHODOLOGICAL CONSIDERATIONS 
The aim in this chapter was to examine MCF-12A cells more closely in terms of the effects 
of E2 in controlling the expression of representative genes normally regulated by ERα in cell 
lines such as MCF-7. These studies were motivated by our observation of a lack of 
proliferative effects of E2 in MCF-12A cells. This seemed paradoxical, considering that 
MCF-12A cells contain the ERα. The hypothesis to be explored was that ERα signalling in 
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these cells might be set up differently from MCF-7 cells, such that the ERα lacks the ability 
to control expression of ER regulated genes. The genes to be analysed were carefully chosen 
according to information available about their expression in the malignant epithelial cell line 
MCF-7 (ESR1, PGR, TFF1, BRCA1, and PRAD1) which reacts to E2 exposure with cell 
proliferation. The direction of gene regulation (up- or down-regulation) can then be compared 
to the effect of E2 reported for the transformed cells. However, since the endogenous 
hormone had no cell cycle promoting properties in MCF-12A cells we also wished to 
compare the effect of E2 in these cells with those of an established mitogenic compound, 
EGF, on the same target genes. To this end, MCF-12A cells were incubated for 12 hours with 
E2 or EGF, and these expression profiles compared.  
In addition to the aforementioned targets, which are genes classically influenced by the 
endogenous hormone E2, the MYC gene was also monitored. The incubation time and the 
genes chosen as targets had been determined beforehand with preliminary experiments (cf. 
Appendix Figure ii and Appendix Figure iii in the appendices’ section). 
In order to remove any estrogenic compound from the medium which could overshadow the 
effect of the added E2, cells were incubated in medium deprived of estrogens by charcoal-
dextran (CD) stripping (phenol-red free medium with CD-treated horse serum, here referred 
to as “assay medium”) for 24 hours prior to the start of the assay. The subsequent incubation 
with E2 (10 nM) or EGF (100 ng/ml) for 12 hours was performed in assay medium as well. A 
detailed description of the entire procedure is given in the material and method’s section 
(Chapter 2). 
3 RESULTS 
3.1 Effect of E2 on gene expression 
The gene expression levels seen after incubation of MCF-12A cells with E2 (10 nM) over 12 
hours were normalised to a sample incubated with the solvent for the same duration, here 
termed solvent control (set to 1 (dotted line) in Figure 31). Surprisingly, E2 failed to 
stimulate the expression of BRCA1, PRAD1 and TFF1 that would be expected to occur in 
ERα competent cells. There was also no indication of a down-regulation of the mRNA coding 
for the ERα which is also normally seen in ERα competent cells after exposure to E2. The 
mRNA levels of BRCA1, PRAD1, ESR1 and TFF1 remained very close to the levels 
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monitored in the solvent control samples. The MYC gene was slightly induced, however, due 
to the variation between the independent experiments (as seen from the error bars), the 
difference to the vehicle control were too small to be detected as statistically significant. The 
strong induction of the PGR gene usually observed in MCF-7 cells also did not occur in 
MCF-12A cells. Instead, the PGR gene seemed slightly down-regulated. In summary, the 
differences between the E2-treated samples and the solvent control samples were not 
statistically significant for any of the genes detected, and the expression pattern typical for 
other ERα competent cells was not observed.  
3.2 Effect of EGF on gene expression 
Incubation with EGF altered the gene expression profile more dramatically than did E2. EGF 
strongly induced BRCA1 and PRAD1 (both show an approximately 4 fold induction over the 
control). The between-experiment variation of the results obtained for BRCA1 were 
considerable, therefore the statistical test performed (Student’s t-test) did not indicate 
statistically significant differences to the control sample. PRAD1, on the other hand, was 
induced by EGF, and the differences in mRNA levels to solvent control reached statistical 
significance (P=0.05). The genes coding for the steroid receptors (ESR1 for ERα and PGR for 
PR) were detected below the control level, however, the differences were not significant. The 
MYC gene was slightly increased to an extent similar to that observed with E2, but again this 
induction was statistically not significant. Although expressed in the MCF-12A cells (as seen 
from the results with solvent- and E2-treated samples), the TFF1 gene was not detected in the 






Figure 31 Effect of E2 (10 nM) or EGF (100 ng/ml) on gene expression in MCF-12A cells 
Samples were taken after a 24h serum-depletion period, followed by 12 hours of incubation with E2 (10 nM) or 
EGF (100 ng/ml), and PCR analysis was performed. Values are means of 4 independent experiments, error bars 
show SEM. The gene expression in the solvent control sample (“G0 blocked) was set to 1 (dotted line) and used 
as the control value against which all other results were normalised. Student’s t-test was performed for 
significance testing. The sample marked with * is significantly different (P=0.05) from the E2 treated sample 
and from the negative control (set to 1). None of the other samples was statistically significantly different from 
negative control (G0 blocked). TFF1 was not detected after treatment with EGF. 
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4.1 The role of E2 for gene expression 
By assessing the expression of genes that in breast cancer epithelial cells such as MCF-7 are 
regulated by ERα in the wake of activation by E2 we investigated the signalling roles of the 
receptor in MCF-12A cells. In contrast to breast cancer epithelial cells, MCF-12A cells did 
not progress into the cell cycle after exposure to E2. In numerous studies with MCF-7 breast 
cancer epithelial cells, BRCA1, PRAD1, PGR and TFF1 were shown to be strongly induced 
upon E2 treatment. The ESR1 gene is typically down-regulated in response to E2.  
It came to a surprise to us that the endogenous hormone E2 did not significantly alter the 
expression of any of the genes monitored in this study. Since E2 did not have an impact on 
cell cycle progression in MCF-12A cells, it may be argued that proliferative genes such as 
MYC or PRAD1 should not be altered by exposure to the hormone. The receptor ERα for 
which E2 is a ligand, however, can be expected to be affected in any case when the ligand is 
present. Treatment with an estrogen should result in a decline of the receptor mRNA level, 
caused by a negative feedback loop. Such a feedback is mediated directly by the ligand-
bound, activated receptor which associates with an ERE in the promoter domain of the 
receptor gene, and has been shown in MCF-7 and other breast cancer cells (Silva et al. 2010; 
Bourdeau et al. 2008; Cho et al. 1991; Berkenstam et al. 1989). It is noteworthy though that 
an increase of ESR1 mRNA levels has also been reported, albeit not in human tissue (Ing 
2005). Clearly, in the MCF-12A neither such regulation occurred. The receptor is expressed 
in this cell line (E.Silva, personal communication), yet apparently did not react with the target 
sequence in the promoter region of the ESR1 gene. This would suggest that either E2 did not 
bind sufficiently its target receptor, which is highly unlikely, or that the receptor was not 
activated by the bound ligand. If the latter is the case, then the function of the ERα for the 
MCF-12A cells is still unclear.  
Similar to E2, the endogenous hormone progesterone also plays an important role for normal 
development of the mammary gland. The effects of the hormone are mediated through the 
nuclear progesterone receptors of which two isoforms exist, which differ only by one amino 
acid. Interestingly, estrogens are required to induce the expression of PR, and mammary 
epithelial cells that express PR also express ERα (Lange 2008). Similar to the ERα, the 
ligand-activated PR dimerizes and then associates with target sequences in the DNA 
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(progesterone response elements, PRE), more specifically in the promoter region of target 
genes, to regulate their expression (Scarpin et al. 2009). Both mRNA and protein expression 
of PR were shown to be induced as a result of E2 treatment in the rat uterus (Kraus and 
Katzenellenbogen 1993), and even more significantly in malignant MCF-7 mammary 
epithelial cells (Silva et al. 2010). Also the amount of receptor protein was markedly 
increased in all cell types (Kraus and Katzenellenbogen 1993; Cormier et al. 1989; Welshons 
and Jordan 1987). However, the direction of the gene regulation may also depend on the cell 
type, e.g. in vaginal epithelium E2 up-regulated PGR, whereas in uterine epithelium it 
resulted in down-regulation (Kurita et al. 2000). Thus, the observation that E2 did not alter 
the expression of the PGR gene was surprising considering the observations made with the 
other cell types. As was speculated above, the process usually triggered by ligand-binding on 
the ERα seems to be disrupted, and the lack of effect of E2 on ESR1 may explain the outcome 
of E2 exposure on PGR regulation. 
Similar to the PGR gene, E2 had no effect on the expression of the TFF1 gene. This is in 
contrast to observations reported from other breast epithelial cell lines: in neoplastic human 
epithelium, the TFF1 gene was found to be highly expressed (Poulsom et al. 1997), and in 
MCF-7 mammary carcinoma cells expression was increased under E2 induction (Prest et al. 
2002). TFF1 was also found in normal breast tissue, albeit at lower expression levels than in 
the aberrant tissue (Poulsom et al. 1997). In fact, all TFF genes (1, 2 and 3) are considered 
classical estrogen-regulated genes, and their gene expression profile is used to assess 
estrogenicity of compounds. The up-regulation of TFF1 through E2 exposure in breast cancer 
cells can be mediated through the ERE site found in the TFF1 promoter region, providing a 
docking site for the ligand-activated ERα, but also through an AP-1 site found in the TFF1 
sequence (reviewed by Perry et al. 2008). The AP-1 site allows the ER to trigger additional 
genes that do not contain ERE site and thus cannot be activated directly by the receptor. 
When signal transduction through the MAPK pathway is involved, AP-1 is the preferred site 
to achieve TFF1 activation (Espino et al. 2006), but crosstalk between the kinase and receptor 
signalling has also been reported (Barkhem et al. 2002). Hence the endogenous hormones 
may employ several mechanisms to act on TFF1, and so the lack of an up-regulation 
presented here was therefore very surprising, but underlined once more the unusual role of 
this hormone in the MCF-12A cells.  
The BRCA1 protein is an important product needed to balance proliferation and repair 
mechanisms, and is switched on when mitogenic factors act on the cell. Although E2 was not 
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significantly mitogenic in the MCF-12A cells, the lack of effect of the hormone on BRCA1 
induction was surprising, since estrogens are known to induce maximal mRNA levels of 
BRCA1 in human breast cancer (MCF-7) cells (Spillman and Bowcock 1996). Yet Chen and 
colleagues (1996) detected the highest expression in S phase (Chen et al. 1996), which was 
certainly not reached after 12 hours after which the PCR analysis of the MCF-12A was 
performed, others have reported that the BRCA1 gene expression peaked in late G1 phase 
(Gudas et al. 1996; Vaughn et al. 1996), and some even observed significant mRNA 
accumulation as early as 5 hours after addition of E2 (Marks et al. 1997) (all in MCF-7 cells). 
Although the hormone did not have an effect on cell cycle progression (cf. Chapter 4, page 
89), the stimulation of the MCF-12A with E2 lasted for 12 hours, so the question why no 
change of BRCA1 was seen with E2, remained. The mode of action of E2 on BRCA1 gene 
regulation provides a possible explanation. It was found that estrogen does not regulate the 
gene directly, but in an indirect fashion: in several breast cancer cell lines, Marks and co-
workers (1997) showed that the induction of the BRCA1 is dependent on accumulation of 
synthesised DNA. When ERα+ MCF-7 cells were stimulated with the mitogenic factors EGF 
or IGF-1 instead of E2, the BRCA1 gene was also induced, suggesting that the effect of E2 on 
the genes only occurs as a result of E2 being a mitogenic stimuli. Evidence pointing the same 
direction exists for retinoic acid (RA). RA, a mitogen for MCF-7 cells, but no other cell line 
(as demonstrated by an increase of cells in S phase), induced BRCA1 only in the cell line 
where it also stimulated cell division (Marks et al. 1997). Relating these findings to the 
observations made in MCF-12A cells, we suggest that E2 did not increase BRCA1 mRNA 
levels in MCF-12A cells because it failed to induce DNA synthesis sufficiently, whereas a 
strong mitogenic compound should induce BRCA1.  
E2 also failed to induce the PRAD1 gene, coding for cyclin D1. Cyclin D1 is a protein whose 
expression is classically increased before the onset of S phase, resulting from input from 
growth factors, and the cyclin-dependent kinase complexes are important for phosphorylation 
of several key substrates involved in cell cycle progression and proliferation. Treatment of 
ERα+ breast cancer cells with E2 was reported to result in an increase of PRAD1 mRNA 
levels within less than an hour (Castro-Rivera et al. 2001, and references herein). Albeit the 
PRAD1 promoter does not display an estrogen responsive element, its expression is thought 
to be enhanced as a direct outcome of the association of the translocating ERα with the 
transcription factors AP-1, Sp-1, and CREB (Silva et al. 2010; Castro-Rivera et al. 2001; 
Sabbah et al. 1999). The observations made in the MCF-12A on PRAD1 suggest once more, 
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that the receptor is not enabled to exert is functions observed in the malignant epithelial cells 
upon ligand activation.  
The sole target that seemed to be induced upon E2 treatment was the gene coding for the 
transcription factor Myc, however, the analysis results varied between experiments, therefore 
the induction was statistically not significant when compared to the negative control, treated 
with the vehicle only. Similar to PRAD1, MYC is induced upon stimulation with mitogenic 
factors, and the expression of the Myc protein, a transcription factor, is crucial for successful 
cell cycle progression. The regulatory region of the MYC gene contains an ERE, which 
potentially can be bound by the ligand-activated estrogen receptor (Dubik and Shiu 1992). 
The finding that this gene was not induced by stimulation of the cells with E2, despite the 
presence of a signal enhancing element, is in line with the observations made on other genes 
in this cell line.  
4.2 Impact of EGF on gene expression 
Thus far, the results obtained with E2 on the expression of the target genes chosen were 
assessed in relation to the effects of E2 reported for the correspondent malignant cell line 
MCF-7. To understand better the signalling in MCF-12A cells, we sought to investigate a 
reference case, where a growth factor strongly induces cell cycle progression and 
proliferation. We compared the results obtained from the studies with E2 to those with EGF, 
a growth factor shown to have proliferative effects on MCF-12A cells.  
The steroid receptors ESR1 and PGR were both detected at very low levels after incubation 
with EGF; however, the downregulation was not statistically significant. The observation 
made with ESR1 is more or less in line with results from MCF-7 cells, where a decrease of 
ERα expression as a result of EGF action has been reported, on a transcriptional and 
translational level (Silva et al. 2010; Stoica et al. 2000; Cormier et al. 1989). However, in 
order for EGF to decrease the expression of the receptor gene, the ERα itself must have been 
activated first. Bunone et al. (1996) examined extensively the mechanism by which EGF 
could act on the nuclear receptor, and found that ER stimulation by EGF targeted the 
activation function 1 (AF-1) domain in the receptor, and more specifically its serine residue 
Ser118. Exactly this residue is phosphorylated by MAP kinases. The role of the MAPK 
pathway for activation of ERα was confirmed with a dominant negative Ras mutant which 
significantly reduced the efficiency of EGF to trigger ERα (Bunone et al. 1996). Possibly, the 
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same signalling pathway was in place in the MCF-12A cells. The MAP kinases were shown 
to be strongly up-regulated upon treatment with EGF in these cells (discussed in Chapter 7), 
and could then phosphorylate ERα. Subsequently, the activated receptor would bind the ERE 
domain in its target, resulting in a decrease of receptor gene expression. It should be noted 
though that Stoica and coworkers (2000) found that the regulation of ERα by EGF (in MCF-7 
cells) was mediated rather through the protein kinase B (Akt) than the MAP kinase (Stoica et 
al. 2000). In order to verify the assumption that in the MCF-12A the MAPK pathway was 
triggered, assessment of ESR1 mRNA levels after incubation with a specific MAPK inhibitor, 
which would be expected to disrupt the down-regulation of the receptor, would be necessary. 
The progesterone receptor was also under investigation in the study by Stoica and colleagues 
(Stoica et al. 2000). Using the same concentration of EGF (100 ng/ml), they found that 
expression of the PGR in MCF-7 cells was induced after 6 hours, but to a smaller degree than 
with E2, whereas others report no effect of EGF on PGR expression (after 24 hours) (Silva et 
al. 2010). It seems that also in the MCF-12A cells, PGR is not under the control of mitogenic 
pathways (triggered by EGF), and since EGF was the stronger mitogen for MCF-12A cells 
than E2, the lack of effect of E2 is also conceivable. Possibly, PGR mRNA levels are 
regulated by other signals, because the receptor does have a function in non-transformed 
cells. 
Analysis of the TFF1 gene came as a surprise, since in none of the samples treated with EGF, 
it was detectable. In all other samples (control and E2-treated) it was expressed at rather low 
levels (compared to the expression levels of the housekeeping gene β-actin), so its 
disappearance suggested a down-regulation, although this assumption could not be analysed 
statistically, for obvious reasons. Usually, a positive correlation between mitogenic 
stimulation with EGF and TFF1 expression is found. For example, up-regulation of TFF1 
upon EGF incubation has been observed in MCF-7 breast epithelial cells (Silva et al. 2010; 
El-Tanani and Green 1997), and inhibition of the tyrosine kinase activity of the EGFR 
resulted in a reduction of the TFF1 mediated growth in kidney cancer epithelial cells 
(Rodrigues et al. 2003). Additionally, induced overexpression of the TFF1 gene led to an 
increase in S phase numbers of MCF-7 cells, suggesting a role for TFF1 in cell cycle 
progression (Amiry et al. 2009). Since the MCF-12A cells relied heavily on EGF for cell 
cycle progression, the downregulation of TFF1 with this growth factor was surprising, even 
more so since TFF1 and EGFR signalling share functions such as migration, increased 
proliferation and anti-apoptotic features (Emami et al. 2004). On the other hand, the finding 
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that EGF did not induce TFF1, although the growth factor promotes cell cycle progression in 
MCF-12A, confirms the result with E2, underlining once more that E2 is unable to promote 
cell cycle progression in the normal breast epithelial cells because it fails to induce 
proliferative genes.  
Looking at the treatment with EGF strictly as a purpose for comparing the effect of E2 with 
an actual growth factor, the characteristics of BRCA1 are in line with TFF1, in the sense that 
in the MCF-12A cells, EGF has more impact on the expression of genes that are classically 
under the control of pro-proliferative factors, than does E2. Although the variation between 
the independent experiments was relatively high, so that the increase in mRNA levels was 
actually not statistically significant, the mean value of all results indicates that there was an 
increase in mRNA levels. In fact, it seemed to be the strongest induced target, or at least the 
difference between E2 and EGF treatments was most pronounced with BRCA1.  
Nevertheless, the only significant increase in mRNA levels produced by EGF was observed 
with the gene coding for cyclin D1, PRAD1. As has been mentioned above (cf. section 1.4 of 
this chapter), cyclins are established key regulators of the cell cycle, and cyclin D1 has been 
shown to be essential for successful progression from G1 phase into S phase. Since EGF 
promoted cell cycle progression (as seen from the flow cytometric results in Chapter 4), the 
increase of PRAD1 mRNA levels by EGF was quite expected, and is in agreement with 
numerous reports about the link between growth factor stimulation and cyclin D1 induction 
(Klein and Assoian 2008; Rieber and Rieber 2006; Chou et al. 1999; Lavoie et al. 1996; 
Sutherland et al. 1993). 
Finally, the effect of EGF on mRNA levels of MYC was very similar to the lack of impact of 
E2 on this gene. Although the level of MYC expression does not vary in cells that are 
continuously exposed to serum (Rabbitts et al. 1985; Thompson et al. 1985), it is virtually 
undetectable in quiescent cells, followed by a rapid rise in mRNA levels upon growth factor 
stimulation (Facchini and Penn 1998; Ran et al. 1986; Bravo et al. 1985; Curran et al. 1985). 
Therefore, it may be expected to see an induction of MYC as a result of the EGF exposure. 
However, the cells were analysed after an incubation period of 12 hours, which may be too 
late for detection of MYC induction, since it has been reported that mRNA levels peak 2 to 4 
hours after stimulation, and decline subsequently (Handler et al. 1990; Dean et al. 1986). In 
order to assess the true impact of EGF on MYC regulation in MCF-12A cells, samples need to 
be analysed at earlier time points after addition of the growth factor. However, since the aim 
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of EGF exposure in this assay was to compare it to the effect of E2 treatment, this was not 
performed here, but is presented in Chapter 7 below. 
4.3 E2-triggered signalling in MCF-12A versus MCF-7 cells 
Although only a handful of targets were monitored, we were able to conclude from the assays 
performed with E2 in comparison to EGF that the non-transformed MCF-12A epithelial cells 
are entirely differently affected by E2 than the malignant cell line MCF-7. Not only did E2 
not stimulate the cells to continue their cycle, as discussed in the previous Chapter 4, but also 
its impact on genes that are well known to be regulated by the hormone in MCF-7 cells, was 
absent in all targets. This may be regarded as a feature of normal epithelial cells, and in 
reverse, lead to the conclusion that responsiveness to E2 is characteristic for transformed 
cells. This thought has been discussed in the literature, with a particular focus on the role of 
cyclin D1, for several reasons. Firstly, it was noticed that cyclin D1 is overexpressed in 
primary breast cancer cells which were in a very early stage of malignancy (Weinstat-Saslow 
et al. 1995). Secondly, it was observed in MCF-7 cells that their ability to overcome a G1 
block depended on estrogen induced cyclin D1 transcription (Wilcken et al. 1997). The 
ability of estrogens to drive cyclin D1 expression is thus considered crucial for the 
proliferation of ER
+
 breast tumours, and although PRAD1 lacks an ERE, the effect of the 
hormone is probably transmitted through an AP-1 site in the promoter of the gene (Wisdom 
et al. 1999; Planas-Silva et al. 1999 and references herein; Brown et al. 1998). In line with 
these observations, it has been established that the presence of an ER per se is not sufficient 
to promote proliferation as a result of estrogen stimulation (Zajchowski et al. 1993; Jiang and 
Jordan 1992). On the other hand, it was shown that in normal human breast tissue, 
proliferating cells are sparse among those cells expressing an ER (which accounted for only 
around 15% of all cells), whereas in mammary tumours, the majority of ER
+
 cells were 
dividing (Clarke et al. 1997).  
Taken together, these findings indicate that ER
+
 cells responsiveness to estrogens, by 
increasing cyclin D1 transcription or, ultimately, by proliferating, is a feature of aberrant cell 
behaviour. In this respect, the insensitivity of the MCF-12A cells (which do express the ERα) 
to E2 emphasises their non-transformed character. The quite different, but crucial role of 





The first and foremost aim of this chapter was to clarify the role of the endogenous hormone 
E2 in the MCF-12A cells. E2 did not have a significant effect on cell cycle progression when 
used instead of a growth factor in the discontinuous exposure assay (Chapter 4). Therefore, a 
closer examination of the mRNA levels of typically estrogen-regulated genes was decided. 
Two proliferative genes, PRAD1 and MYC, which were significantly induced upon the pro-
proliferative incubation with EGF, were assessed after E2 stimulation. Additionally two 
genes that are classically up-regulated upon E2 stimulation, BRCA1 and TFF1, were also 
examined, as well as two genes coding for estrogen-sensitive receptors (ESR1 and PGR). 
The conclusion from the flow cytometric analysis, that E2 did not have a proliferative effect 
on MCF-12A cells, was confirmed by the analysis of PRAD1 and MYC, which were both not 
significantly up-regulated, in contrast to stimulation with EGF. The lack of mitogenic 
properties of E2 in MCF-12A cells was further supported by the results on the BRCA1 gene.  
In summary, the results found with E2, in comparison to EGF, at the two different endpoints, 
S phase evaluation by flow cytometry and mRNA analysis of mitogen-dependent genes, were 
consistent with each other. The results on the usually mitogen-independent, but estrogen-
regulated targets ESR1, PGR and TFF1, suggest an atypical role for E2 in the MCF-12A 
cells, when compared to the correspondent malignant cell line MCF-7, but are in line with the 
hypothesis that E2-responsiveness indicates transformation, whereas normal cells do not react 
to hormone stimulation, despite the presence of estrogen receptors. 
In the following chapter we will further explore the impact of EGF, which did not only 
induce the proliferative gene PRAD1, but more importantly promoted cell cycle progression 
very strongly. In particular the signalling pathways that are triggered by EGF to achieve cell 






Signal transduction for cell cycle re-entry 
1 INTRODUCTION 
Having established a discontinuous assay scheme that allows quiescent MCF-12A cells to re-
enter the cell cycle upon two distinct exposures to defined growth factors, the next stage of 
the investigations was to find out which signalling pathways were activated during these 
pulses and which of these were decisive in advancing the cell cycle. The discontinuous 
exposure consisted of a 30 minutes pulse with epidermal growth factor (EGF), followed by a 
3.5 hour resting period and a second pulse of 10 hours, with administration of EGF in 
combination with insulin. It yielded good results in terms of the percentage of cells advancing 
into the S and G2+M phases after a total release time of 18 hours. This set-up was used 
throughout the next series of experiments presented in this chapter, where specific kinase and 
lipase inhibitors were added during the exposures, together with the respective growth 
factor(s), in order to determine which of the targeted enzymes were involved in the G1 to S 
phase transit. 
To develop criteria for the selection of appropriate inhibitory agents, we first had to establish 
which kinases are activated by EGF and insulin in epithelial cells. Growth factors are ligands 
for their specific receptors which relay the message from outside the cell into intracellular 
compartments. Both EGF and insulin act through cell surface receptor tyrosine kinases 
(RTK), which are transmembrane proteins: on their extracellular domain, they bind specific 
(growth) factors, and the intracellular domain encodes the tyrosine kinase which propagates 
the signal. The superfamily of RTKs comprises a variety of different subclasses. The human 
EGF receptors (HER) 1 to 4, also called ErbB receptors, are part of the type I receptors of the 
superfamily. The type II receptor family members consist of the insulin receptors. The 
receptors of type I and II have in common that they have leucine-rich (L) and cysteine-rich 
(CR) domains which have a role in ligand binding and stabilisation. They are distinguished 
by their form of appearance on the membrane: type I receptors exist as monomers, whereas 
type II receptors are found as disulfide linked dimers. In total, there are more than a dozen of 
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family members, including also receptors for factors such as vascular-endothelial growth 
factor (VEGF) and the platelet-derived growth factor (PDGF). The common feature of the 
RTKs, as the name suggests, is that they phosphorylate various intracellular substrates on 
their tyrosine residues. 
In the following sections, the mode of actions of EGF and insulin on their respective 
receptors will be discussed in more detail. 
1.1 Epidermal growth factor (EGF) and its receptor, EGFR 
1.1.1 Structure of the receptor 
During his studies on the nerve growth factor, Stanley Cohen isolated a protein from the 
salivary gland of mice which he injected into newborn animals. This resulted in remarkable 
anatomical changes: both tooth eruption and eyelid opening occurred much (several days) 
sooner, but weight gain was slowed down (Cohen 1962). The protein was characterised as 
epidermal growth factor (EGF) a few years later (reviewed by Gill et al. 1987). His work on 
this growth factor also led him to discover the corresponding receptor (Cohen et al. 1980), 
and for these major findings he received the Nobel Prize in 1986. 
The EGFR, also known as ErbB1 or HER1, is a 180 kDa large glycoprotein and possesses 
one trans-membrane domain, the extracellular ligand-binding domain and on the intracellular 
side its kinase binding domain and a long C-terminus with several tyrosine residues as 
phosphorylation targets (Figure 32). The ectodomain consist of 4 domains named L1, L2, 
CR1 and CR2, but only the first two are the targets for ligand binding, and the major binding 
domain seems to be L2. CR1 mediates dimerisation of the receptor molecule, whereas CR2 is 
responsible for stabilising it (Walker et al. 2004). The transmembrane domain extends into 
the juxtamembrane region and primarily serves as a site for the shutdown loop, through 
negative feedback by the extracellular signal-regulated kinases (Erk) and protein kinase C 





Figure 32 Schematic representation of EGFR monomer 
The leucine-rich (L) and cysteine-rich (CR) domains are found on the extracellular site of the receptor and are 
responsible for binding of the ligand. The tyrosine kinase is found on the C-terminal site (adapted from Ward et 
al. 2007). 
 
1.1.2 Mode of action of EGF on its receptor (EGFR): 
To date, seven ligands of the EGFR have been identified, but only the interactions with EGF 
will be discussed here. The EGFR is activated upon binding of a ligand molecule. The 
receptor then dimerises to form either a homodimer or a heterodimer with another HER, 
preferably with the ErbB2, and phosphorylates itself. 
Each molecule of EGF is clamped between the L1 and L2 domains from the same EGFR 
molecule, so that it is in contact with only one receptor in the dimer. For optimal activity of 
the dimer, the EGFR requires direct protein-protein interactions between the C-terminus of 
one kinase and the N-terminal domain of the other kinase (Figure 33), so that this asymmetric 
conformation displays an elongated shape compared to a symmetric dimer (Hubbard 2006). 






Figure 33 Schematic representation of dimerised EGFR 
Signalling by the EGFR requires interaction between the kinase domains of two receptor monomers, whereby 
one activates the other. The ligand bound monomer pushes the inactive monomer towards its activation loop for 
full activity of the dimer (adapted from Hubbard 2006). 
 
It should be noted that the EGFR can form heterodimers with other members of the ErbB 
family, so that ligands not specific for the EGFR can still incite signal transduction. On the 
other hand, no ligand is known thus far for the ErbB2, but when this receptor forms a 
heterodimer with EGFR, it provokes the strongest mitogenic response of all dimers possible 
(Yarden and Sliwkowski 2001).  
1.1.3 Mechanisms of signal transduction by the EGFR 
The autophosphorylated and activated EGFR provides docking sites for SH2 domains, and 
attracts different linker proteins to these sites. One possible linker to begin with is the adaptor 
protein Grb2, which contains several Src homology (SH) domains, one SH2 and two SH3 
domains. The SH2 domain of the Grb2 protein will bind directly to the EGFR and provides a 
link between the receptor and the transducer molecule Sos (Rozakis-Adcock et al. 1993). A 
group of factors termed Signal Transducer and Activator of Transcription factors (STATs) 
also contain SH2 domains that enable them to link to the EGFR; the activated STAT 
translocates to the nucleus where it can bind to a variety of target genes (Quesnelle et al. 
2007). The Shc protein was identified as a Src homology (SH2) containing proto-oncogene 
that complexed with, and was phosphorylated by, the activated EGFR (Pelicci et al. 1992). 
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However, more recently it became clear that Shc binds to the receptor preferably via its 
phosphotyrosine-binding (PTB) domains, subsequently bringing in the adaptor protein Grb2 
(Ravichandran 2001). Finally, the Src protein, which contains a SH3 and SH2 domain, 
followed by the catalytic (tyrosine kinase) domain and a regulatory tyrosine phosphorylation 
site on its C-terminal end, may associate with the EGFR (Luttrell et al. 1994). 
It is interesting to note that Grb2 may connect to the receptor in two different ways: firstly, 
the by direct binding of the adaptor to the receptor on its residues Y1068 and Y1086, and 
secondly, via the Shc protein, which is associated to the EGFR through different residues 
(Y1173 and Y992). It is not completely understood yet if these different modes of attachment 
result in distinct functional roles, or if the recruitment modus is cell-type specific (Jorissen et 
al. 2003; Batzer et al. 1994). 
1.2 Insulin and the insulin receptors 
1.2.1 Structure of the receptor 
Insulin has been discovered much earlier than EGF. It was isolated in 1922 (Banting and Best 
1922), and thirty years later, it became the first protein to have its primary amino acid 
structure sequenced, for which Frederick Sanger received the Nobel Prize in 1958. 
Insulin is a ligand to several receptors: the family of insulin receptors comprises the insulin 
receptor (IR), the receptor for insulin-like growth factor / type I (IGF-1R), and the insulin 
receptor related receptor (IRR). The IR exists in two isoforms (IR-A and IR-B) (Lee and 
Pilch 1994). All three receptor types usually exist as homodimers, although hybrids between 
the IR and the IGF-1R were found in cells that express both receptor types, but their 
physiological role is unknown (De 2004). Since the highest affinity of insulin is for the IR, 






Figure 34 Schematic representation of the IR 
Similar to the EGFR (see Figure 32), the IR has leucine-rich (L) and cysteine-rich (CR) domains on the 
extracellular side for ligand binding, but the IR is present as a stable heterotetramer on the cell surface (adapted 
from Ward et al. 2007). 
 
The IR consists of an α-chain (130 kDa of size), which is entirely extracellular and contains 
the insulin-binding site, and a β-chain (95 kDa of size) that is composed of an extracellular 
region, a single transmembrane domain and a cytoplasmic region (Figure 34). The two chains 
are disulfide-linked, and in turn two of these heterodimers are held together by disulfide 
bonds at the α-chains. Thus, unlike other RTK, the insulin receptor is present on the cell 
surface as a stable dimer. Binding of an insulin molecule results in a conformational change 
of the β-chains so that they can initiate autophosphorylation. The ectodomain consist of 6 
domains, named L1, L2, CR and the fibronectin (type III) domains FnIII-1 to -3. L1, CR, L2 
and FnIII-1 are parts of the α-chain, whereas the fibronectin domains 2 and 3 belong to the β-
chain. The transmembrane domain consists entirely of the β-chain. The intracellular region of 
the IR contains the kinase domain neighboured by two regulatory regions (the 




1.2.2 Mode of action of insulin on its receptors 
The IR and the IGF-1R are homologous kinases that bind both, insulin and IGF-1, albeit with 
different affinities (insulin attaches to the IR with high affinity, whereas the affinity of IGF-1 
is low for the IR). Interestingly, the IR-A (but not IR-B) binds the type II insulin like growth 
factor with an affinity similar to that of the IGF-1R. High-affinity binding is accompanied by 
structural compaction of the receptor and not by extension as in the case of the EGFR. 
For the IRR, no ligand is known so far, and its physiological function is unknown, although 
the generation of triple gene knockout mice showed that the complete receptor family is 
required for male sexual differentiation (Nef et al. 2003). 
1.2.3 Mechanisms of signal transduction by the IR and the IGF-1R 
In contrast to the EGFR and most other RTKs which form stable complexes directly with 
their effectors through their SH2 domains, the mechanism by which the IR transmits its 
signals is biochemically different. The process of autophosphorylation of the IR exposes 
binding sites for the PTB domains of the insulin receptor substrates (IRS). The IRS are 
members of a small family of docking proteins, with IRS-1 and IRS-2 as the main substrates. 
These substrates are then available for binding with SH2 containing proteins. However, it has 
been shown that the activated IR can also complex with the Shc protein as its substrate, 
which itself contains a SH2 domain and through this can bind the adaptor molecule Grb2 
(Sasaoka and Kobayashi 2000). The insulin receptor also phosphorylates the multisite 
docking protein Grb2-associated binder-1 (Gab-1) and -2. Thus, Gab-1 and Gab-2 are also 
considered as members of the IRS family, which means they can transmit signals from the IR 
towards several kinase pathways (Lehr et al. 2000; Holgado-Madruga et al. 1996). 
1.3 Signalling pathways triggered through activation of the EGFR and IR 
The pathways mainly implicated in cell growth and proliferation are the MAP kinase and the 
PI3 kinase pathways. Both are triggered upon RTK activation, and therefore will be discussed 
in more detail. Furthermore, PLC was shown to be a substrate for the EGFR, and may 
function as a co-activator of the other mentioned kinases, therefore the PLC/PKC pathway 




1.3.1 The mitogen-activated protein kinase (MAPK) pathway 
A key player for signal transduction from the RTKs is the adaptor molecule Grb2. Grb2 is a 
23 kDa small protein, consisting of a sequence of three Src homology domains, SH3-SH2-
SH3. The SH2 domain binds to specific domains on the activated receptors, whereas with its 
SH3 domain it is constitutively bound to the guanine nucleotide exchange factor Sos 
(Rozakis-Adcock et al. 1993; Buday and Downward 1993). Sos exchanges GDP for GTP on 
the small G protein Ras (Batzer et al. 1994). Active in its GTP-state, Ras binds to the N-
terminus of Raf-1 (Vojtek et al. 1993), a serine/threonine-specific protein kinase and an 
activator of the MAPK kinases (MEK), which in turn activate the MAP kinases Erk 1 and 
Erk2. Erk1 and 2 catalyse the phosphorylation of nuclear transcription factors, ultimately 
resulting in enhanced proliferation. Stable overexpression of Grb2 enhances insulin-induced 
activity of the ERKs, but not when the SH2 domain binding properties are affected by point 
mutations, demonstrating the importance of the integrity of this adaptor protein (Skolnik et al. 
1993). Upon EGF stimulation, overexpression of Grb2 was shown to increase the amount of 
Ras in the GTP-bound state (Kazlauskas 1994).  
The MAP kinase pathway may also be triggered through a slightly altered mechanism, 
namely through the Src tyrosine kinase. It was shown that the Src protein is tightly connected 
to the EGFR. Firstly, overexpression of the Src enhances EGF-mediated proliferation in 
epithelial cells (Luttrell et al. 1988), and conversely, inhibition of the Src protein blocks 
EGF-mediated DNA synthesis (Roche et al. 1995). This allows the assumption that Src is a 
signal transducer located downstream of the EGFR. The Src protein attracts adaptor proteins 
such as Grb2 for activating Sos, resulting in the activation of the Ras molecule, which again 
triggers the MAP kinase cascade. Docking of Gab is also considered essential for activation 
of the MAPK pathway because it targets Shp2 to its appropriate location for its key substrate 
Ras (Gu and Neel 2003), and Shp2 is required for full and sustained activation of Ras (Neel 
et al. 2003). 
1.3.2 The phosphatidyl-inositol-3-kinase (PI3K) pathway 
There are four classes of PI3 kinases, with the enzymes of class I being the most abundant, 
and the best studied ones. Class I PI3Ks are heterodimeric proteins, with a 110 kDa catalytic 
subunit (p110) and the regulatory subunit of 55-85 kDa of size (called p85). Several 
mechanisms of PI3K activation exist: 
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The p85 contains a p110 binding site between two SH2 domains, and an additional SH3 
domain. These domains allow the PI3 kinase to be recruited either directly or indirectly to the 
receptors (Foster et al. 2003; Fry 1994). The direct binding of the p85 is only possible in an 
EGFR heterodimer: the EGF receptor (ErbB1) can form a heterodimer with a receptor from 
the same family, namely ErbB3. It is the latter that then binds p85 which is the regulatory 
subunit of the PI3 kinase and therefore activates the whole enzyme (Soltoff et al. 1994). The 
EGFR as well as the ErbB2 lack the p85-SH2 recognition domain which is necessary for 
binding the regulatory adaptor protein. Nevertheless, the p85 subunit can bind indirectly, 
through Grb-2, to the RTKs: first, the adaptor protein Grb2 binds to the EGFR, then the Gab-
1 molecule (Grb2-associated binder) is recruited. The Gab family are docking proteins that 
lack enzymatic activity, but they provide binding sites for SH2 domain containing proteins. 
In fact, Gab provides a major route for PI3K activation in all mammalian systems, especially 
for receptors lacking a p85 binding site, and has been shown to link the EGFR with the PI3 
kinase pathway (Wohrle et al. 2009a; Wohrle et al. 2009b; Gu and Neel 2003; Gu et al. 
2000).  
The Src protein is equally responsible for activating the PI3K pathway, because Src can 
recruit the p85 subunit, whose binding leads to completion of the PI3-kinase and its 
activation (Fry 2001). 
Thus, the PI3K pathway may be triggered through activation of both, the EGRF and the IR. 
The phosphatidyl-inositol kinases target proteins which contain a lipid recognition module; 
from these, the activated PI3K produces inositol lipids which recruit proteins with a 
pleckstrin homology (PH) domain. The best known example for such a protein, and the best 
studied PI3K substrate, is the Akt kinase (also called protein B kinase, PKB). The PI3K 
signalling can be stopped by phosphatases, and the strongest termination reaction is mediated 
by the tumour suppressor gene product PTEN. Indeed, PTEN was found to be down-
regulated in some human cancers. In quiescent cells, PI3K activity increases in two waves 
following growth factor stimulation. Inhibition of PI3K up to 2 hours before entry into S 
phase reduced c-Myc (a protein important for S phase progression) levels for several hours 
afterwards, and also the number of cells able to enter S phase (Kumar et al. 2006). This report 






1.3.3 The phospholipase C (PLC) pathway 
Phospholipase C and D are both substrates for the activated epidermal growth factor receptor. 
In mammalian tissues, 5 different groups of phospholipase C have been identified (PLCβ, γ, 
δ, ε, ζ), each group consisting of several isoforms. The PLCs contain SH2 domains, through 
which they are bound to the tyrosine residues 992 and 1173 of the EGFR upon mitogen 
stimulation. The binding results in relocalisation of the usually cytosolic PLCγ1 and γ2 to the 
membrane, where they catalyse the hydrolysis of inositol phospholipids (phosphatidyl-
inositol 4,5-diphosphate) into inositol-triphosphates (IP3) and diacylglycerol (DAG) 
(Nishizuka 1995). PLC gamma possibly also gets activated through the Grb2 protein, notably 
the binder Gab-1 which provides docking sites for the SH2 domain of the PLC (Gu and Neel 
2003). 
DAG is the co-factor for the protein kinase C (PKC) which is an activator of MAP kinases, 
both the JNK pathway and the Erk pathway. However, different studies suggest that several 
isoforms of PKC may be involved in the activation of these distinct MAPK pathways, 
depending on the stimulus and the cell type (Pysz et al. 2009; Koivunen et al. 2006; 
Hagemann and Blank 2001). IP3 on the other hand mediates release of calcium from the cell, 
affecting Ca
2+
 dependent pathways and potentiates the PKC activation. Downstream targets 
of PKC are the Erk1/2 kinases, the glycogen synthase kinase 3 (GSK3) and NFκΒ (nuclear 
factor kappa beta) whose constitutive activation is associated with inflammatory diseases as 
well as some cancer forms (Kim et al. 2006). Thus, the signalling towards the phospholipid 
metabolism through EGFR is also linked to (increased) proliferation, as is the more direct 
activation of the classical MAPK cascade (Koivunen et al. 2006; Nishizuka 1995) 
1.4 Key mechanisms for the transition from G0/G1 into S phase 
There are numerous biochemical processes taking place in the cell, at different levels after the 
stimulation with growth factors, which need to be completed successfully in order to achieve 
progression through the G1 phase into synthesis state. The key mechanisms in this multistep 
process will be discussed in this section, and are depicted schematically in Figure 35.  
1.4.1 The restriction point and its role in controlling proliferation  
The restriction point (R point) is the point in the cell cycle where processes are initiated that 
lead to the assessment of the cell’s ability to successfully undergo the next round of 
replication. If the assessment is positive, the R point represents the point of no return, because 
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the cell will complete one full cycle, even if environmental conditions change during the 
completion, e.g. when growth factors are withdrawn. Hence, the R point is also defined as the 
time point when the cell acquires serum independence. However, the R point is not a mere 
additional checkpoint in the cell cycle, since its function is different from that of a 
checkpoint. During a checkpoint, the cell ensures that its genome is intact, and that the 
previous steps of the cell cycle have been executed properly. If this is not the case, the cell is 
stopped at this control point until the genome has been repaired, and if repair is not possible, 
the cell will undergo apoptosis. In contrast, the R point can be passed if sufficient external 
signals have been received, and if this was not the case, the cell will withdraw from the cell 
cycle into a quiescent state. Importantly, this state can be left again when the cell is exposed 
to specific growth factors over an extended time, and the full round of cell cycle phases will 
be completed.  
The activation of the MAPK pathway is essential for allowing a cell to pass the restriction 
point. In quiescent NIH3T3 cells, the activity of the Erk1/2 kinases must be sustained until 
late G1 for successful S phase entry. Inhibition of this pathway, even shortly (2 hours) before 
the onset of S phase, resulted in abandonment of DNA replication (Yamamoto et al. 2006). 
However, the activity of the Erk kinases declined quickly after entry into S phase and was not 
required for completion of DNA replication. This is in agreement with previous findings that 
put the R point up to a few hours before synthesis, but the exact onset of it seems to be cell 
type dependent. In the following sections, the signalling events that are taking place around 
the R point are presented and put into context with each other. 
1.4.1.1 Elevation of the transcription factor c-Myc  
The c-Myc protein is often overexpressed in human cancers. The role of c-Myc as an 
oncoprotein is supported by the observation that cell cycle arrest as a consequence of mitogen 
withdrawal (or another growth-inhibitory signal) can be overcome through ectopic expression 
of c-Myc. This protein has a pivotal role in cell cycle progression. Its activation is sufficient 
to induce cell cycle entry, even in the absence of growth factors, and conversely treatment of 
quiescent cells with growth factors increases c-Myc expression (Kelly et al. 1983). 
Expression of c-Myc is important for accumulation of the cyclins, which themselves are 
essential for G1 to S phase transition (discussed below): c-Myc is able to induce expression 





 by inducing labile forms of those proteins (Hermeking et al. 1995). 
Hanson et al. (1994) demonstrated the importance of the transcription factor with c-myc 
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heterozygous cells in which they observed a clear delay in cyclin E expression during G1. 
Consequently, Rb phosphorylation, which follows the expression of cyclin E, was also 
delayed. The same result was obtained whether the cyclin protein or the RNA levels were 
analysed. All effects in the heterozygous cell line were reversed when transfected with a c-
myc transgene (Hanson et al. 1994). 
c-Myc is also a phosphorylation substrate for MAP kinases (English et al. 1998; Alvarez et 
al. 1991). In fibroblasts, signalling to Erk1/2 and induction of c-Myc expression were both 
necessary for cell cycle progression (Jones and Kazlauskas 2001). Erk1/2 directly enhanced 
the stability of the c-Myc protein by phosphorylating a specific serine residue (Ser62) (Sears 
et al. 2000). One target of the PI3K effector Akt is the glycogen synthase kinase 3 (GSK3). 
This protein kinase is constitutively active in unstimulated cells and phosphorylates c-Myc 
and cyclin D to keep them inactive. Phosphorylation of GSK3 by Akt turns off the catalytic 
activity of this enzyme, resulting in the activation of pathways that are normally repressed by 
GSK3. Conversely, specific PI3K inhibitors block growth factor induced elevation of c-Myc, 
in various cell types (Schild et al. 2009; Li et al. 2008; Chanprasert et al. 2006; Liang and 
Slingerland 2003; Chen and Sytkowski 2001). 
1.4.1.2 Elevation of levels of cyclin dependent kinases 
Cyclins were discovered as key regulators of the cell cycle in sea urchin eggs and fission 
yeast by Tim Hunt and Sir Paul Nurse, who shared the Nobel Prize 2001 for this work 
together with Leland H. Hartwell. 
In mammalian cells, there are two types of cyclins important for the cell cycle stages from G1 
to S phase, the D-type and the E-type cyclins. G1 progression depends on the sustained 
expression of D-type cyclins, which, in turn, depends on mitogenic stimulation, so that 
cyclins provide a link between mitogen signalling and the cell-cycle machinery. The 
overexpression of D-type cyclins in fibroblasts led to an accelerated progression through the 
G1 phase, with a premature entry into S phase (Quelle et al. 1993), and overexpression of 
cyclin D1 is also a feature of several human cancers (Arber et al. 1996a; Arber et al. 1996b). 
The cyclins represent the regulatory part of the binary system of cyclin-dependent kinases 
(CDKs), which is completed by a catalytic subunit, the kinase. In mammalian cells, two types 
of CDKs exist that are important for the G1 to S transition: 
Firstly, the CDK4 and CDK6 that are related to D-cyclins (D1, D2 and D3). These complexes 
are activated at mid-G1, their primary target being the Retinoblastoma protein (pRb), whose 
phosphorylation process they initiate (Ewen et al. 1993). Secondly, CDK2, which is activated 
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with cyclin E; this complex is slightly delayed compared with the CDK4/6 and acts at the 
G1/S transition. 
1.4.1.2.1 The MAPK pathway and the cyclin dependent kinases 
To further reveal how the MAP kinases support G1/S transitions, different links upstream and 
downstream in this pathway have been examined. For example, the small G-protein Ras 
upstream of MAPK and MEK strongly phosphorylates Erk1/2, therefore its role in cell cycle 
progression was assessed: an inducible dominant negative Ras mutant in NIH3T3 was used to 
show that if Ras expression is delayed after stimulation with EGF, the cells are unable to 
leave the G1 phase. This was the case even if the negative Ras was induced up to 3 hours 
after the addition of EGF (Takuwa and Takuwa 1997). The Ras mutant also inhibited 
downregulation of p27
Kip1
 which is an inhibitor for the cyclin-dependent kinases. On the 
other hand, increased activation of Ras induced significant overexpression of cyclin D1, 
shown in fibroblasts as well as mouse mammary gland epithelial cells (Liu et al. 1995; 
Filmus et al. 1994), and shortened the time necessary for G1 completion (Winston et al. 
1996). 
Direct links between the MAP kinase cascade and cyclins have been studied as well: e.g. the 
activation of Erk1/2 was found to be necessary for transcriptional induction of the cyclin D1 
gene (Lavoie et al. 1996), and in addition, this activation needed to be sustained in order to 
accumulate sufficient cyclin D1. Inhibition of Erk1/2 up to 4 hours after the addition of the 
mitogen resulted in G1 arrest (Weber et al. 1997). 
1.4.1.2.2 The PI3K pathway and the cyclin dependent kinases 
The substrate of the PI3 kinase, Akt, was shown to up-regulate cyclin D1 expression in 
mammary epithelium, thus linking this pathway directly to cell cycle progression 
(Hutchinson et al. 2001). Growth factor stimulation of quiescent MCF-7 cells led to increased 
cyclin D1 synthesis, which was blocked with specific PI3K inhibitors, but not with a MEK1 
inhibitor (Dufourny et al. 1997). The increase in protein levels was the result of cyclin D1 
mRNA with an extended half life. Again, the stabilisation of the mRNA could be reversed 
with a specific PI3K inhibitor, but the MEK1 inhibitor had no effect (Dufourny et al. 2000). 






1.4.1.3 Decrease of p27Kip1 and p21Cip1  




 (reviewed by 
Bartek and Lukas 2001; and by Ekholm and Reed 2000). p27
Kip1
 transcription and protein 
levels are maximal in G0 and early G1, and high p27
 Kip1
 is required for the G1 arrest induced 
by growth factor deprivation. p27
Kip1
 levels fall abruptly with exit from quiescence and 
during G1 progression (Hengst and Reed 1996). Cyclin D1 is able to sequester p27
Kip1
 from 
the nucleus into the cytoplasm, thus making cyclin-dependent kinase 2 (CDK2) available for 
binding with cyclin E (Perez-Roger et al. 1999). CDK2 is inhibited in the nucleus by p27
Kip1
, 
and the amount of this protein in the nucleus must drop below a certain level to release a 
sufficient amount of the kinase for formation of CDK2. The CDK2 complex itself 
phosphorylates again p27
Kip1
, leading to whose further degradation (Philipp-Staheli et al. 
2001; Albrecht et al. 1999). p21
Cip1
 also needs to be decreased, as shown in liver cells of 
p21
Cip1-/-
 mice where complete removal of the inhibitor resulted in accelerated G1-
progression (Albrecht et al. 1998). Conversely, accumulation of p21
Cip1
 leads to binding to 
and inactivation of CDKs in the G1 phase. 
1.4.1.3.1 The MAPK pathway and the inhibitors p21Cip1 and p27Kip1 





. These must be decreased below a certain threshold for successful 
transition from G1 to S phase. It has been suggested that the Ras/Erk1/2 signalling pathway is 
directly involved in the mitogen-induced downregulation of p27
Kip1
 because inhibition of 
MEK1 prevented the reduction of p27
Kip1
 protein and its mRNA, whereas direct activation of 
ERK (through a constitutively active form of MEK) led to a reduction of p27
Kip1
 protein and 
mRNA, demonstrated in smooth muscle cells (Sakakibara et al. 2005). Similar observations 
were made in a malignant breast epithelial cell line MCF-7 that overexpressed the ErbB2: the 
presence of this receptor reduced p27
Kip1
 and increased cyclin D1 (Lenferink et al. 2001). 
This is because Erk1 and Erk2 phosphorylate p27
Kip1
 and so make it a target for degradation. 
The same was shown for p21
Cip1
. In non-malignant breast epithelial cells, this inhibitory 
protein was phosphorylated, thus target for degradation, following the activation of the MAP 





1.4.1.3.2 The PI3K pathway and the inhibitors p21Cip1 and p27Kip1 
The Cdk inhibitor p27
Kip1
 is phosphorylated for its degradation upon growth factor induced 
stimulation of the PI3K pathway, as was demonstrated with the specific inhibitor LY294002 
in intestinal epithelial cells (Sheng et al. 2001), in several breast cancer cell lines (Motti et al. 
2004) and in renal epithelial cells (Kim et al. 2009). 
1.4.1.4 Hyperphosphorylation of the retinoblastoma protein 
The retinoblastoma protein (pRb) represents the critical factor in determining the timing of 
the restriction point: in its partially (hypo-) phosphorylated state pRb suppresses cell cycle 
progression. These inhibitory properties are lost when the protein becomes phosphorylated 
and therefore inert. The R point is passed once the Rb protein has been hyper-phosphorylated, 
and this happens in two steps. First, the phosphorylation of the protein is initiated by the 
complex of the cyclin-dependent kinases (CDK) 4 and 6, which beforehand must become 
activated through cyclin D1 (CCND1). The second phase of phosphorylation is achieved 
through the CDK2 (which has to be cyclin E-activated earlier). The phosphorylation of pRb 
disrupts its association with E2F transcription factor family members, starting off the 
transcription of genes required for DNA replication in synthesis phase (Bracken et al. 2004; 
Harbour and Dean 2000; Weinberg 1995). Generally speaking, the inactivation of Rb family 
proteins and CDK inhibitors creates positive feedback loops and reduces the cell’s 
dependency on mitogens, eventually leading to the irreversibility of the S phase entry.  
1.4.1.4.1 The MAPK pathway and the Retinoblastoma protein 
The Ras kinase, the upstream activator of the MAP kinase, is linked directly to the cell cycle 
via the retinoblastoma protein, as Rb
-/- 
mouse embryonic fibroblasts (MEFs) had a reduced 
requirement for Ras to start DNA synthesis. The same observation was made by Peeper and 
co-workers (1997) in two different cell lines, both Rb
+/+
, where Ras elimination led to G1 
arrest, whereas in Rb
-/-
 lines, DNA synthesis still took place, despite the lack of Ras. The 
specificity of the Rb dependence for Ras was confirmed by successful induction of a G1 
arrest with different means (Cdk inhibitors) in both cell types (Rb positive and negative). 
These results suggest that the inactivation of pRb is one of the functions of Ras signalling that 
promotes cell proliferation. Interestingly, the relationship between Ras and pRb is 
bidirectional, as demonstrated by Lee et al. (1999) in MEFs: the Rb
-/- 
cells displayed 
increased levels of Ras, which were lowered when pRb was reconstituted (Lee et al. 1999; 
Peeper et al. 1997; Mittnacht et al. 1997). Assays involving directly the MAP kinase and the 
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retinoblastoma protein as targets showed in human melanoma cells with constitutively active 
Erk1 and 2, that the inhibition of the MEK1 (upstream of the MAP kinases) resulted in hypo-
phosphorylation of the retinoblastoma protein (Kortylewski et al. 2001). 
1.4.1.4.2 The PI3K pathway and the Retinoblastoma protein 
Dufourny et al. (1997) found that IGF-1 stimulates DNA synthesis and proliferation in MCF-
7 cells, and after 16 hours of stimulation, the pRb was markedly increased. This could be 
reversed by the specific PI3K inhibitor LY294002, but not by an MEK1 suppressor, 
indicating the specificity of the signal mediated by IGF-1 for the PI3 kinase (Dufourny et al. 
1997). 
1.4.2 Phospholipase pathways 
Since PLC acts upstream of PKC, which activates the MAP kinases Erk and JNK, it is 
conceivable that all implications of the mitogen-activated pathway for the processes in the G1 
to S phase transition are also applicable to the phospholipase pathways. This is supported by 
the finding that RNAi mediated knockdown of several different PLC groups resulted in 
abandoned proliferation of fibroblast cells, because DNA synthesis was affected (Kaproth-
Joslin et al. 2008). 
Evidently, the MAP kinase and the PI3 kinase both have crucial roles in triggering events 
necessary for the transition from G1 into S phase. Thus, the disruption of either pathway most 
likely will provide valuable information about the signalling network activated in the MCF-
12A cells. Additionally, the use of a PLC inhibitor may reveal if the PKC feeds into those 






Figure 35 Schematic overview of molecular mechanisms involved in cell cycle progression 
The key molecular mechanisms responsible for successful cell cycle progression, as described in detail in the 
section 1.4 of this chapter, are initiated by dimerisation of the receptor tyrosine kinases (RTK), induced by 
binding of a ligand. Kinases and lipases may be activated directly by the dimerised RTK, e.g. the Src and PI3 
kinases and the phospholipase C (PLC), or through an adaptor protein, such as Grb2. The signals triggered by 
the ligand are propagated via different pathways, resulting in activation of the Myc transcription factor and the 
cyclin D/CDK4 (CDK6) and cyclin E/CDK2 complexes. These complexes are responsible for 
hyperphosphorylation of the retinoblastoma protein (Rb), commencing cell cycle progression.  
2 OBJECTIVES AND METHODOLOGICAL CONSIDERATIONS 
The aim of this part of the work is to investigate the signalling networks in MCF-12A cells 
that have a role in promoting cell cycle progression within the framework of the 
discontinuous exposure assay. On the basis of information about the kinases that are activated 
downstream of EGFR and IR, the objective was to characterise their involvement in cell 
cycle progression from G1 to S. Of particular interest was to analyse which signalling events 































triggered at the same time. If so, is one pathway more prominent than the other, or are all of 
equal importance during the first and second pulse? If, for example, EGF is administered 
during the first pulse of growth factor stimulation, is only the EGFR activated, and if so, does 
this receptor trigger multiple cascades, or is its action more restricted?  
Considering the importance of the three pathways discussed above for cell cycle progression, 
we selected inhibitors that target critical elements of these pathways. The features of the 
chosen inhibitors, their mode of action and important considerations for experimental design 
are discussed below. 
PD98059 binds selectively to MEK1 (a MAPKK) and so prevents its activation by the 
upstream located Raf-1 kinase. Therefore, the effectors Erk1/2 (which are MAP kinases) will 
not be phosphorylated (Cowley et al. 1994). 
LY294002 is a highly selective inhibitor of PI3K, and also blocks the PI3 kinase-dependent 
Akt phosphorylation and kinase activity (Vlahos et al. 1994). 
The pyrazolo-pyrimidines PP1 and the related compound PP2 were the first inhibitors found 
for the Src family kinases, and PP2 is still the most selective inhibitor for Src available 
(Hanke et al. 1996). For this reason it was selected for our studies. 
Finally, U73122 inhibits selectively receptor-coupled PLC dependent processes, but is not 
specific for a subclass of the PLC lipases; instead, it inhibits all isotypes of the 
phospholipases C (β, γ δ, etc.). 
For every experimental procedure presented in this chapter, the MCF-12A cells were pre-
incubated with the inhibitor alone (in basal medium, 20 minutes, at the concentrations 
specified in the material and methods’ section (Chapter 2)), before addition of fresh basal 
medium containing the growth factor(s). This medium also contained the inhibitor at the 
same concentration as during the pre-incubation period, so that the total exposure to 
inhibitors lasted 50 minutes (in case of the first pulse) or 10h 20min (for the second pulse). 
The pre-incubation step was important as to occupy and block the receptors on the cell 
surface before the presence of the growth factors, since triggering of signalling pathways by 
ligand binding is a very fast mechanism. If the inhibitors were added at the same time with 
the growth factors, it is likely that the receptor was activated before the inhibitor reached the 
cell surface. The concentrations of the inhibitors to be used had been established beforehand 
in our laboratory, with the exception of the PLC inhibitor U73122. Its optimal concentration 
for our use (1 µM) was experimentally assessed, based on suggestions from the supplier.  
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The percentages of cells in the various cell cycle phases were normalised to the negative 
control sample (G0 blocked cells), as described before (Chapter 3, page 53). The positive 
control samples were from cells that had received both pulses with the growth promoting 
factors, but no inhibitors. Instead of the pre-incubation times, these samples were exposed to 
basic medium for 20 minutes, in order to compensate for any stress-induced effects from the 
washing steps. The data obtained by flow cytometry were subjected to a Student’s t-test to 
determine significant differences between the treatments with inhibitors and the control 
samples. It was expected that incubation with inhibitors would hinder the cells from re-
entering the cell cycle. Thus, the significance test was performed as a comparison to the 
positive control. A significance test in relation to the negative control is less suited, because it 
cannot be assumed that the inhibitors cancel out completely the effect of growth factor 
stimulation on cell cycle progression.  
3 RESULTS 
First, the effects of inhibiting specific kinases or a lipase during the first pulse of growth 
factor administration was examined. In this set of experiments, the inhibitors were present for 
a total of 50 minutes only (20 minutes pre-incubation in basal medium, followed by the first 
pulse of 30 minutes with EGF and the respective inhibitor). Three out of the four inhibitors 
tested had a marked effect on S phase progression (Figure 36). The strongest disruption was 
observed with the MEK1 inhibitor PD98059 (20 µM), which reduced the number of cells 
found in S+G2+M phase significantly compared to the positive control, almost to the level of 
the G0 blocked sample. Of comparable magnitude were the effects of the PLC inhibitor 
U73122 (1 µM), although with this compound, the variation between experiments was higher 
than with the MEK1 inhibitor, as seen from the size of the error bar, so that the reduction of 
the S phase percentage was less significant when compared to the positive control. 
Administration of the PI3K inhibitor LY294002 (20 µM) during the first pulse also decreased 
the number of cells found in S+G2+M phase at the end of the assay, whereas the Src inhibitor 





Figure 36 Effect of specific inhibitors administered during the first pulse on cell cycle progression of 
MCF-12A cells 
Effect of MEK1 inhibitor (PD98059, 20 µM), PI3K inhibitor (LY294002, 20 µM), Src inhibitor (PP2, 25 µM) 
or PLC inhibitor (U73122, 1 µM) when added in the first pulse of growth factor administration in the 
discontinuous exposure assay. All samples were treated with the second pulse of growth factors and were 
analysed after a total release time of 18 hours. Percentages obtained with flow cytometry were normalised to the 
negative control (G0 blocked sample, set to 1). Values show the mean of 4 independent experiments, error bars 
show SEM. Student’s t-test was performed for significance testing, samples marked with * (P=0.1) and ** 
(P=0.05) are significantly different from the positive control (C+). Positive control: 1st pulse (30min) = 50 ng/ml 












































































































Next, we examined whether any of these inhibitors would interfere with cell cycle 
progression when administered during the second pulse of growth factor exposure. As seen in 
Figure 37, the MEK1 inhibitor PD98059 (20 µM) was again able to significantly reduce the 
fraction of cells that progressed into the S phase, when compared to the positive control. This 
compound reduced the number of S phase cells to a similar level as when it was administered 
during the first pulse. However, the strongest reduction was seen with the PI3K inhibitor 
LY294002 (20 µM): under its impact, no cells were able to leave the quiescent state. Equally 
strong was the effect of the Src inhibitor PP2 (25 µM). The mean fraction of cells treated 
with the PLC inhibitor U73122 (1 µM) that had progressed to S phase was decreased 
compared to the positive control, but again, as with the sample treated during the first pulse, 
the variation between experiments was considerable. As a consequence, the difference was 








Figure 37 Effect of specific inhibitors administered during the second pulse on cell cycle progression of 
MCF-12A cells 
Effect of MEK1 inhibitor (PD98059, 20 µM), PI3K inhibitor (LY294002, 20 µM), Src inhibitor (PP2, 25 µM) 
or PLC inhibitor (U73122, 1 µM) when added in the second pulse of growth factor administration in the 
discontinuous exposure assay. All samples were treated with a first pulse of EGF and were analysed after a total 
release time of 18 hours. Percentages obtained with flow cytometry were normalised to the negative control (G0 
blocked sample, set to 1). Values show the mean of 4 independent experiments, error bars show SEM. Student’s 
t-test was performed for significance testing, samples marked with **are significantly different from the positive 
control (P=0.05). Positive control (C+): 1st pulse (30min) = 50 ng/ml EGF, 2nd pulse (10h) = EGF + insulin (20 
+ 100 ng/ml). 
 
The marked reduction in S phase progression with both the MEK1 and PI3K inhibitors 
indicates that both pathways, the MAP and the PI3 kinase pathways, were activated through 
the combined action of EGF + insulin, but that the inositol dependent pathway played a more 
important role at this stage of the cell cycle. It was therefore interesting to see if the addition 
of both the MEK1 inhibitor PD98059 (20 µM) and the PI3K inhibitor LY294002 (20 µM) 






































































































phase, or perhaps even to inhibit cell cycle progression completely. Administration of both 
inhibitors was then repeated for the second pulse, and the results are shown in Figure 38. The 
combined action of the two inhibitors during the first period of incubation did not decrease 
further the progression through G1 into S phase. The percentages of cells that were found in 
S+G2+M phase were very similar to the results obtained with cells that were incubated with 
each inhibitor separately. Treatment with both inhibitors together during the second pulse did 
reduce the fraction of cells that progressed into the cell cycle to the levels observed in growth 
arrested controls, but the effect was not different from that seen with the PI3K inhibitor 
individually which already decreased this number to the lowest level possible, equal to the 
G0 blocked sample.  
 
Figure 38 Effect of combined inhibition of MEK1 and PI3K on cell cycle progression of MCF-12A cells 
Effect of the combination of the MEK1-inhibitor PD98059 (20 µM) and the PI3K-inhibitor LY294002 (20 µM) 
when added either in the first or the second pulse of growth factors in the discontinuous exposure assay. All 
samples were analysed after a total release time of 18 hours. Percentages obtained with flow cytometry were 
normalised to the negative control (G0 blocked sample, set to 1). Positive control (C+): 1st pulse (30min) = 50 











































































This series of experiments was aimed at studying the pathways that are activated in MCF-
12A cells upon treatment with the discontinuous exposure assay, representing a combination 
of growth factors at two discrete time points, both necessary for cell cycle re-entry. The use 
of several inhibitors, specific for three different kinases and one lipase, revealed the sequence 
in which the MAP kinase, the PI3 kinase and the phospholipase pathways are activated upon 
growth factor stimulation, as well as details about the adaptor molecules involved. An 
overview of the signal cascades activated by the two investigated growth factors, EGF and 
insulin, is given in Figure 39 and Figure 40.  
 
 
Figure 39 Overview of cascades downstream of EGRF involved in cell cycle progression in MCF-12A cells 
The EGRF is a receptor tyrosine kinase which, once dimerised, associates with a multitude of molecules to 
trigger the PI3K, MAPK and PLC pathways. For more details please refer to the relevant sections 1.1.3 and 1.3 





































Figure 40 Overview of cascades downstream of IR involved in cell cycle progression in MCF-12A cells 
The IR is present as a stable heterotetramer on the cell surface and binds to insulin receptor substrates 1 and 2 
(IRS1 and IRS2), as well as the adaptor molecules Gab-1 and Gab-2, which are also considered receptor 
substrates. Different signalling cascades are triggered at the level of the receptor substrates. For details, please 
refer to the relevant sections 1.2.3 and 1.3 in the introduction of this chapter. The sites of action of the inhibitors 
used are marked with X. 
 
4.1 First pulse of growth factors (EGF) 
S phase progression was markedly disrupted with inhibitors for MEK1 and PI3K in the first 
pulse. This suggests that the first incubation with EGF triggered two pathways, the MAP 
kinase and the PI3 kinase mediated pathways. Both seemed to be equally important, because 
with the specific inhibitors, the cell cycle progression was affected to the same extent. The 
effects observed were similar to those where the growth factor was omitted completely from 
































time point. It is important to note that the effects observed cannot be explained in terms of 
residual inhibitory molecules remaining in the culture dishes after the first pulse, because 
after removal of the culture medium, the cells were washed twice with buffer before addition 
of fresh basal medium. Therefore, any remaining inhibitor would be present at a much diluted 
concentration only. 
It is conceivable that two independent pathways were set in motion as a result of the 
activation of one type of receptor tyrosine kinase: the dimerised receptor provides docking 
sites for molecules that contain a SH2 domain, and for that reason attracts an array of 
proteins. These proteins include the non-receptor tyrosine kinase Src, the adaptor molecules 
Grb2 and Shc, and the regulatory protein p85. Firstly, p85 is the regulatory unit of the 
phosphatidyl-inositol-3 kinase (PI3K), hence upon binding of the subunit to the EGFR, the 
PI3 kinase may have become activated. The adaptor molecules Grb2 and Shc do not have 
catalytic properties themselves, however, they are essential for transducing signals from a 
receptor to the kinases located further downstream, namely the PI3 kinase (through Gab-1 
which binds p85) and the mitogen-activated protein kinase (through the exchange factor Sos 
that activates Ras). Finally, the Src kinase phosphorylates a multitude of substrates, including 
focal adhesion proteins, structural proteins such as tubulin, the phospholipase Cγ and the 
protein kinase Cδ, and the molecules Shc and p85. The last two evidently connect the Src 
with the main pathways of PI3 and MAP kinases, as reviewed in detail by Thomas and 
Brugge in 1997 (Thomas and Brugge 1997). However, Src was apparently not involved in the 
signalling generated by EGF in the first instance, because the specific Src inhibitor PP2 was 
unable to prevent cell cycle progression. When rendered inactive through reversible 
inhibition, Src can be effectively bypassed through direct activation of Shc and Grb2 by 
EGFR (see Figure 39 and 40). Based on these observations it was concluded that in quiescent 
MCF-12A cells, EGF stimulated activation of both PI3 and MAP kinases was mediated 
entirely through the adaptor molecules Shc and Grb2. 
The Src kinase is an activator of the MAP and PI3 kinase, situated much further upstream in 
the signalling cascades. As an alternative to this tyrosine kinase, it was tested if an inhibitor 
of a lipase, also located further upstream than the previously investigated MEK1 and PI3 
kinases, would hinder cell cycle progression. PLC indirectly acts on PKC, as it provides co-
factors necessary for PKC activity. PKC phosphorylates different types of MAP kinases 
(Erk1, Erk2 and JNK). PLC itself is activated directly by the dimerised EGFR, as it is able to 
bind to the receptor via a SH2 domain. In the light of these interconnections, it was 
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speculated that in the MCF-12A cells, the PLC inhibitor targeted another relatively far 
upstream activator, exclusive to the MAPK cascade. Indeed it was observed that the PLC 
inhibitor hindered cell cycle progression to an extent similar to the kinase inhibitors. Hence 
three different pathways were activated by dimerisation of the EGFR, PI3K, PLC and 
Ras/Raf-1/Erk1/2, and all of them were equally important for promoting cell cycle re-entry. 
4.2 Second pulse of growth factors (EGF and insulin) 
4.2.1 The MAPK and PI3K pathways and mediation of signalling through 
Src kinase 
The MAPK and the PI3K pathways were activated also during the second pulse, with 
consequences for cell cycle progression. At this time, the PI3 kinase pathway seemed to be 
more important in terms of cell cycle progression, considering that the fraction of cells 
hindered from cell cycle entry was larger upon administration of the PI3K inhibitor than with 
the MEK1 inhibitor. The mean value for the S+G2+M phase percentages was even below the 
percentages found for the cells blocked in G0 after treatment with the PI3K inhibitor 
LY294002 suggesting that disruption of the PI3K pathway alone during the second pulse was 
able to keep additional cells in quiescence. The combination of both the PI3K and MEK1 
inhibitors was not able to reduce the number of escaped cells further than to the negative 
control level (G0 blocked cells). 
Another important finding was that inhibition of PLC during the second pulse had very little 
impact on hindering cell cycle entry. This is in contrast to the situation during the first pulse, 
where administration of the PLC inhibitor U73122 significantly disrupted cell cycle 
progression.  
Further differences were seen in relation to Src. The specific inhibitor PP2 reduced the 
numbers of cells found in S phase to the same extent as the PI3K inhibitor. This suggests that 
the activation of the PI3 kinase pathway during the second pulse seemed to be mediated 
mainly through the Src kinase. In contrast, during the first pulse, Src signalling was found to 
be redundant.   
The Src kinase is indeed involved in a range of signal transductions that control cell growth 
and proliferation, as well as apoptosis. Interestingly, this kinase is not only activated by 
receptors, but can itself modulate RTKs (Bromann et al. 2004). The relationship between the 
non-receptor tyrosine kinase Src and the RTK was first shown with the PDGF receptor to 
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which Src bound through its SH2 domain (Mori et al. 1993). The binding of Src releases it 
from its autoinhibited, membrane bound state by opening the intramolecular loop of the 
domains; the tyrosine residues are then phosphorylated, and the kinase site is active. The 
importance of the association of Src with the receptor was demonstrated in quiescent 
fibroblasts: upon stimulation with PDGF, those cells showed an increased Src kinase activity. 
Moreover, this also correlated with higher levels of active PI3 kinase (Kypta et al. 1990). The 
implications of this relationship for cell cycle progression were assessed by Courtneidge et al. 
(1993): fibroblasts with a catalytically inactive form of the Src kinase were incapable of 
progressing through the cell cycle under growth stimulation (Courtneidge et al. 1993). Their 
inability to leave the G1 phase was a result of failed DNA synthesis, but this was rescued 
when the transcription factor Myc was injected (Barone and Courtneidge 1995). 
Of special interest in this context is that the EGFR is often overexpressed together with Src in 
mammary tumours (Muthuswamy et al. 1994), and that the Src kinase has been shown to 
physically associate with the EGFR and HER2 receptor in breast cancer cells (Biscardi et al. 
1998). The malignant cells that overexpressed both kinases also showed a stronger increase 
of DNA synthesis upon stimulation with EGF, further underlining the importance of the 
communication between Src and EGFR for proliferation (Biscardi et al. 1998). The Src 
kinase is not only mediating EGFR signalling, but it even potentiates the effect of the 
receptor on proliferation, because it phosphorylates the receptor again on a different residue, 
as shown in fibroblast cells (Biscardi et al. 2000; Tice et al. 1999). Increased Src activity led 
to loss of cell-cell adhesion and increased invasiveness in malignant cells. In normal 
epithelial cells, increased Src resulted in loss of adherence junctions. Underlying this effect of 
the Src was an overly induced PI3 kinase (Kotelevets et al. 2001). Taken together, these 
observations suggested that overexpression of Src contributes to tumour progression. 
In normal breast epithelial cells (MCF-10A cell line), the overexpressed Src kinase also 
stimulated proliferation, in cooperation with the Grb2-associated binder 2 (Gab-2) (Bennett et 
al. 2008). Gab-2 serves as a linker between a receptor and the PI3 kinase (by binding p85) or 
the MAP kinase, by binding Shp 2. Likewise, in mouse mammary epithelium, Src ablation 
disrupted cell cycle progression and cyclin expression, elevating at the same time the 
expression of Cdk-inhibitors (Marcotte et al. 2011). 
Clearly, the Src kinase plays an important role for transducing growth promoting signals from 
the receptor to the downstream kinases, and especially the EGF receptor acts in tune with this 
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kinase. From the results presented in this chapter, it was concluded that a similar strong 
relationship between these two kinases also existed in the MCF-12A cells. However, it is 
somewhat surprising that the predominantly activated pathway was the PI3 kinase cascade, 
because signalling through the EGFR is classically associated with the MAP kinase cascade. 
When the Erk1/2 pathway was disrupted, S phase progression was significantly hindered, but 
the effect was not as strong as with the PI3K- and the Src-inhibitors. Obviously, with the 
experimental set-up employed here, it was not possible to distinguish the effects of the two 
different growth factors in the second incubation period, but the potential role of insulin and 
its receptor IR needs consideration here: 
One of the proteins shown to interact with IRS-1 after insulin stimulation is the Src family 
member Fyn (Sun et al. 1996). This interaction is possible through the SH2 domain of Fyn. 
Viewed in the context of the results presented here, it would suggest that MCF-12A cells 
utilized the Src family member Fyn for signalling. Fyn is also actively inhibited by PP2, the 
molecule that was used for the inhibitory experiments shown here. However, according to 
Thomas and Brugge (1997), no difference in Fyn kinase activity has been observed after 
insulin treatment (Thomas and Brugge 1997). More recently, however, insulin was shown to 
cause Src activity in muscle cells, and physical association of the kinase with the IR. At the 
same time, the Src inhibitor PP2 disrupted insulin-induced phosphorylation of the IR 
(Rosenzweig et al. 2004). Crosstalk between IRS and Src for phosphorylation of focal 
adhesion proteins was reported in CHO cells (El et al. 2001). On the other hand, insulin 
receptor tyrosine kinase substrates (IRTKs) are important for cell motility; migration of 
malignant fibroblasts was enhanced with high, Src-induced phosphorylation of IRTKs (Chen 
et al. 2011). Although these observations were made in different systems, the possibility that 
a similar relationship between the insulin receptor and the Src kinase existed also in the 
breast epithelial cells cannot be dismissed.  
However, one needs to bear in mind that insulin was not absolutely required for cell cycle 
progression of the MCF-12A cells. In Chapter 4, it was shown that the cells were able to re-
enter the cell cycle after serum-depleted induced G0 block when EGF only was administered 
in both incubation times. Such an exposure regime resulted in almost the same fraction of 
cells in S+G2+M phase than seen with the positive control treatment. On the other hand, 
insulin is also able to induce MAP kinase signalling, which is initiated through the binding of 
the Grb2 adaptor to the IRS: 
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4.2.2 Crosstalk between the pathways that are triggered through EGF and 
insulin 
Without a doubt, there are many similarities between the cascades that are triggered by 
activation of the EGFR and the IR. It is not evident if these pathways, when triggered in the 
same cell, are attenuated by each other, signal completely independent of each other, or even 
reinforce each other through crosstalk mechanisms. To know which of these three 
possibilities is most likely in place in MCF-12A cells is important for assessing the effect that 
the growth factors EGF and insulin had on the epithelial cells. Published work about crosstalk 
between mitogenic signalling pathways mainly handles overlapping functions between the 
estrogen receptor (ER) and the IGF-1R, because the ER activity plays an important role in 
breast cancer, and the signals of the IGF-1R and the ER have been found to enhance each 
other. Therefore it might be of importance to attenuate both receptors for the treatment of the 
disease (Hamelers and Steenbergh 2003). Comparatively little work has been done to 
systematically investigate the overlaps between the cascades triggered by the EGF and the 
IGF-1R, and even less for the EGFR with IR. In colon carcinoma cells, EGFR activation was 
found to be downstream of the IGF-1R, because an inhibitor for the PI3K (activated by IGF-
1R) resulted in loss of EGFR activation (Hu et al. 2008b). Both activities, originating from 
EGRF and IGF-1R, also target the pro-apoptotic protein BAD, but their downstream 
pathways phosphorylate BAD in different residues, thus enhancing each other’s effect 
(Gilmore et al. 2002). In HepG2 (human liver hepatocellular carcinoma) cells, EGF was able 
to activate IGF-1R. This transactivation was mediated by the Src kinase: EGF stimulated the 
tyrosine phosphorylation of Src, and induced its association with the IGF-IR. EGF induced 
IGF-1R activation could be repressed by the specific inhibitor PP2. EGF also induced 
phosphorylation of IRS-1 and IRS-2, pointing towards the possibility of a heterodimer in 
these cells (Hallak et al. 2002). This different kind of crosstalk between the receptor types 
indeed happens: both the ErbB-family receptors and the IGF-1R and the IR have been found 
to form heterodimers with each other, even between families, with full cellular functionality, 
which could mediate resistance to anticancer therapies (Jin and Esteva 2008). 
4.2.3 The phospholipase pathway 
The phospholipases are bound to growth factor receptors (PDGFR and EGFR) upon growth-
factor induced activation of the receptors, and mediate mitogenic signalling through offering 
an additional docking site for Grb2 with their associated Ras/Raf-1 signalling. The PLCs 
141 
 
therefore link the MAP kinase pathway in an additional way to the EGFR. The disruption of 
the lipase presented a somewhat more direct inhibition of the EGF-mediated MAP kinase 
signalling, than the MEK1 inhibitor, because at this point of inhibition, crosstalk between two 
or more pathways may already have taken place, at a higher level of signal transduction (at 
the stage of Grb2, because this adaptor spreads to both cascades). Unfortunately, the PLC 
inhibitor during the second pulse yielded mixed results: in one exposure experiment, cell 
cycle progression was clearly impaired with the lipase inhibitor, but in the second assay, this 
result was not seen. The experiment was carried out four times in total, but the percentages 
for the S phase fraction were highly variable, so that the difference between the treated and 
the control samples was statistically not significant.  
5 CONCLUSIONS 
It is concluded that the activation of the EGFR through EGF in the first pulse was propagated 
via the Erk1/2 kinases, through two different mechanisms, first the activation of PLC, and 
secondly through binding of adaptor molecules that transduce the signal via the Ras/MEK1 
pathway. The latter mechanism then also relayed signals towards the PI3 kinase pathway, and 
both cascades seemed to be equally important during the first pulse. Bearing in mind the 
function of the restriction point (which is to ensure that the signals thus far received are 
sufficient to induce and pursue transcription), it seems conceivable that these two pathways 
converge further downstream, for one single purpose, which is to induce transcriptional 
activity leading to cell cycle activation. 
The second pulse of growth factors (EGF combined with insulin), triggered several pathways 
through the EGFR and the IR. In contrast to the first pulse, the Src kinase was strongly 
involved in signal transduction leading to cell cycle progression. Since Src is mainly 
associated with the EGFR, it seemed that EGF participated to a greater extent to activating 
downstream signals, than did insulin. One could be inclined to interpret that insulin indeed 
has a weak but measurable role in promoting PI3K activity, because when the PI3 kinase was 
inhibited, the percentage of S phase cells was slightly more reduced than with the Src 
inhibitor. In order to assess the contribution of each single receptor-bound transducer (Src, 
IRS), further experimentations are necessary, which employ more specific inhibitors, e.g. as 
to interrupt Grb2 and its associated binders. Additionally, repetitions of the assay with the 
lipase inhibitor during the second pulse would be of interest, especially in the light of the 
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findings by Choi et al. (2005) in kidney cells (HEK cells), where Grb2 association with PLCγ 
resulted in negative regulation of the EGFR-mediated cell signalling (Choi et al. 2005). 
It is now necessary to seek molecular explanations for the observations made in this chapter 
by investigating the identity of the signalling molecules present after the first and the second 
pulse of growth factor administration. What is the nature of the signals triggered during the 
first pulse, and how are these signals taken forward to promote cell cycle entry during the 





Regulation of gene and protein expression 
for G1/S transition 
1 INTRODUCTION 
An array of diverse processes needs to take place in an orderly fashion for cells to be able to 
successfully progress out of the quiescent state through G1 into S phase. For MCF-12A cells, 
an experimental set-up was developed where, after serum-depletion for accumulation in the 
G0 phase, the cells received different growth factors in a discontinuous fashion at two distinct 
time points. This discontinuous stimulation was sufficient to bring the cells back into the cell 
cycle, as demonstrated by elevated numbers of S phase cells at the end of the assay. In the 
previous Chapter 6 we employed specific kinase inhibitors to develop hypotheses about the 
kinases involved in S phase induction during the two distinct pulses in the discontinuous 
exposure assay. However, the use of kinase and lipase inhibitors is an indirect method of 
investigation which cannot reveal which signalling molecules are indeed activated by the 
various growth factors during the discontinuous exposure assay. Here, immunoblotting of cell 
lysates against specific kinase antibodies was conducted, firstly to establish the identity of the 
enzymes activated during cell cycle progression, and secondly the specificity of the inhibitors 
used. In addition to these two aspects, molecular explanations for the observations made in 
the previous Chapter 6 were sought. To realise this aim, it was necessary to analyse other 
targets as well. A review of the signalling molecules considered for this part of the work is 
given in the following section. 
1.1 Exploring the molecular basis of cell cycle progression – selection of 
targets 
1.1.1 Signalling kinases Src, Akt, Erk1/2 
The general association of external growth factors with intracellular signalling was discussed 
in the previous Chapter 6. The importance of the kinases Src, Akt and Erk1/2 is recapitulated 




The Src kinase is not immediately involved in the induction of gene and protein expression. 
However, it provides a link between growth factor receptors and intracellular signalling 
molecules and triggers several pathways that have pivotal roles for the positive regulation of 
transcription factors and the transition from the quiescent state into S phase (Thomas and 
Brugge 1997). Thus the activity levels of the Src kinase were monitored by immunoblotting.  
Akt is phosphorylated by the PI3 kinase, which can be activated either by the Src kinase, or 
by associating directly with ligand-bound receptors. Phosphorylation of Akt, which is 
synonymous with activation of the PI3K pathway, in the G1 phase is essential for subsequent 
initiation of DNA synthesis induced by growth factors. Together with the MAPK pathway it 
ensures a rapid increase in c-Myc expression (Liang and Slingerland 2003). The role of the 
transcription factor c-Myc was detailed previously (cf. pages 99 and 121). 
The mitogen-activated protein kinase (MAPK) cascade is the best studied signalling pathway 
in mammalian cell lines; the involved kinases transduce signals from extracellular, receptor-
bound growth factors into the cell, eliciting growth and proliferation. The cascade may be 
triggered by several molecules situated between the MAPK kinase (MEK) and the dimerized 
receptor. The MAP kinases include the ERK1, ERK2, the p38 MAP, and the JNK kinases. 
These are phosphorylated by the MAPK kinases such as MEK1 and MEK2. MEKs in turn are 
activated by Raf, which needs to be phosphorylated beforehand by the small G-protein Ras 
(Ramos 2008). In fibroblast cells, the Ras protein was shown to be required for S phase 
initiation, in response to serum stimulation, and – in a sufficiently high concentration – 
promoted DNA synthesis also without the addition of serum (Mulcahy et al. 1985).  
1.1.2 Transcription factor c-Myc 
The link between the growth factor stimulation and the transcription factor Myc has been 
established at numerous levels, as well as the role of Myc in cell cycle progression. Most of 
these investigations were carried out in quiescent fibroblast cells, which were also used to 
show the following: 
 the stimulation with PDGF for a few hours resulted in a significant increase of MYC 
RNA levels, and the amount of RNA found was in direct correlation to the 
concentration of the growth factor (Kelly et al. 1983). 
 Inhibition of DNA synthesis by a Src antibody was rescued with constitutively 
expressed Myc (Barone and Courtneidge 1995), 
145 
 
 but MEK induced DNA synthesis was shown to be also dependent on the activation of 
the PI3K pathway (Treinies et al. 1999). 
 The Ras and Myc proteins both have been identified as critical components which are 
key for the control of normal cell growth: as shown by Leone and colleagues (1997), 
overexpression of Myc alone or constitutive activation of Ras alone was insufficient 
for Cdk activity in G1 phase, but co-expression of Myc together with activated Ras 
induced S phase (Leone et al. 1997). 
 When Ras expression was delayed after stimulation with EGF, cells were unable to 
leave the G1 phase. This was the case even if a dominant negative Ras mutant was 
induced up to 3 hours after the addition of EGF (Takuwa and Takuwa 1997). 
 The ability of the Raf kinase to induce Myc was severely impaired after addition of 
the inhibitor PD98059, providing a direct correlation between MEK1 and the 
transcription factor (Sears et al. 1999). Additionally, the MAP kinases Erk1 and 2 
directly enhanced the stability of the Myc protein by phosphorylating a specific serine 
residue on it (Ser62), and this residue was also important for proper degradation of the 
protein, providing a switch for keeping the balance between activation and 
disassembly of Myc (Sears et al. 2000; Sears et al. 1999). 
 These stability enhancing properties of the kinases could be important for the overall 
role of the transcription factor, because it is very unstable: the level of Myc was 
shown to be very low in quiescent cells, but peaked within 2 hours of stimulation, 
followed by a rapid decline to half-maximal levels. This is in agreement with reports 
of a very short half-life (< 1 hour) of the protein in growing cells. On the other hand, 
the degradation of Myc was slowed down by activating the Ras pathway (Sears et al. 
1999). 
 In different fibroblast cell lines, the activity of the Erk1 and Erk2 together with the 
induction of Myc expression were both necessary for cell cycle progression (Jones 
and Kazlauskas 2001). 
Because of these correlations between growth factor stimulation, the activation of Src, Ras, 
PI3 and MAP kinase cascades and the transcription factor during cell cycle progression, the 
expression pattern of Myc was examined in the MCF-12A cells during the discontinuous 
exposure, at two different levels: transcription of the gene coding for c-Myc was monitored 




1.1.3 Cyclin D1 
Cyclins are now established as key regulators of the cell cycle. There are two types of cyclins 
in mammalian cells important for the transition from one cell cycle stage into the other, the 
D-type and the E-type cyclins. Cyclin D1 has been shown to be essential for successful 
progression from G1 phase into S phase. The mitogen-activated protein kinases Erk1 and 
Erk2 were found important for inducing the transcription of the cyclin D1 gene in early G1 
phase in response to growth factor stimulation, and its expression must be continuous for 
successful cell cycle progression. The relationship between growth factor activated cascades 
and the cyclins was examined at different levels in numerous studies: 
 The transcription factor Myc protein induced expression of D-type cyclins (Perez-
Roger et al. 1999) 
 The Ras protein and the MAP kinase both activated cyclin D1 transcription (Albanese 
et al. 1995; Filmus et al. 1994) 
 The induction of cyclin D1 was controlled by the activation of the MAP kinases Erk1 
and Erk2 (Lavoie et al. 1996), and the addition of the MEK1 inhibitor PD98059 at 
several hours after exposure to a mitogen in serum-starved cells (PDGF in the case of 
fibroblasts) resulted in a significant decrease in the expression of cyclin D1, both at 
the protein and the mRNA level. The continued expression of cyclin D1 was disrupted 
after the inhibition of the MAP kinase compared to uninhibited control cells, 
demonstrating a requirement for sustained MAPK activation throughout G1 for the 
positive regulation of cyclin D1 (Weber et al. 1997). 
 However, overly enhanced activity of the cyclins is not desired since the 
overexpression of D-type cyclin protein led to a shorter G1 phase (faster progression 
through G1) and a premature entry into S phase (Liu et al. 1995; Quelle et al. 1993). 
 In line with these reports is the observation that the gene coding for cyclin D1 was 
found to be overexpressed in many human cancers (Arber et al. 1996a; Arber et al. 
1996b). 
It was important to investigate relationships between mitogen stimulation of quiescent cells 
and the expression of cyclin D1 also in the mammary epithelial cell line MCF-12A. Because 
induction of cyclin D1 is dependent on transcription factors such as c-Myc, and because 
translation and synthesis may take several hours, with the protein product being detectable 
only at the very end of the discontinuous exposure assay, cyclin expression was examined at 
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the gene level only: the transcription into mRNA of the gene coding for cyclin D1 (CCND1 
or PRAD1) was monitored during the discontinuous exposure assay and compared to cells 
that were exposed continuously to serum. The regulation of the genes that code for the cyclin 
D1 was an interesting endpoint for the discontinuous exposure assay, because if this gene was 
elevated in the MCF-12A cells following two distinct pulses of mitogens, this would confirm 
that the cells did not require a constant input from growth factors.  
2 OBJECTIVES 
In the previous chapter, the flow cytometric results revealed that inhibition of the Src kinase, 
MEK1, PI3K and PLC each affected cell cycle re-entry, but to different extents at different 
times. For example, inhibition of MEK1 during the first administration of growth factors 
reduced markedly the percentage of cells that arrived in S phase. Although MEK1 may be 
activated through the Src kinase, the inhibitor for Src (PP2) had no effect on cell cycle re-
entry. Thus, the MAPK pathway did not seem to be activated via the Src kinase. 
Blocking of MEK1 activity during the second administration of growth factors also resulted 
in a decrease of S phase numbers, and the same was observed with the PI3 kinase inhibitor. 
This could mean that both these kinases (MEK1 and PI3K) are required for cell cycle re-
entry. However, the Raf-1 kinase may also be triggered by PI3K, which puts the MAP kinase 
pathway under the control of PI3K. Hence, it is possible that only activation of the PI3K 
pathway is required to trigger all other signals necessary for cell cycle re-entry.  
The aim of the work presented in this chapter was to uncover the proteins that are important 
for cell cycle re-entry of MCF-12A cells, or at least to identify the proteins that are not 
decisive for cell cycle entry, by a negative exclusion approach. To achieve this, the kinases 
affected by the inhibitors tested previously were investigated more closely by assaying for 
their phosphorylation status over time during the discontinuous exposure assay. Keeping in 
mind the possible crosstalk between pathways, the phosphorylation events were also 
investigated under the effect of different specific enzyme inhibitors, to reveal the 
relationships between different kinases. A kinase was considered not to be decisive for cell 
cycle progression if it was phosphorylated whilst cell cycle progression was not successful. 
Additionally we wished to verify the status of key transcription factors that are required for 
successful cell cycle progression, also as a function of suppressed kinase activity. We were 
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especially interested in monitoring the c-Myc protein, which was shown to be crucial for cell 
cycle re-entry of fibroblast cells (Jones and Kazlauskas 2001). 
In detail, the objectives of this chapter were 
i. To confirm the expression of specific key genes and proteins in the MCF-12A cells, 
as a consequence of the discontinuous exposure to growth factors. The endpoints 
chosen were: 
 The expression of the genes coding for the transcription factor c-Myc and cyclin D1. 
These were determined by reverse transcription (RT) real-time PCR at different time 
points in the discontinuous exposure assay. 
 Changes in the levels of c-Myc protein expression were assessed by immunoblotting 
at different time points in the discontinuous exposure assay.  
 The phosphorylation state of kinases Src, Erk1/2, and Akt (as the downstream effector 
of PI3K), at different time points in the discontinuous exposure assay. 
 
ii. To confirm that the expression or phosphorylation of these key genes and proteins 
was indeed a result of the activation of the pathways that had been established before 
(MAPK, PI3K and PLC pathway), the same endpoints were assessed after treatment 
of cells with specific inhibitors for MEK1, PI3K or PLC. These specific kinase and 
lipase inhibitors were added either during the first or the second pulse, and the 
protein targets described above were assayed. Since activation of the PLC pathway 
during the second pulse was not necessary for S phase entry (its inhibition did not 
interfere with cell cycle progression), the impact of the PLC pathway for the second 
pulse was not examined further. 
3 METHODOLOGY 
In order to monitor the events that seemed most relevant, the following approach was taken: 
Cells were rendered quiescent, and then released from the G0 block with the discontinuous 
stimulation assay, as before. To test the effect of the inhibitors, the cells were pre-incubated 
with inhibitors in basal medium for 20 minutes at 37°C and then stimulated with the growth 
factor during each pulse, in the presence of inhibitor. For the analysis of Src, Akt and Erk1/2 
kinase activation as a result of the first administration of growth factors, the routine first pulse 
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of EGF (50 ng/ml) for 30 minutes was not carried out in full length, but lysates were 
produced 10 min after the addition of the growth factor, in order to assess the early 
phosphorylation events. Accordingly, the positive control sample (quiescent cells incubated 
with 50 ng/ml EGF in basal medium) was also lysed after 10 minutes of incubation with 
EGF. To analyse the phosphorylation status as a result of the second pulse, lysates were 
produced at different time points after the addition of EGF and insulin. For the positive 




For the assessment of c-Myc expression, different time points were chosen. These were 
determined based on the immunoblots where c-Myc was detected over the full length of the 
discontinuous exposure assay. Since c-Myc is not expressed immediately, the positive control 
lysate was produced 2 hours after the start of the incubation (when the effect of inhibitors 
during the first pulse was to be determined), and 6 hours after the start of the incubation in 
the case where inhibitors during the second pulse were assessed. 
To ensure that the bands in the blots were derived from the proteins under investigation, the 
position of the bands was compared to the molecular size marker added to each gel (cf. 
Chapter 2). All assays were performed in three independent experiments, but only 
representative immunoblots are shown.  
In parallel to the immunoblotting samples, for each independent experiment one additional 
sample was incubated according to the standard discontinuous exposure regime (cf. Figure 
24) and analysed with flow cytometry as described before. This was performed as an internal 
control in order to monitor the cell cycle phase distributions when assessing the expression 
and phosphorylation of aforementioned proteins at the earlier time points. No changes in the 





4.1 Detection of Erk1/2 activity 
4.1.1 Activation of the mitogen-activated protein kinases Erk1 and Erk2 
As seen in Figure 41, the mitogen-activated protein kinases Erk1 and Erk2 were strongly 
phosphorylated within 10 minutes of addition of the growth factor EGF during the first pulse 
of administration. The phosphorylated state lasted for more than 30 minutes, but after 2 hours 
the activity of the kinases decreased markedly, presumably because the levels of EGF had 
decreased considerably. Upon incubation with the second set of growth factors (EGF + 
insulin) at 4 hours after the start of the assay, the kinases were again strongly phosphorylated, 
but then the activity receded slightly for about two hours. After 7 hours, the kinases showed a 




Figure 41 Detection of phosphorylated Erk1/2 over time in the discontinuous exposure assay 
Immunoblots of MCF-12A cell lysates were obtained at different time points during the discontinuous exposure 
assay EGF (50 ng/ml) from 0 to 30 min, EGF + insulin (20 + 100 ng/ml) from 4h to 14h) and assayed against 
phosphorylated Erk1/2 (upper row). Equal loading of protein was monitored by probing against β-actin (bottom 
row). “G0” was the negative control sample from quiescent cells, and Erk1,2 activity was not detected in this 
sample. 
  





1st pulse 2nd pulse
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4.1.2 Inhibition of MEK1, Src, PLC and PI3K and the impact on Erk1/1 
activation 
During the first pulse of EGF treatment, application of the inhibitors PD98059 and PP2 led to 
a complete disruption of Erk1/2 phosphorylation, whereas the inhibitor for the PI3 kinase 
(LY294002) did not induce diminutions of Erk1/2 phosphorylation (Figure 42). When using 
U73122, an inhibitor for the phospholipase C, contradictory results were obtained. In one 
experiment, the effects on Erk1/2 were negligible (Figure 42), but in another independently 
repeated experiment phosphorylated Erk1/2 could not be detected after administration of the 




Figure 42 Detection of phosphorylated Erk1/2 after incubation with inhibitors during the first pulse 
Immunoblots of MCF-12A cell lysates obtained 10 minutes after the addition of EGF (50 ng/ml) (positive 
control C+), or EGF in combination with an inhibitor (MEK1 inhibitor PD98059 (PD) at 20 µM, Src inhibitor 
PP2 at 25 µM, PLC inhibitor U73122 at 1 µM, or PI3K inhibitor LY294002 (LY) at 20 µM). Lysates were 
assayed against phospho-Erk1/2 (upper row). Equal protein loading was monitored by probing against total 
Erk1/2 (middle row). “G0” was the negative control sample from quiescent cells where no Erk1,2 
phosphorylation could be detected. The bottom row recapitulates the results from the previous Chapter 6 and 
indicates the effect of the inhibitors on cell cycle re-entry (- = no cell cycle progression, + = successful cell 






Figure 43 Detection of phosphorylated Erk1/2 after incubation with PLC inhibitor during the first pulse 
Immunoblots of MCF-12A cell lysates obtained 10 minutes after the addition of EGF (50 ng/ml) (positive 
control C+), or EGF in combination with the PLC inhibitor (U73122 at 1 µM). Lysates were assayed against 
phospho-Erk1/2 (upper row). Equal protein loading was monitored by probing against β-actin (bottom row). 
“G0 blocked” was the negative control sample from quiescent cells. 
  





1st pulse (10 min) 
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re-entry - + -
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During the second exposure to PP2 (Figure 44), when the Src kinase was inhibited, Erk1/2 
phosphorylation was not strongly suppressed, but it was lowered considerably at the 7 hour 
time point. When the PI3 kinase was disrupted with LY294002, phosphorylation of Erk1/2 
was weaker throughout the entire exposure time, but still more pronounced than in the 




Figure 44 Detection of phosphorylated Erk1/2 after incubation with inhibitors during the second pulse 
Immunoblots of MCF-12A cell lysates obtained at several time points after the release from serum-depletion 
with the discontinuous exposure assay (1st pulse with EGF (50 ng/ml), 2nd pulse with EGF + insulin (20 ng/ml 
and 100 ng/ml), positive control C+). During the 2nd pulse, the cells were additionally incubated with an 
inhibitor (Src inhibitor PP2 at 25 µM, or PI3K inhibitor LY294002 at 20 µM). Lysates were assayed against 
phospho-Erk1/2 (upper row). Equal protein loading was monitored by probing against β-actin (middle row). 
“G0 blocked” was the negative control sample from quiescent cells. The bottom row recapitulates the results 
from the previous Chapter 6 and indicates the effect of the inhibitors on cell cycle re-entry (- = no cell cycle 
progression, + = successful cell cycle progression).  
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4.2 Detection of Akt kinase activity 
4.2.1 Activation of the phosphatidyl-inositol-3 kinase effector protein kinase 
B (Akt kinase) 
The phosphatidyl-inositol-3 kinase (PI3K) phosphorylates directly the Akt kinase, therefore 
Akt was considered a useful target for monitoring the activity of PI3K. Akt was strongly 
phosphorylated after the first incubation with EGF, but its activity disappeared completely 2 
hours after the start of the incubation (Figure 45). Following the second addition of growth 
factors at 4 hours, Akt was again phosphorylated strongly, and this activity level was 




Figure 45 Detection of phosphorylated Akt over time in the discontinuous exposure assay 
Immunoblots of MCF-12A cell lysates obtained at different time points during the discontinuous exposure assay 
(EGF (50 ng/ml) from 0 to 30 min, EGF + insulin (20 + 100 ng/ml) from 4h to 14h). Lysates were assayed 
against phosphorylated Akt kinase (upper row). Equal loading of protein was monitored by probing against β-
actin (bottom row). “G0 blocked” was the negative control sample from quiescent cells. 
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4.2.2 Inhibition of Src and PI3K and its impact on Akt kinase activity  
The phosphorylation of the Akt enzyme during the first incubation with EGF was completely 
abolished by inhibition of the Src and the PI3 kinases with PP2 or LY294002, respectively 
(Figure 46). It should be noted that the level of Akt phosphorylation detected in the quiescent 
cells in some cases was almost as high as in the positive control sample (seen in Figure 46), 
also in other immunoblots prepared with lysates from independently performed experiments. 
During the second pulse with mitogens (Figure 47), activation of the Akt kinase could be 
suppressed by the PI3K inhibitor, but not to levels seen in negative controls, whereas 
inhibition of the Src kinase did not have a strong effect on Akt phosphorylation at these later 




Figure 46 Detection of phosphorylated Akt after incubation with inhibitors during the first pulse 
Immunoblots of MCF-12A cell lysates obtained 10 minutes after the addition of EGF (50 ng/ml) (positive 
control C+), or EGF with one inhibitor (Src inhibitor PP2 at 25 µM or PI3K inhibitor LY294002 (LY) at 20 
µM). Lysates were assayed with phospho-Akt antibodies (upper row). Equal protein loading was monitored by 
probing against total Akt (middle row). “G0 blocked” was the negative control sample from quiescent cells. The 
bottom row recapitulates the results from the previous Chapter 6 and indicates the effect of the inhibitors on cell 
cycle re-entry (- = no cell cycle progression, + = successful cell cycle progression).  
 














Figure 47 Detection of phosphorylated Akt after incubation with inhibitors during the second pulse 
Immunoblots of MCF-12A cell lysates obtained at several time points after the release from serum-depletion 
with the discontinuous exposure assay (1st pulse with EGF (50 ng/ml), 2nd pulse with EGF + insulin (20 ng/ml 
and 100 ng/ml), positive control C+). During the 2nd pulse, the cells were additionally incubated with one 
inhibitor (Src inhibitor PP2 at 25 µM, or PI3K inhibitor LY294002 at 20 µM). Lysates were assayed against 
phospho-Akt (upper row). Even protein loading was monitored by probing against total Akt (middle row). “G0 
blocked” was the negative control sample from quiescent cells. The bottom row recapitulates the results from 
the previous Chapter 6 and indicates the effect of the inhibitors on cell cycle re-entry (- = no cell cycle 
progression, + = successful cell cycle progression).  
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4.3 Detection of Src kinase activity 
4.3.1 Activation of the tyrosine kinase Src 
As seen in Figure 48, the Src kinase was found to be activated shortly after the addition of 
EGF in serum-depleted cell populations, and although the phosphorylation decreased after 
EGF had been washed out, a low level of activated Src kinase was maintained almost 
throughout the entire experiment. When the second pulse of growth factors was added, the 
kinase was not strongly phosphorylated immediately, but a significant increase in band 
intensity after 6 hours was observed (corresponding to 2 hours after the start of the second 
pulse). The loading of the sample of the following time point (7h) was somewhat reduced, 
therefore a more pronounced increase at this time cannot be excluded completely. This 
immunoblot was repeated twice, but the bands were even fainter both times, however, the 
only bands where an increase compared to the G0 blocked cells was definitely observed in 




Figure 48 Detection of phosphorylated Src over time in the discontinuous exposure assay 
Immunoblots of MCF-12A cell lysates obtained at different time points after the release of cells from serum-
depletion with the discontinuous exposure assay (EGF (50 ng/ml) from 0 to 30 min, EGF + insulin (20 + 100 
ng/ml) from 4h to 14h). Lysates were assayed against phosphorylated Src kinase (upper row). Equal loading of 
protein was monitored by probing against β-actin (bottom row). “G0 blocked” was the negative control sample 
from quiescent cells. 
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4.3.2 Inhibition of Src and PI3K and its influence on Src kinase activity  
Although activation of the Src kinase was detected with EGF (Figure 48), no impact of Src 
kinase inhibition in the first pulse was seen with flow cytometric analysis of S phase 
progression (Chapter 6, page 129). Therefore immunoblotting for the Src kinase with 
inhibitors was carried out only with samples produced during the second pulse of growth 
factor exposure. The results are shown in Figure 49. When using antibodies against 
phosphorylated Src, the background was relatively strong in all blots, making interpretation 
of the results difficult. Nevertheless, it was concluded that the Src kinase was inhibited 
efficiently by the inhibitor PP2. It was assumed that the slight increase in Src kinase detected 
after 6 hours despite the presence of PP2 was due to the higher protein amount loaded. But 
this also demonstrated that the Src kinase was not completely disrupted by its specific 
inhibitor. With the PI3 kinase inhibitor LY294002, Src kinase activity was not detected at the 
beginning of the 2
nd
 incubation, but a considerable band appeared at the 6h time point, which 
disappeared again within one hour.  
 
 
Figure 49 Detection of phosphorylated Src after incubation with inhibitors during the second pulse 
Immunoblots of MCF-12A cell lysates obtained at several time points after the release from serum-depletion 
with the discontinuous exposure assay (positive control (C+) = 1st pulse with EGF (50 ng/ml), 2nd pulse with 
EGF + insulin (20 ng/ml and 100 ng/ml). During the 2nd pulse, the cells were additionally incubated with an 
inhibitor (Src inhibitor PP2 at 25 µM, or PI3K inhibitor LY294002 at 20 µM). Lysates were assayed against 
phospho-Src (upper row). Even protein loading was monitored by probing against β-actin (middle row). “G0 
blocked” was the negative control sample from quiescent cells. The bottom row recapitulates the results from 
the previous Chapter 6 and indicates the effect of the inhibitors on cell cycle re-entry (- = no cell cycle 
progression, + = successful cell cycle progression).   
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4.4 The transcription factor Myc 
4.4.1 Detection of c-Myc during the discontinuous exposure assay 
The protein Myc was detected 2 hours after the release of the cells from the G0 block (Figure 
50). This time point coincided with the time when the cells did not receive any growth 
factors, but when they were kept in basal medium. The amount of synthesised protein then 
diminished, but was elevated again two hours after the addition of the second growth factor 
(at the 6 hour time point), and was detected to a similar extent for at least 2.5 hours after 
administration of growth factors EGF and insulin. However, after ten hours of exposure 
(during the 2
nd
 pulse), the amount of protein declined again to the negative control levels, 




Figure 50 Detection of c-Myc over time during the discontinuous exposure assay 
Immunoblots of MCF-12A cell lysates obtained at different time points after the release of cells from serum-
depletion with the discontinuous exposure assay (1st pulse with EGF (50 ng/ml), 2nd pulse with EGF + insulin 
(20 ng/ml and 100 ng/ml)). Lysates were assayed using anti-Myc antibodies (upper row). Equal loading of 
protein was monitored by probing against β-actin (bottom row). “G0 blocked” was the negative control sample 
from quiescent cells.  
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4.4.2 Influence of kinase inhibitors on c-Myc levels 
During the first pulse, the synthesis of the c-Myc protein was disrupted with all of the 
inhibitors tested, PD98059 (PD), PP2, LY294002 (LY), or U73122 (Figure 51). The strongest 
disruption was seen with the Src inhibitor PP2, followed by LY294002 and U73122, which 
inhibited c-Myc expression to a similar degree. The weakest effect was observed with 
PD98059, however, in other immunoblots prepared (assays with all inhibitors were carried 




Figure 51 Detection of c-Myc after incubation with inhibitors during the first pulse 
Immunoblots of MCF-12A cell lysates obtained 2 hours after the release of the cells from serum-depletion (EGF 
(50 ng/ml) from 0 to 30 minutes (positive control C+), or with additionally one inhibitor (MEK1 inhibitor 
PD98059 (PD) at 20 µM, Src inhibitor PP2 at 25 µM, PI3K inhibitor LY294002 (LY) at 20 µM, or PLC 
inhibitor U73122 at 1 µM). Lysates were assayed against c-Myc (upper row). Even protein loading was 
monitored by probing against β-actin (middle row). “G0 blocked” was the negative control sample from 
quiescent cells. The bottom row recapitulates the results from the previous Chapter 6 and indicates the effect of 






Figure 52 Detection of c-Myc after incubation with inhibitors during the first pulse 
Immunoblots of MCF-12A cell lysates obtained 2 hours after the release of the cells from serum-depletion (EGF 
(50 ng/ml) from 0 to 30 minutes (positive control C+), or with additionally one inhibitor (MEK1 inhibitor 
PD98059 (PD) at 20 µM). Lysates were assayed against c-Myc (upper row). Even protein loading was 
monitored by probing against β-actin (middle row). “G0 blocked” was the negative control sample from 
quiescent cells. The bottom row recapitulates the results from the previous Chapter 6 and indicates the effect of 
the inhibitors on cell cycle re-entry (- = no cell cycle progression, + = successful cell cycle progression).  
  










During the second pulse only inhibitors for the Src and the PI3 kinase were tested, shown in 
Figure 53, because these were the pathways demonstrated to be most important at these time 
points. However, neither inhibitor reduced significantly the amount of c-Myc synthesised at 
the time where it could be detected first (6h, cf. Figure 50). On the other hand, with both 
inhibitors tested, the bands at the 7h time point were already weaker, compared to the 
positive control (C+) and compared to the bands observed at 7h and 8.5h without any 




Figure 53 Detection of c-Myc after incubation with inhibitors during the second pulse 
Immunoblots of MCF-12A cell lysates obtained at several time points after the release from serum-depletion 
with the discontinuous exposure assay (1st pulse with EGF (50 ng/ml), 2nd pulse with EGF + insulin (20 ng/ml 
and 100 ng/ml), positive control C+). During the 2nd pulse, the cells were additionally incubated with one 
inhibitor (Src inhibitor PP2 at 25 µM, or PI3K inhibitor LY294002 at 20 µM). Lysates were detected with anti-
Myc antibodies (upper row). Even protein loading was monitored by probing against β-actin (middle row). “G0 
blocked” was the negative control sample from quiescent cells. The bottom row recapitulates the results from 
the previous Chapter 6 and indicates the effect of the inhibitors on cell cycle re-entry (- = no cell cycle 







4.5 Regulation of genes for transition from G1 phase to S phase 
4.5.1 Detection of gene coding for transcription factor Myc 
Cells were accumulated in the G0 phase through serum-depletion as before, and stimulated to 
re-enter the cell cycle. This was achieved by adding either complete growth medium to the 
cells and exposing them continuously (continuous serum stimulation), or with isolated growth 
factors, added at two distinct times (i.e. by the discontinuous stimulation assay, as described 
previously). After exposure, RNA was extracted for detection of gene expression. The 
detected levels were analysed by using Student’s t-test to determine if they are significantly 
different from the levels observed in the negative control (G0 blocked cells). Samples that 
were significantly different from the negative control (G0 blocked sample) are marked with * 
(P=0.05). As seen in Figure 54, already after the first pulse, the c-MYC gene was expressed at 
levels four times higher than in the quiescent cells. However, this strong induction receded 
relatively quickly. At 2 hours into the release time, the expression of the gene was not 
different from the negative control, and at the later time points, the expression was even 
lower than in quiescent cells. The mode of treatment did not have an influence on c-MYC 
expression; since with continuous serum stimulation, the pattern of gene induction was the 
same as with the discontinuous exposure assay, except from the 2 h time point, where the 




Figure 54 Regulation of the gene coding for Myc protein in MCF-12A cells over time in the cell cycle 
Samples of cells were taken at different time points after release from serum-depletion. The gene expression in 
the negative control sample (“G0 blocked) was set to 1 (dotted line) and used as the control value against which 
all other results were normalised. Values shown are the mean of three independent experiments; error bars show 
SEM. Student’s t-test was performed for significance testing. Samples marked with * are significantly different 
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4.5.2 Expression patterns of PRAD1 
Expression of the PRAD1 gene (coding for cyclin D1) showed higher variation between the 
different time points and between serum stimulated, growth factor stimulated, or quiescent 
cells than expression of c-MYC. Differences between the mRNA levels were tested for their 
statistical significance with a Student’s t-test. Samples that were significantly different from 
the negative control (G0 blocked sample) are marked with * (P=0.05). The induction of 
PRAD1 in cells stimulated according to the discontinuous exposure assay became significant 
after 4 hours, where expression levels four times higher than in quiescent cells were seen. 
They remained elevated until the end of the assay at 18 hours. Although for the 14 h time 
point the variation between experiments was high, and therefore the gene expression level 
was not statistically different from the negative control, a higher absolute mean value than in 
quiescent cells was observed. In contrast, the continuously stimulated cells showed highly 
induced expression of PRAD1 over the entire time, except from the 2h time point, where the 
mRNA level was not different from quiescent cells. A peak of nine fold induction was 






Figure 55 Regulation of the gene coding for cyclin D1 protein in MCF-12A cells over time in the cell cycle 
Samples of cells were taken at different time points after release from serum-depletion. The gene expression in 
the negative control sample (“G0 blocked) was set to 1 (dotted line) and used as the control value against which 
all other results were normalised. Values shown are the mean of four independent experiments; error bars show 
SEM. Student’s t-test was performed for significance testing. Samples marked with * are significantly different 
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Figure 56 Overview of protein expression and phosphorylation over time in MCF-12A cells 
Immunoblots of MCF-12A cell lysates obtained at several time points after the release from serum-depletion 
with the discontinuous exposure assay (1st pulse with EGF (50 ng/ml), 2nd pulse with EGF + insulin (20 ng/ml 
and 100 ng/ml), positive control C+). Lysates produced were assayed for the phosphorylation status of Src 
kinase, Erk1/2 and Akt kinase, or for expression of c-Myc protein. This figure consists of the immunoblots 
shown in Figure 41, Figure 45, Figure 48 and Figure 50. 
 
5.1 Protein activities during the first pulse of stimulation 
The results obtained in this chapter are recapitulated in Table 10, together with the 
observations made on S phase entry in the previous chapter. The aim of the investigations 
was to reveal which of the targets examined (pErk1/2, pAkt, pSrc or c-Myc) was decisive for 
cell cycle progression. 
During the first pulse of stimulation, cell cycle re-entry was prevented by the MEK1 inhibitor 
(PD98059), but does this mean that MEK1 activity was absolutely required for S phase 
progression? MEK1 activity was also strongly inhibited by the Src inhibitor PP2, but 
disruption of Src during the first pulse did not prevent cells from entering S phase. From 
these observations it can be concluded that pErk1/2 was not decisive for cell cycle re-entry. If 
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it were, then inhibition of Src by PP2 should also have blocked the cells from cell cycle 
progression. 
The links between the different targets observed so far and presented in this and the previous 
chapter are discussed in detail in this section. The aim was to draw conclusions regarding 
which proteins are required for cell cycle progression in MCF-12A cells during the first 
pulse. Alternatively, signalling molecules which can be excluded as being decisive for cell 
cycle progression were to be pinpointed. A similar matrix was established for the proteins 
monitored during the second pulse, which is presented further below. 
 
Table 10 Impact of specific kinase and lipase inhibitors during the first pulse on expression and 
phosphorylation of proteins and cell cycle re-entry 
Overview of the results obtained with flow cytometry (transferred from chapter 3) for cell cycle re-entry, and 
with immunoblotting for the phosphorylation status of Erk1/2, Akt and Src kinase, and the expression of c-Myc, 
after incubation with specific kinase and lipase inhibitors (MEK1 inhibitor PD98059, PI3K inhibitor LY294002, 
Src inhibitor PP2, PLC inhibitor U73122) during the first pulse of growth factor administration. nd = not 
determined. 
impact of inhibitor 
(1st pulse) on: 
PD98059 LY294002 PP2 U73122 
cell cycle progression ↓ ↓ ↔ ↓ 
pErk1/2 ↓ ↔ ↓ ↔ 
pAkt nd ↓ ↓ nd 
pSrc nd nd nd nd 
c-Myc ↓ ↓ ↓ ↓ 
 
5.1.1 The mitogen-activated protein kinases Erk1 and Erk2 
The activation of Erk1 and Erk2 was assayed by immunoblotting, and it was shown that they 
are phosphorylated rapidly after the addition of the growth factors, at both times of 
stimulation. The initial increase in phosphorylation, after the first pulse, was not sustained, 
but decreased after 2 hours. The activity during the first pulse (first 30 minutes of incubation) 
was efficiently suppressed by PD98059, an inhibitor specific for MEK1, which is the main 
activator of Erk1/2, as well as by PP2, the Src kinase inhibitor. Disruption by PD98059 was 
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expected, since the MAP kinase kinase MEK1 activates Erk1/2 by phosphorylation of the 
threonine and tyrosine residues within their activation loop (Pearson et al. 2001). The 
observation that the Src kinase inhibitor PP2 had a suppressive effect on levels of 
phosphorylated Erk1/2 became interesting when viewed in the light of the results shown in 
Chapter 6 where PP2 had little impact on cell cycle progression. Both results taken together 
mean that the Src kinase had a considerable role in the phosphorylation of Erk1/2, but at the 
same time, inhibition of Src did not hinder S phase entry. These observations allow the 
conclusion that phosphorylation of Erk1/2 is not decisive for cell cycle progression in MCF-
12A cells. They also suggest that activated Src is not required for cell cycle re-entry. But 
there are alternative pathways relevant for the transition from G1 into S phase; these other 
options include the activation of the PI3K and the PLC pathway (both can be activated 
directly through the dimerised RTK, not involving the Src kinase). Both alternatives are 
conceivable, when taking into account the results shown in the previous Chapter 6 and Table 
10, where inhibition of these pathways during the 1
st
 pulse reduced considerably the number 
of cells entering S phase. Only the protein kinase B (Akt), being the pivotal member of the 
PI3K pathway, was investigated with the immunoblotting assays, and the results are 
discussed in detail below. 
5.1.2 The phosphatidyl-inositol-3 kinase effector protein kinase B (Akt 
kinase) 
The expression of the protein kinase B, also termed Akt kinase, was monitored because this 
kinase is the main effector of the PI3 kinase. The PI3K is activated by receptor tyrosine 
kinases and holds a key function for triggering cascades that signal for cell cycle progression. 
Activated PI3 kinase induces cyclin D1 transcription (a key regulator of the G1/S phase 
transition), mediated by the serine/threonine kinase Akt (Gille and Downward 1999). 
Additionally, Akt inhibits glycogen synthase kinase 3 (GSK3β), which in turn is an inhibitor 
of cyclin D1 (van Weeren et al. 1998). When the activation of Akt was assayed with 
immunoblotting, it showed strong phosphorylation within 10 minutes of addition of EGF. 
The activity disappeared when the growth factor was removed at the end of the 1
st
 pulse. This 
means that PI3K was rapidly activated by the EGFR while the receptor was dimerized, and 
that its activity receded when the ligand was washed out. Phosphorylation of Akt was 
prevented completely by the PI3K inhibitor LY294002, which was to be expected because 
signalling from RTKs towards Akt is transmitted predominantly through PI3K. Since 
inhibition of PI3K with LY294002 hindered substantially cell cycle re-entry (shown by flow 
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cytometry, as did inhibition of MEK1 with PD98059), it seemed that this pathway was 
necessary for cell cycle progression; however, inhibition of the Src kinase with PP2 during 
the first pulse (30 minutes with EGF) disrupted Akt phosphorylation as well, but when the 
number of cells arriving in S phase was assessed (cf. Chapter 6), no effect of Src inhibition 
during the 1
st
 pulse had been observed. Thus, these findings reflect the results with the Src 
inhibitor on Erk1/2 phosphorylation, and also demonstrate that phosphorylation of Akt was 
not decisive for S phase entry.  
It must be mentioned that Akt may be phosphorylated independently of the Src kinase, by 
binding of the p85 subunit to the EGRF, either directly or via Grb-2, with subsequent 
activation of PI3K. However, if this activating mechanism was in place during the first pulse 
in MCF-12A cells, the Akt kinase should have been detected in its phosphorylated state, 
despite the inhibition of Src.  
5.1.3 The Src kinase 
The Src kinase was chosen as an endpoint because it is usually associated with the EGFR, 
and generally mediates signals from RTKs to a multitude of downstream pathways. 
Assessment of the protein assays for the Src kinase was difficult because of the strong 
background compared to the bands of interest. Nevertheless, a clearly increased 
phosphorylation of the Src kinase was observed after 10 minutes of addition of EGF, and the 
activated state was maintained until the end of the first incubation period, followed by a 
decrease in activity, albeit not to negative control levels. However, the activity of the kinase 
at this time seemed of no importance in terms of cell cycle progression, because inhibition of 
Src during the first pulse had no effect on progression.  
5.1.4 The transcription factor c-Myc 
c-Myc is a protein important for proliferation and growth, since it increases the expression of 
proliferative genes, and their transcription into the gene products. This protein was found to 
be essential for driving fibroblast cells out of quiescence in a discontinuous experimental set-
up (Jones and Kazlauskas 2001), and therefore it was of interest to assess its expression in the 
epithelial breast cells as well. The protein was expressed 2 hours after the start of the assay. 
Although EGF had already been washed out at this time, it is highly likely that the c-Myc 
increase was the direct result of the first pulse, because expression of this transcription factor 
requires at least one hour after growth stimulation. Hence, the timeline found in the MCF-
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12A cells for the c-Myc increase is in good agreement with publications from other cell lines 
(Waters et al. 1991). It also means that the MCF-12A cells did not require constant 
stimulation with mitogens to produce c-Myc. 
During the first pulse of growth factor administration, expression of c-Myc was disrupted by 
all kinase and lipase inhibitors tested, albeit to different degrees and never to the same extent 
as seen with serum starvation. The most pronounced effect was observed with the Src kinase 
inhibitor. Since Src kinase inhibition did not prevent cell cycle progression, this observation 
suggests that expression of c-Myc after the first pulse was not critical. The inhibition of c-
Myc with the PI3K and PLC inhibitors (LY294002 and U73122, respectively) mirrored the 
results from the cytometric experiments: both inhibitors reduced S phase numbers, but did not 
prevent progression entirely; likewise, they reduced the expression of c-Myc, but never to 
negative control levels. In this assay, the smallest effect was seen with the MEK1 inhibitor 
PD98059, which was unexpected when considering the flow cytometric results (where 
PD98059 was shown to have the strongest effect on disrupting cell cycle progression). An 
explanation for the discrepancy between the impact of the MEK1 inhibitor on S phase 
numbers and on c-Myc expression could be that c-Myc was not the sole transcription factor 
triggered by the MAPK pathway. Moreover, c-Myc is not induced exclusively by Erk1/2, but 
also by the PI3K pathway, as well as the PLC pathway.  
As with the observation made in the presence of the Src inhibitor, with the other kinase 
inhibitors it was concluded that expression of the transcription factor after the first pulse is 
not decisive, although it cannot be excluded that residual activity of the transcription factor 
was sufficient to induce S phase entry. These deductions may be substantiated by either 
immunoblotting for the presence of other transcription factors, such as activator protein (AP-
1) or STATs, which may be activated by the dimerized EGFR, and by inhibiting c-Myc 
directly and monitoring S phase entry with flow cytometry.  
5.2 Protein activities during the second pulse of stimulation 
Table 11 shows an overview of the results obtained with the use of inhibitors during the 
second administration of growth factors. The impact of the inhibitors on cell cycle re-entry 
(presented in Chapter 6) as well as on the phosphorylation and expression of the target 
proteins is shown. The conclusions drawn from our observations are discussed in detail in 
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this section, with the focus on excluding the proteins from the matrix that are not decisive for 
cell cycle progression. 
Table 11 Impact of specific kinase and lipase inhibitors during the second pulse on expression and 
phosphorylation of proteins and cell cycle re-entry 
Overview of the results obtained with flow cytometry (transferred from chapter 3) for cell cycle re-entry, and 
with immunoblotting for the phosphorylation status of Erk1/2, Akt and Src kinase, and the expression of c-Myc, 
after incubation with specific kinase and lipase inhibitors (MEK1 inhibitor PD98059, PI3K inhibitor LY294002, 
Src inhibitor PP2, PLC inhibitor U73122) during the second pulse of growth factor administration. nd = not 
determined. 
impact of inhibitor 
(2nd pulse) on: 
PD98059 LY294002 PP2 U73122 
cell cycle progression ↓ ↓ ↓ ↔ 
pErk1/2 nd ↓ ↔ nd 
pAkt nd ↓ ↓ nd 
pSrc nd ↔ ↓ nd 
c-Myc nd ↓ ↓ nd 
 
5.2.1 The mitogen-activated protein kinases Erk1 and Erk2 
During the second incubation period, the Erk 1/2 activity was maintained until the end of the 
assay, although a slight decrease was observed at 6 and 7 hours. The following time points 
(8.5 and 14 hours) seemed to feature another (minor) increase in kinase activity, but this may 
also have been caused by a slightly higher amount of total protein loaded. Only one 
representative immunoblot is shown, but in every immunoblot performed, the kinase activity 
was seen strongest directly after the addition of the growth factors in the second pulse, and 
most likely diminished gradually during the 10 hours of incubation. It is noteworthy that 
Erk1/2 was reported to be degraded rapidly at the beginning of S phase (Meloche 1995), but 
in the assays presented here, even at the 14 hour time point (end of second pulse), the kinases 
were still more phosphorylated than in the negative control. 
Several studies documented that upon continuous mitogen stimulation of fibroblast cells, the 
activation of these kinases is taking place in a biphasic manner, therefore the fact that 
phosphorylation of Erk1/2 in two distinct waves (Erk1/2 was not continuously in its 
phosphorylated state) was sufficient for MCF-12A cells to re-enter the cell cycle is in 
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agreement with these reports (Meloche and Pouyssegur 2007; Kahan et al. 1992). 
Phosphorylation of Erk1/2 seemed repressed by the Src inhibitor PP2, but only at the latest 
time point assessed (7 hours), so that it is very likely that this observation instead mirrored 
the decreased phosphorylation of Erk1/2 at the time points 6 and 7 hours observed in Figure 
41, where activity of Erk1/2 was assessed. However, phosphorylation of Erk1/2 during the 
2
nd
 pulse was clearly suppressed by an inhibitor specific for the PI3 kinase (LY294002). The 
inhibition was not total, since there were still bands detected for pErk1/2, whereas in the 
quiescent cells, no phosphorylation at all was seen. Taking these two observations into 
account, and considering at the same time that inhibition of Src decreased the percentage of S 
phase cells further than inhibition of MEK1 (PP2 resulted in S phase numbers equal to 
quiescent cells, whereas PD98059 resulted in cell cycle arrest of approximately half of the 
cells), the following conclusions can be drawn: 
Firstly, that activation of the MAPK pathway was not decisive on its own for cell cycle re-
entry, since S phase induction was disrupted even when MEK1 activity was seen, but 
contributed to it (since the MEK1 inhibitor PD98059 resulted in a decreased number of S 
phase cells). Secondly, that MEK1 activity was not triggered by the Src kinase. And finally, 
the disruption of Erk1/2 phosphorylation by the PI3K inhibitor points towards a crosstalk 
between the MAP and the PI3 kinases. The mechanisms that could be involved in such a 
crosstalk are discussed below.  
It must be remembered that the PI3K may be activated in different ways. Firstly, the small, 
regulatory subunit p85 can bind to specific docking sites on the dimerized receptor, which 
then recruits the larger p110 subunit and completes the enzyme. Additionally, the p85 subunit 
may be bound indirectly to the receptor, through the Grb2 adaptor molecule which associated 
with its binder Gab-1. And lastly, an alternative binding through Grb2 is possible as well: 
Grb2 binds and activates Sos, which triggers Ras. The Ras kinase in turn activates the 
catalytic subunit (p110) of PI3K, and this independently of the p85 subunit. It is not clear yet 
if one of these possibilities predominates under specific physiological circumstances 
(Castellano and Downward 2011; Rodriguez-Viciana et al. 1994). Thus, activity of PI3K may 
be regulated by Ras, and it was shown that both enzymes together can form a positive 
feedback loop: initial Ras activation did not require PI3 kinase, but the level of Ras was 
reduced in the presence of the PI3K inhibitor LY294002, suggesting that Ras was, at least 
partly, activated by the PI3 kinase phosphate products (Sasaki et al. 2004). Ras in turn is a 
strong modulator of the MAP3K Raf-1, which activates the downstream effectors MEK1 and 
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MEK2 and thus the subsequent pathway (Kyriakis et al. 1992). The partial inhibition of the 
phosphorylation of Erk1/2 in the MCF-12A cells through LY294002, which disrupts the 
PI3K function, suggests that such a reversed signalling between Ras and PI3K might be in 
place here, so that the observation was not a direct effect of the kinase inhibition, but rather a 
result of a disrupted positive feedback loop. On the other hand, some studies have reported 
that induction of DNA synthesis caused by overexpression of activated MEK1 in quiescent 
fibroblasts, could be blocked by incubation with the PI3K inhibitor LY294002, used also in 
the present work, implying that activation of the Erk1/2 pathway induces the synthesis of 
autocrine growth factors (Meloche and Pouyssegur 2007; Treinies et al. 1999). Unfortunately, 
with the experimental set-up chosen here, it was not possible to distinguish further between 
these possibilities.  
5.2.2 The phosphatidyl-inositol-3 kinase effector protein kinase B (Akt 
kinase) 
Akt was phosphorylated readily upon addition of growth factors during the 2
nd
 pulse. The 
phosphorylation of Akt was prevented almost completely with the PI3K inhibitor LY294002, 
which was to be expected because signalling from RTKs towards Akt is transmitted 
predominantly through PI3K. Inhibition with PP2 prevented Akt phosphorylation, but only 
after several hours of incubation during the second pulse. The observation that PI3K was 
triggered during the second pulse is in good agreement with the flow cytometric data 
presented in the previous chapter where PI3K inhibition was shown to hinder cell cycle re-
entry (Chapter 6). Despite the fact that the inhibitor used acts rapidly to inhibit the targeted 
Src kinase (within 30min), inhibition of Akt phosphorylation was delayed (an effect 
comparable to the negative control was observed only at the 7h time point). This suggested 
that in the first 3 hours of the second pulse, other pathways were important for achieving 
PI3K and Akt activation, and that this activity was stronger than the suppression of Akt via 
PP2. Indeed, PI3K may also be activated independently of Src, as was discussed above. It is 
noteworthy, though, that strong phosphorylation of Akt was noticed occasionally in quiescent 
cells, pointing towards generally high levels of Akt activity. 
Taken together, these observations indicate that the PI3K pathway is triggered following the 
second stimulation with growth factors, and that this activation was required to promote cell 




5.2.3 The Src kinase 
Since the impact of disrupted Src activity on cell cycle progression was determined only 
during the second incubation in the discontinuous assay (established by flow cytometry, cf. 
Chapter 6), the effect of Src kinase inhibition with PP2 was assessed only during the second 
pulse for immunoblotting assays. The addition of EGF together with insulin led to an increase 
in Src phosphorylation, although not to the same extent as during the first pulse, and the 
phosphorylated state was maintained only for a couple of hours. The difference in the extent 
of phosphorylation between the first and the second pulse might be due to the cells being 
more responsive immediately after the starvation period, and less responsive for Src 
activation once they had been exposed to an initial stimulus. As expected, incubation with the 
Src inhibitor PP2 disrupted Src phosphorylation. At a first glance, the PI3K inhibitor seemed 
to have a similar effect on Src phosphorylation, but most likely the fainter bands were a result 
of the lower protein loadings, when compared to the loadings for the same time points with 
the Src inhibitor. This would also be in agreement with the hierarchy in the signalling 
cascade, where Src kinase is located upstream of PI3K. However, visual assessment of the 
bands was difficult by the strong background, and digital image analysis would be needed for 
quantification of the band intensities. It was suggested that for further work, the primary anti-
phospho Src antibody should be diluted in TBST-T buffer only, without added proteins such 
as bovine serum albumin (BSA) or milk powder (cf. Chapter 2), in order to decrease the 
background on the immunoblots. The Src kinase most certainly holds an important position 
for S phase induction in the MCF-12A cells, since its inhibition resulted in a complete stop of 
cell cycle progression, and disrupted severely its downstream target c-Myc. In order to 
definitely establish the necessity of the Src kinase it must be triggered with a specific 
activator, that excludes the simultaneous activation of any other kinase, and cell cycle 
progression should be monitored subsequently. 
5.2.4 The transcription factor c-Myc 
Compared to the 2h time point, the level of c-Myc protein expression was decreased at 4.5 
hours, but elevated again at 6 hours. The exact same pattern of c-Myc expression (band 
appears 2 hours after the start of growth factor stimulation) was observed during the first 
pulse. During the second pulse, the c-Myc protein levels faded slowly over several hours, and 
the protein was degraded entirely before the end of the assay, when mitogens were still 
present. This is evidence for a finely balanced signalling system where the transcription 
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factor is degraded after it has served its purpose, and is not synthesised constantly as a 
consequence of growth factor stimulation.  
The inhibition pattern during the second phase was conclusive: at the 6h time point (where c-
Myc started to appear when no inhibitor was present), it was detected also in the presence of 
either PP2 or LY294002 (Src or PI3 kinase inhibitor, respectively), meaning that these two 
inhibitors did not suppress the expression of the protein, or at least not immediately. 
However, one hour later the amount of c-Myc was markedly reduced with either inhibitor. 
Possibly, inhibition of Src or PI3K did not alter the induction of c-Myc synthesis, but it led to 
a faster degradation of the protein. 
Degradation of c-Myc is triggered by its phosphorylation on the threonine residue (Thr58) 
through the enzyme GSK3β. GSK3β however is inhibited by Akt, once this kinase has been 
phosphorylated by PI3K. In NIH3T3 cells, the PI3 kinase was active in two phases, one 
immediately after growth factor addition, and one in late G1, just before onset of DNA 
synthesis, and the late PI3 kinase regulated c-Myc levels. Inhibition of PI3K at this time 
increased phosphorylation of c-Myc, resulting in reduced levels of stable c-Myc protein and 
hence impaired S phase onset (Kumar et al. 2006). In different fibroblasts (murine 
neuroblastoma cells), the PI3K inhibitor induced post-transcriptional suppression of c-Myc 
(Chesler et al. 2006). Hence, the delayed inhibition of c-Myc in the MCF-12A cells when the 
PI3 kinase pathway was disrupted is similar to the network found in fibroblasts, and 
confirmed the major effect of the inhibitor LY294002 on G1 progression assessed by 
cytometry. Since inhibition of the Src kinase by PP2 during the second pulse also contributed 
to a faster degradation of c-Myc, and impaired cell cycle progression, it may be assumed that 
the second wave of PI3K signalling was mediated partly through the Src kinase, and that this 
pathway is essential for stabilisation of the c-Myc protein. Our results suggest that c-Myc is 
decisive for cell cycle progression in the second pulse, but to reach firm conclusions, the 
impact of direct inhibition of c-Myc expression on S phase entry would need to be assessed. 
5.3 mRNA regulation 
5.3.1 Regulation of the c-MYC gene 
In order to monitor at what time during mitogenic stimulation the mRNA levels of c-MYC 
started to be elevated, analysis of gene expression with RT-real time PCR was performed. 
Interestingly, induction of mRNA expression took place only once, promptly after addition of 
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EGF to the quiescent cells. The amount of c-MYC gene was increased approximately 5-fold 
after 30 minutes, declined rapidly to control levels and remained there throughout the 
remainder of the experiment. This was unexpected since expression of the protein was 
observed not only at 2 hours after the start of stimulation, but also a second time, after six 
hours (corresponding to 2h after the start of the second pulse). This result could mean that 
one or more transcription factors were involved in G1-S transition in these cells, such as 
activator protein (AP-1) or STATs, as was discussed in section 5.1.4 above. Another 
explanation could be that the early, but short increase in c-MYC was sufficient to induce Myc 
protein expression over an extended period of time, even beyond 8 hours after the mRNA 
levels had declined. Although the latter option may seem unlikely, given that the c-Myc 
protein has a short half-life, the possibility of an extended half-life cannot be ruled out 
entirely. Indeed, this idea is supported by the fact that for the protein stability to be sustained, 
signalling from the Ras/Raf-1/MAPK pathway is required (phosphorylation on Ser62 through 
MAPK stabilises c-Myc), as well as signalling through PI3K/Akt for delaying c-Myc 
degradation (by inhibiting phosphorylation on Thr58), and both cascades were present at 
these times in the MCF-12A cells, as shown in Figure 41 and Figure 45. For fibroblast cells it 
even has been reported that induction of c-MYC, together with signalling mediated by Erk1/2, 
at the very beginning of release from quiescence, was sufficient to drive the cells through the 
first portion of G1 phase (Jones and Kazlauskas 2001). 
In addition to these arguments, the pattern of c-MYC mRNA expression was very similar in 
the populations that were serum stimulated to those that had discontinuous stimulation which 
confirmed once more that the MCF-12A cells did not require continuous presence of 
mitogens, but that the discontinuous exposure assay developed in this thesis was successful. 
Also the time elapsed between growth factor stimulation, increase in mRNA levels and 
subsequent protein expression was in agreement with published results (Wasylishen and Penn 
2010; Chesler et al. 2006; Rosenwald et al. 1993; Wosikowski et al. 1992; Lin and Vilcek 
1987; Kelly et al. 1983). 
5.3.2 Regulation of Cyclin D1 
The product of the c-MYC gene (c-Myc) is a transcription factor previously demonstrated to 
be required for cell cycle progression. One target gene for the c-Myc protein codes for cyclin 
D1 (CCND1). Hence it was interesting to follow the expression of CCND1, after the c-MYC 
levels had been monitored.  
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mRNA for CCND1 started to be significantly amplified 4 hours after the start of the release 
from G0 block, meaning that this increase in transcription was a result of the first round of 
growth factor exposure only. The amount of transcript was augmented further gradually over 
time, however, the levels found in cells stimulated discontinuously did not match the 
corresponding induction in serum stimulated cells. There are several explanations for this: 
cyclin D1 usually is maximal in late G1, and this depends strongly on the activity of PI3 
kinase (Gille and Downward 1999). The presence of the phosphorylated kinase in late G1 
was confirmed by immunoblotting (Figure 45), therefore another factor must be missing for 
CCND1 induction. It is unlikely that the reduced CCND1 expression was a consequence of 
the lack of c-MYC gene amplification at the later times during G1 phase, because the pattern 
of c-MYC expression was similar in both experimental set-ups, discontinuous and continuous 
incubation (Figure 54). However, it is possible that one or more other transcription factors are 
activated in serum stimulated MCF-12A cells, and that these factors were missing in the 
discontinuous exposure, as was proposed before (cf. section 5.1.4). Candidates for such 
alternatives would be the activating protein (AP-1) or the signal transducer and activator of 
transcription (STAT) molecules. STATs are a family of proteins downstream of RTKs such 
as the EGFR whose up-regulation leads to cell cycle progression, aberrant proliferation and 
inhibition of apoptosis; notably STAT1 and STAT3 have been shown to be overexpressed in 
human cancers. STAT3 target genes include cyclin D1 and D3. In order to explore the role of 
the STATs in MCF-12A cells, analysis of their mRNA expression would be an interesting 
target, as well as inhibition of STATs (especially during the second pulse) followed by flow 
cytometric analysis for assessing cell cycle progression.  
Clearly, the stimulation of the cells with EGF and insulin during the second pulse did not 
have the same effect on CCND1 expression as did stimulation with complete culture medium. 
It might well be that this difference in CCND1 transcription was a reason why not in all 
independent experiments a consistently high percentage of cells was detected in S phase in 
discontinuously stimulated cells, compared to continuously exposed samples (Chapter 4). 
Indeed, constitutive activation of D type cyclins had been shown to be sufficient to overcome 
mitogen requirement (Sherr and Roberts 1999).  
5.4 A molecular basis for competence and progression in MCF-12A cells 
The objective of this chapter was to examine more closely the events taking place in the 
MCF-12A cells when they were released from the quiescent state (induced by serum 
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depletion) into the cell cycle by pulsing them with defined sets of growth factors, as 
established before and termed discontinuous exposure assay throughout this thesis.  
The pattern of activity of specific proteins, known to play crucial roles for cell cycle 
progression, during the discontinuous exposure assay was established by investigating the 
phosphorylation of Src, Erk1/2, and Akt (to monitor the activity of the PI3 kinase), and the c-
Myc protein levels. Next, cells were subjected to inhibition of the kinases Src, MEK1, PI3K, 
and of PLC, and the same targets (Src, Erk1/2, Akt and c-Myc) were examined. From these 
results, the following signalling network, depicted in Figure 57 and Figure 58, emerged: 
Binding of EGF to its receptor triggered phosphorylation of PI3K and Erk1/2, with and 
without mediation by Src, as well as PLC. PI3K/Akt, PLC and Erk1/2 signals induced c-Myc, 
but to achieve this, activation of Src kinase was not required (since inhibition of Src during 
the first pulse did not disrupt entirely c-Myc protein expression, and did not decrease at all 
the percentages of S phase cells). c-MYC mRNA was up-regulated immediately, and c-Myc 
protein was expressed swiftly. As a consequence, cyclin D1 mRNA was up-regulated.  
At the beginning of the second pulse, Erk1/2 and Akt were phosphorylated strongly. No 
changes in c-MYC mRNA levels occurred, but protein expression increased again 2 hours 
later and expression levels were sustained, potentially because stabilisation of the c-Myc 
protein occurred through phosphorylation of Ser62 (mediated by the MAPK pathway, notably 
Erk1/2) and through inhibition of Thr58 phosphorylation (mediated by PI3K/Akt).  
At the same time, Src was phosphorylated, but to a lesser extent than after the first pulse. 
Disruption of Src during the second pulse did not immediately inhibit phosphorylation of 
Akt, and expression of the c-Myc protein was not affected extensively. Nevertheless, Src 
signalling was crucial for subsequent cell cycle progression, as was PI3K activity. The 
finding that Src inhibition disrupts PI3K activity only partly, but suppresses S phase 
induction entirely, indicates that the Src kinase triggers other kinases as well that contributed 
to cell cycle re-entry. Additionally, it should be considered that two independent mechanisms 
of PI3K activation are in place, first through the direct binding of the p85 subunit to the RTK, 
and the indirect activation of PI3K through binding of the p85 subunit to Src. This 
consideration is further supported by the observation that PI3K was phosphorylated promptly, 
whereas the Src kinase itself was not activated immediately (strong phosphorylation was 
observed only two hours after the start of the second pulse). Hence disruption of Akt 
phosphorylation by the Src inhibitor could only be observed after the time points where Src 
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itself has been activated. However, the studies presented here did not allow it to determine 
which mechanism of PI3K activation was more prevalent in the MCF-12A cells.  
One striking difference between the importance in the first and in the second pulse of the 
proteins monitored was that PLC activity during the first administration was crucial for cell 
cycle re-entry, but not during the second pulse, whereas Src activity was not required during 
the first pulse, but essential during the second pulse. Regarding PLC, it has been reported that 
its activity is induced within minutes following growth factor stimulation in quiescent 
NIH3T3 cells, and peaked after 2 hours of continuous stimulation, dropping markedly after 4 
hours. Moreover, PLC activation as a contributor to cell proliferation was shown to be under 
the control of the (growth factor induced) MAPK pathway (Manzoli et al. 2005 and 
references herein; Ramoni et al. 2004; Manzoli et al. 1997). Considering that these 
observations were made in fibroblast cells, it is possible that PLC inhibition during the 
second pulse did not impact cell cycle progression in our epithelial cells, because this 
pathway was not active anymore, perhaps because the MAPK pathways had also become less 
important for S phase progression at this time. As for the Src kinase, a first approach would 
be to quantify the bands of total and phosphorylated Src kinase, comparing between the first 
and the second pulse, in order to investigate if the divergence in the importance of the kinase 
was due to less protein being phosphorylated as a result of the short first stimulation. It may 
also be considered that simultaneous exposure of the MCF-12A cells to insulin and EGF had 
a more important effect on Src activation than EGF alone, since one publication describes 
that upon stimulation of MCF-7 epithelial cells with insulin-like growth factor II, the Src 
kinase associated with the IGF-IR, followed by a cross-activation of the EGFR (Jones et al. 
2006; Knowlden et al. 2005). In order to verify such a crosstalk in MCF-12A cells, 
stimulation with EGF only in both pulses needs to be performed (which also resulted in a 
high percentage of S phase cells, cf. Chapter 4), monitoring the activity level of Src kinase.  
In summary, the observations made with the discontinuous exposure assay were consistent 
with other studies showing that even when cell cycle progression was achieved by continuous 
exposure to mitogens, the signalling events took place at two distinct times. This was 
reported mainly for PI3K which induces one early wave of signalling and a second wave in 
late G1 (Kumar et al. 2006; Balciunaite et al. 2000; Jones et al. 1999). Based upon this, 
Kazlauskas’ group suggested a “two wave” hypothesis: a first, short (< 60 min) exposure to 
mitogens makes the cell competent, that is, it initiates the cell to leave the G0 state to 
progress into the early phase of G1. At this time, the cell needs a second mitogenic input that 
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results in elevation of cyclins and progression through late G1 into S phase (Jones and 
Kazlauskas 2001). The signals that drive cells through one or the other part of G1 are not 
necessarily mutually exclusive, as shown by Jones and Kazlauskas (2001). For example, 
MEK activity was required during both growth factor pulses for successful DNA synthesis, 
and c-Myc protein was expressed at two distinct time points in fibroblasts (Jones and 
Kazlauskas 2001). However, input from the signals must be temporally coordinated to 
provide the correct protein and lipid products at the right time. This explains why the 
intervening time between the two pulses of growth factor administration may not be extended 
infinitely. In fibroblast cells, the second growth factor was administered 8 hours after the 
first, but the longer the two pulses were apart, the fewer cells were able to progress into S 
phase. Indeed, the later wave of c-Myc protein expression was observed at 9h, shortly after 
the start of the 2
nd
 pulse, whereas in continuously PDGF-stimulated cells, c-Myc was 
expressed after 6 hours already (Jones and Kazlauskas 2001). Taking together these 
observations, they suggest that c-Myc needed to be available at a certain time during the cell 
cycle for successful G1 progression, and that cells were unable to process the signals from the 
c-Myc protein if it was expressed too late. (To support this assumption one would need to 
monitor c-Myc expression in the fibroblasts under the conditions of a delayed second pulse). 
In the MCF-12A cells, it was shown that the resting time between the pulses may be up to six 
hours long for successful cell cycle re-entry, although higher S phase numbers were yielded 
with a shorter intervening time of four hours, which accordingly was chosen for the routine 
regimen (Chapter 4). The observations that the intervening time could not be extended to 
more than six hours and that c-Myc protein was strongly expressed at 6h (and could already 
be detected at 4.5h), was not only in excellent accordance with the results from fibroblasts; 
they also imply that similar to fibroblast cells, the mammary epithelial cells required c-Myc 
protein during a defined time frame to be able to progress through G1, whereas rapid 
degradation of the c-Myc (unstable protein due to PI3K inhibition), or lack of the late wave 
of protein expression altogether (due to the absence of a second pulse of growth factors), 
meant that the cells were not able to take the signals from the first pulse further. An 
appropriate experimental set-up to substantiate this would be to monitor c-Myc protein 
expression in MCF-12A cells that are continuously stimulated, as well in discontinuously 
exposed cells where the intervening time is prolonged. Despite the lack of such confirmation, 
it could be concluded that the results shown in this chapter, taken together with the 
observations presented in the previous chapters, make it plausible that a competence / 






Figure 57 Schematic representation of signalling pathways activated in MCF-12A cells during the first 
pulse of growth factor administration  
The kinases shown on the left side all contributed to cell cycle progression, although none of the three pathways 
examined (MAPK, PI3K and PLC) was decisive for cell cycle progression. The kinases shown on the right hand 





























Figure 58 Schematic representation of signalling pathways activated in MCF-12A cells during the second 
pulse of growth factor administration 
The EGRF and the IR, activated by EGF and insulin, respectively, triggered the MAPK and PI3K pathways, as 
well as the Src kinase, which activated PI3K additionally. All kinases added to cell cycle progression, but only 
the Src kinase was determined to be vital. It is suggested that the PI3 kinase contributed to MEK1 activity by a 

















A different set of proteins was activated with the first incubation with growth factors than 
after the second pulse. The first pulse resulted in strong phosphorylation of Erk1/2, Akt and 
Src, and c-Myc was expressed in a delayed fashion (2 hours later). The second pulse led 
again to an immediate phosphorylation of Erk1/2 and Akt, whereas Src was activated 
considerably later. Expression of c-Myc was delayed as well, as before. We could conclude 
that not all activated proteins were indeed required to induce the cell cycle, but selective 







The objective of the work presented here was to investigate signals that are activated for cell 
cycle progression in normal mammary epithelial cells. This is of great importance, since it 
has been recognised that the vast majority of all breast cancers originate in the mammary 
epithelium. In the epithelium, the neoplastic cells initially are retained in the milk ducts by 
normal epithelial cells, and may even be reverted back to un-transformed states through 
signalling from the normal cells. The signalling in normal cells controls cell cycle 
progression, proliferation, and differentiation, and these features are of relevance for 
sustaining the protective barrier in the mammary epithelium. In order to better understand 
why this shield fails in tumorigenesis, it is necessary to better define the proliferative signals 
emitted by normal epithelial cells. The basic process for proliferation is cell cycle 
progression, which is regarded as successful when the R point is passed. The R point is 
defined as the hyperphosphorylation of the Rb protein, occurring up to several hours before 
entry into S phase. Previous research has shown that the passage of the R point does not 
require constant exposure to growth factors, but that proliferative signals are accumulated 
over time, resulting eventually in sufficient phosphorylation of the Rb protein. The 
accumulating signals are transmitted through cascades which form a complex network of 
kinase activities, triggered by a plethora of growth factors present in the culture medium. The 
networks in place for controlled proliferation need to be studied level by level and they can 
only be dissected if the effectors at the very top of the cascade are well defined as well.  
As a model for the normal human mammary epithelium, we chose the MCF-12A cell line. 
This cell line is not used widely and comparatively little is known about its receptor 
phenotype and the signalling pathways initiated from there. Cell cycle re-entry was induced 
with defined growth factors, with the aim to elucidate these aspects: the role of three major 
pathways (MAPK, PI3K and PLC) for cell cycle progression was investigated closely by 
monitoring the kinases Akt, Erk1/2 and Src, as well as c-Myc and cyclin D1, and the impact 




1 MAIN CONTRIBUTIONS 
In order to study in detail the cell cycle progression in MCF-12A cells, an assay was 
developed which first induced quiescence by serum depleting the cells for 24 hours, and then 
released the cells into S phase by exposing them to complete culture medium. 
Entry into S phase was monitored with flow cytometry, and the acquired data was analysed 
using initially three different methods of cell cycle analysis (automated analysis based on the 
Dean-Jett-Fox algorithm, the Watson algorithm, or manual analysis), in order to determine 
the most suitable approach. A systematic comparison between these methods was then 
performed and showed that cell cycle specific software with an embedded algorithm based on 
the Watson model consistently gave higher percentages for the fraction of cells that make up 
the S and G2+M phase peaks than when the frequency histograms were analysed by the user 
(i.e. setting the gates between the cell cycle phases manually). However, the differences 
between these two approaches were statistically not significant. On the other hand, results 
obtained following analysis with an algorithm based on the model according to Dean-Jett-
Fox were shown to be skewed. This led us to conclude that the Dean-Jett-Fox algorithm was 
not suitable for the work presented here. 
Having established that the automated analysis using software with an embedded Watson 
algorithm was the most suitable method for our purpose, a discontinuous exposure regimen to 
induce cell cycle progression was put in place, which enabled us to determine a set of defined 
growth factors sufficient for cell cycle re-entry. In detail, the quiescent cells were stimulated 
with a first pulse of EGF, lasting for 30 minutes, after which the cells were left without any 
growth factors. The second pulse started 4 hours later and consisted of a combination of EGF 
with insulin, incubating for 10 hours. At the end of the second pulse, cells were left again 
without any growth factors for 4 hours, to give them time to progress into S phase. The total 
length of the assay therefore added up to 18 hours, which had been determined beforehand 
with continuous serum stimulation to be a reasonable time point to assess cell cycle re-entry. 
With this discontinuous assay we saw as many cells progress into S phase as after continuous 
exposure to complete growth medium. The precise timing of the discontinuous exposure 
assay, as well as the use of defined growth factors and the sequence in which they were 
administered, enabled us to study the important signals for progression out of quiescence and 
through G1 into S phase. 
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First of all, the significance of the two distinct pulses was assessed, and it was found that both 
pulses were required for full competence of the MCF-12A cells to progress into S phase, 
although the first pulse was considerably shorter than the second pulse. Omission of the first 
pulse resulted in a significant reduction of the number of cells able to leave the quiescent 
state, with around one third fewer cells found in S phase at the end of the assay time.  
Next, we wanted to analyse whether the sequence of administration of different growth 
factors was important for S phase progression. Indeed, it was found that the combination of 
insulin in the first pulse and EGF in the second pulse resulted in a significant number of cells 




 insulin), was not 
able to bring cells out of quiescence. One could argue that this result may be due to the 
second pulse being much longer than the first incubation, however, as was established above, 
both incubation periods were required by the cells. Moreover, when E2 was applied instead 
of a growth factor during the first pulse, and the cells were stimulated with EGF+insulin 
during the following longer administration, they were unable to exit the quiescent state. 
Hence, it seemed that the signals responsible for cell cycle progression needed not only to be 
switched on, but moreover to be triggered in a specific order.  
An additional aim of the work with estradiol was to examine its effect on the regulation of 
proliferative genes. Estradiol is an endogenous hormone of the estrogen family which has an 
important function for the development of the mammary gland in general, but especially for 
the fate of epithelial cells. However, the role of estradiol in the MCF-12A cell line is not yet 
well characterised. PCR analysis of genes that, in human mammary cancer epithelial MCF-7 
cells, are typically regulated by this steroid hormone showed that the proliferative genes MYC 
and PRAD1 were not induced by estradiol, whereas EGF resulted in an increased expression. 
This was in line with the observations made on cell cycle progression. We also investigated 
genes that are under the control of the estrogen receptor ERα (PGR, TFF1, BRCA1 and 
ESR1), but none of them was significantly altered after estradiol exposure. It has been 
suggested in the literature (Anderson 2002; Clarke et al. 1997) that estrogen-induced 
proliferation of breast epithelial cells is a sign of transformation, and our results support this 
hypothesis. It has become clear, that the molecular mechanisms involving the ERα are not the 
same in the MCF-12A cells than in other ERα+ breast epithelial cells, such as the MCF-7 
cells. Possibly, the relocation of the ligand-bound ER towards the ERE situated in the 
promoter region of target genes is disrupted, and the lack of effect of E2 on the regulation of 
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genes displaying an ERE may be explained by such a defective mechanism between the 
receptor and the responsive element. 
Next, we sought to identify the signalling cascades that are triggered when the MCF-12A 
cells were stimulated to cell cycle re-entry. Cells were initially exposed to EGF for 30 
minutes, after which the growth factors was washed out and cells were kept in basal medium 
until the beginning of the subsequent pulse. This ensured that during the first pulse, only 
EGFR was activated. Experiments with specific inhibitors for MEK1 (activator of the MAP 
kinases), PI3 kinase, Src kinase and PLC indicated that the signalling through EGFR in the 
first pulse was mediated through three pathways, the MAPK, the PI3K and the PLC 
pathways, and that all these pathways were employed to a similar extent. Surprisingly, the 
Src kinase did not seem to be involved in signal transduction from the EGFR to MEK1 or 
PI3K, suggesting that signalling from the dimerised EGFR to these two kinases was mediated 
entirely through the adaptor molecules Shc and Grb2. 
During the second pulse, which lasted 10 hours, the cells were exposed to EGF and insulin. 
Tests with the same specific inhibitors as for the first pulse revealed that in this phase 
signalling through PI3K prevailed. The MAP kinase pathway was also triggered, albeit to a 
lesser extent than PI3K, whereas the PLC pathway had a minor role. Interestingly, inhibition 
of the Src kinase at this time resulted in an almost complete disruption of cell cycle 
progression. Several explanations for this difference to the function of Src during the first 
pulse can be considered: Firstly, it could be that the activation of the Src kinase was entirely 
triggered through the insulin receptor, which is ligand bound during the second, but 
obviously not during the first pulse. Interaction between insulin receptor substrates (IRS) and 
Src indeed has been shown in several cell lines, although not in epithelial cells. The second 
possibility would be that EGFR indeed triggered Src kinase, but only during the second pulse 
and not during the first. Even though such a selective (time dependent) association between 
these two kinases seems rather unlikely, it should not be ruled out entirely because the MCF-
12A cells could be stimulated to cell cycle progression when exposed exclusively to EGF in 
the discontinuous assay (using a higher concentration of EGF during the second pulse when 
insulin was omitted). 
Subsequently, activation of these kinases as a result of growth factor stimulation was 
confirmed with immunoblotting. In contrast to the flow cytometric analysis, where S phase 
entry was assessed only at the end of the assay, the phosphorylation status of the kinases was 
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monitored at several time points during the exposures. It was found that Erk1/2 as well as the 
Akt and Src kinases were phosphorylated readily upon addition of EGF during the first pulse, 
but the activated status was not sustained. Inhibition of Src reduced induction of these 
kinases, which suggested that upon Src inhibition, the cells were still able to trigger the 
MAPK and PI3K pathways to a sufficient extent, because Src disruption did not reduce the 
number of cells progressing into S phase. All kinases (Src, Erk1/2 and Akt) were again 
phosphorylated upon incubation with the second set of growth factors. This time the 
observations made with Src inhibition were in accordance with the flow cytometric results, as 
it resulted in disruption of Erk1/2 and Akt activation. Src itself was also phosphorylated as a 
result of stimulation with EGF and insulin. 
Additionally, the protein and gene expression of the transcription factor c-Myc was 
examined. The protein was detected with a delay of approximately 2 hours after the start of 
each pulse, and was degraded during the incubation time of the second pulse, albeit the 
continued presence of growth factors. The expression levels of c-Myc mRNA were in good 
agreement with this observation, peaking 1.5 hours before the protein was first detected. 
However, the mRNA levels stayed low afterwards, albeit the renewed increase in protein 
levels during the second pulse. This was surprising, but the same observation was made in 
cells that were continuously exposed to complete growth medium (containing serum), 
suggesting that c-Myc protein indeed required only one initial stimulation to be fully 
expressed.  
One more factor that was monitored on the gene expression level was cyclin D1, which must 
be elevated for successful transition from G1 into S phase. The mRNA levels of cyclin D1 
lacked a sharp increase during the discontinuous exposure assay, but showed a significant 
raise in cells stimulated continuously. This result suggested that discontinuous exposure was 
not sufficient to induce this mitogenic gene to its full extent, but more importantly, that the 
cells were able to compensate to a large extent for this. 
The initial idea to develop a discontinuous exposure assay for the MCF-12A stemmed from a 
publication by Jones and Kazlaukas (2001) who showed that fibroblast cells rendered 
quiescent were able to enter the cell cycle upon triggering of specific factors at distinct time 
points (Jones and Kazlauskas 2001). More precisely, they showed that the initial phase of 
signalling required activation of MEK and c-Myc, whereas the PI3K pathway dominated the 
second pulse. The authors hypothesised that any mitogen that triggers the named factors 
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would be able to drive quiescent cells into the cell cycle, and that there is a common 
signalling cascade by which growth factors elicit such a response.  
As for the PI3K signalling during the second phase of stimulation, we were able to confirm 
the importance of this pathway for cell cycle progression of MCF-12A cells. The fact that it 
was activated by a different set of growth factors (EGF+insulin vs. PDGF used for the 
fibroblast cell line NIH3T3) supports further the aforementioned hypothesis. However, it is 
worth remembering that inhibition of MEK1 during the second pulse also markedly disrupted 
S phase entry of MCF-12A cells. Therefore, the signalling important at this time point for cell 
cycle progression, at least of MCF-12A cells, cannot be restricted to a single pathway.  
Focusing on the factors activated during the first pulse, we found an up-regulation of MYC, 
followed by an increase in the protein expression of the transcription factor c-Myc, as a result 
of the exposure to EGF. Similar to in the NIH3T3 cells examined by Jones and Kazlauskas 
(2001), we showed that the activation of MEK1 in the initial wave was crucial for S phase 
entry of MCF-12A cells. In order to verify that triggering these two factors, MEK1 and c-
Myc, was indeed sufficient to drive the cells through the first portion of G1 phase, it may be 
envisaged to assess other (growth) factors that are able to induce these two proteins in the 
MCF-12A cells. These (growth) factors should then be interchangeable with one another for 
the administration during the first pulse.  
The order in which the proteins are required for cell cycle progression, could hence explain 
why a specific sequence of growth factors was unable to render cells competent for entry into 
S phase, such as the combination of EGF (1
st
 pulse), followed by insulin (2
nd
 pulse), as 
discussed above. This result suggests that insulin is not capable of activating fully the PI3 and 
the MAP kinases, but on the other hand it seems sufficient to induce MEK1 as well as 
expression of c-Myc. This hypothesis is further supported by the results obtained with E2 
(administered during the first pulse), followed by an exposure to EGF+insulin, which did not 
induce cell cycle re-entry. Indeed, we saw that E2 had no effect on the MYC gene, of which 
an up-regulation would be needed to increase the expression of the transcription factor c-
Myc.  
One other aspect to consider when discussing the role of c-Myc is the degradation of this 
protein, which was completed before the end of the second pulse, when EGF and insulin were 
still available. This demonstrated that c-Myc is required at specific times only to support 
successful cell cycle progression, and does not need to be expressed constantly. We speculate 
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that this protein is one of the decisive factors why the intervening time between the two 
pulses cannot be stretched beyond 6 hours, in accordance with the competence/progression 
system described by Jones and Kazlauskas in 2001 (Jones and Kazlauskas 2001). This model 
proposes that the initial administration drives cells through the first portion of G1 phase, but 
most importantly renders them responsive to further stimulation. Then they require a second 
mitogenic input which enables them to actually progress into S phase. However, their 
responsiveness declines over time, and eventually the cells return to the quiescent state. 
Therefore, if the second stimulus is received too late, it will have no effect on the cell cycle. 
It may be that the MCF-12A cells require a certain amount of c-Myc protein to remain 
responsive, and if the expression falls below a certain threshold, e.g. by constant degradation 
after the first pulse, they are unable to compensate for this during the second administration.  
1.1 Limitations 
Conclusions drawn from the effect of specific kinase inhibitors, as well as from the 
immunoblotting assays for detection of kinase activities, were based on results obtained with 
the standard discontinuous exposure assay, developed for the work presented here. This assay 
used EGF and insulin as growth factors, but the importance of insulin to the overall outcome 
remained undetermined, since it was shown that EGF only in both pulses had a similarly 
strong mitogenic effect on the MCF-12A cells as the mixture of growth factors. Thus, if some 
key experiments were carried out with EGF as the sole growth factor, the role of insulin for 
mitogenic signalling in these cells may become clearer. 
Although the use of specific inhibitors for MEK1, PI3K and Src contributed to the finding 
that activation of the Src/PI3K pathway during the second pulse was indispensable for cell 
cycle progression, the function of the Src kinase during the first pulse remained ambiguous, 
because it was shown to be phosphorylated after the first stimulation, but its inhibition did not 
hinder cell cycle re-entry. The use of a Src-specific activator could clarify these issues. 
Similarly, the role of the PKC pathway could not be pinpointed, owing to the considerable 
inter-experimental differences in the cell cycle analysis seen with the PLC inhibitor during 
the second pulse. It should be considered to employ a different inhibitory compound, e.g. an 




2 FUTURE WORK 
The role of insulin in contributing to cell cycle progression did not become entirely clear. In 
order to reveal it further, it would be very informative to test whether all the protein 
phosphorylation events and gene expression patterns are the same when both pulses consist 
of EGF alone (at a higher dose). Especially the activity level of PI3K needs to be examined 
closely under these conditions, because the mechanism through which PI3K is activated upon 
EGF stimulation depends strongly on the composition of the EGF receptor: only a 
heterodimer consisting of EGFR, for which EGF is the ligand, and ErbB3, which contains a 
p85 recognition motif, is able to activate the PI3K. All other receptor dimer combinations 
recruit the p85 subunit in an indirect fashion, which involves several adaptor proteins. 
Mapping of the receptor population would help to understand which activation mechanism is 
predominant in these cells, and this could be achieved by immunocytochemistry, targeting the 
four ErbB subtypes. Additionally, such a staining could be performed also for the IR and its 
substrates IRS-1 and 2, to further elucidate the contribution of insulin in the original 
discontinuous exposure assay.  
Analysis of the role of the Ras protein during the discontinuous exposure assay should be 
considered as well: since the specific PI3K inhibitor, when applied during the second pulse, 
had a suppressive effect on the phosphorylation of Erk1/2, it was assumed that a feedback 
loop was in place, which involved signalling through the Ras kinase. In order to test the 
probability of this suggestion, it would be interesting to assay for Ras activity. This should be 
done for several time points throughout the 18 hours duration of the discontinuous exposure 
assay. Additionally, the activity of Ras should be monitored in cells that are continuously 
stimulated, either with complete growth medium or only with EGF. This experiment would 
serve to elucidate whether the Ras kinase is activated in two waves in the MCF-12A cells. 
Such an alternating activity has been suggested to be a general feature of Ras action.  
In order to utilise the ideas presented here for breast cancer treatment, a co-culture of MCF-
12A together with the correspondent transformed line of MCF-7 cells should be set up. After 
inducing quiescence in both cell types, the growth factors and hormones examined in this 
thesis could be tested for their diverse effects on cell cycle progression in the cancer cell line, 
compared to the MCF-12A cells. To this end, flow cytometric analysis with previous sorting 
of cells according to the cell line would need to be performed. Mitogens may be found that 
induce S phase entry specifically in one cell line, but not the other. On the molecular level, 
193 
 
the pathways that are activated in each cell line for cell cycle progression should be 
compared. Again, if a kinase is found that is triggered in one cell line, but not the other, this 
protein may be specifically targeted to induce quiescence in the transformed cells. In 
summary, the findings from these examinations may have implications for cell cycle specific 
approaches to chemotherapy, targeting specifically the malignant cells in an environment in 
the mammary gland that consists of transformed as well as of normal tissue.  
3 FINAL CONCLUSION 
The MCF-12A cell line is derived from normal breast tissue and is therefore a good model for 
epithelium in the mammary gland. Evidence was presented that these cells do not necessitate 
continuous exposure to serum, but that timely targeted stimulation with defined growth 
factors is sufficient to trigger all signalling cascades required for cell cycle progression. An 
overall better understanding of the function of three major pathways and key proteins 
involved in cell cycle re-entry was achieved. Additionally, the effect of the endogenous 
hormone estradiol on important hormone-dependent genes and cell cycle progression was 
elucidated. These results may contribute to develop cell cycle phase specific cancer 
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Appendix Figure i Percentage of MCF-12A cells in S phase after release with different concentrations of 
EGF 
G0 accumulation was induced with serum-depletion for 24 hours (0.5% CD-HS), after which the starvation 
medium was removed and different concentrations of EGF in starvation medium were added for 20 hours. Cell 
cycle analysis was performed by flow cytometry carried out after staining of DNA with PI. Values show the 
mean of 3 independent experiments, error bars show SEM. Student’s t-test was performed for significance 
testing. Samples marked with * (P=0.1) and ** (P=0.05) are significantly different from the positive control 
released with complete growth medium.  
 
 





































Appendix Figure ii Regulation of mRNA in MCF-7 cells following 12h incubation with 10nM estradiol 
(E2) 
MCF-7 cells were seeded in 6-well plates with complete growth medium (MEMα with 5% fetal bovine serum 
(FBS)) and incubated 24h at 37°C. Subsequently, cells were incubated 24h (37°C ) in assay medium (phenol 
red-free MEMα with 2% CD-treated FBS) before treatment with estradiol (10 nM in assay medium, 12h at 
37°C) was performed. RNA-extraction and rt-PCR analysis was performed as described for MCF-12A cells in 
Chapter 2 above. Values show the mean of 3 independent experiments, error bars show SEM. Student’s t-test 
was performed for significance testing. Sample marked with * are significantly different (P=0.1) from the 
negative (vehicle) control which was set to 1 (dotted line) and to which all other samples were normalised. After 
12h with estradiol, MCF-7 cells showed detectable up-regulation of ESR1, MYC and TFF1 genes, coding for 
the estrogen receptor α (ERα), c-Myc transcription factor and trefoil peptide 1, respectively. Following from 
these results, incubation of MCF-12A cells with E2 and EGF was decided to be performed for 12h. 
 

































Appendix Figure iii Regulation of mRNA in MCF-12A cells following 24h and 6h incubation with 10nM 
EGF 
MCF-12A cells were seeded and samples were prepared for mRNA expression analysis as described above in 
Chapter 2. Before mRNA extraction, samples were incubated for 24h with EGF (100 ng/ml). Values show the 
mean of 3 independent experiments, error bars show SEM. Student’s t-test was performed for significance 
testing. Sample marked with * are significantly different (P=0.1) from the negative (vehicle) control which was 
set to 1 (dotted line) and to which all other samples were normalised. Significant regulation was observed on 
ESR1 mRNA only (coding for ERα). However, since no significant induction was seen for the proliferative 
genes MYC and TFF1, MYC was analysed additionally after 6h, but no up-regulation was observed. In the light 
of the findings for the same genes in MCF-7 cells (cf. Appendix Figure ii), it was decided to analyse mRNA 
regulation in MCF-12A cells exclusively after 12h of incubation with EGF (100 ng/ml) or E2 (10 nM). 
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Appendix Table i Overview of G0/G1 percentages found for negative control samples with flow cytometry 
The table shows for each figure presented the lowest and the highest percentage found for the negative control 
sample (G0 blocked sample), as well as the number of different batches used for independent experiments 
presented in each table. 
Figure G0 block range [%] G0 block range [%] number of batches 
Figure 10 58.01 92.9 2 
Figure 15 50 81.3 4 
Figure 17 60.5  1 
Figure 18 60.5  1 
Figure 19 77.2  1 
Figure 20 83.38  1 
Figure 21 83.9 86 1 
Figure 22 64.2 86 1 
Figure 23 71.8 89 3 
Figure 25 60.5 70.8 2 
Figure 26 82.9 92.9 3 
Figure 27 62.7 87.5 3 
Figure 28 74 87.5 3 
Figure 29 79.2 89.83 2 
Figure 30 70.91 72.8 2 
Figure 36 74 89.83 3 
Figure 37 74 89.83 3 
Figure 38 83.95 88.42 1 
 
